Antibody	Antibody binding type	PDB or other structure	Ab patient	Clonal lineage	Isolation paper(Pubmed ID)	Neutralizing antibody feature	Germline paper(Pubmed ID)	Germline software & DB	Heavy V (IGHV)	Heavy D (IGHD)	Heavy J (IGHJ)	Heavy CDR3 length	Heavy CDR3 seq	HC SHM NA (%)	HC SHM AA (%)	 Light V (IGKV or IGLV)	Light J (IGKJ or IGLJ)	Light CDR3 length	Light CDR3 seq	LC SHM NA (%)	LC SHM AA (%)	 Light chain type	ADCC	Type	Species	Aliases	LANL comments	Mean panel IC50	SD panel IC50	# assays	CATNAP ID	Immuno ID
0.5gamma	gp120 V3 // V3 glycan (V3g)		KTS376 		Yoshimura2010(20504942) 	0.5Î³ epitope;Mutations coupling nAb resistance with ceniciviroc sensitivity	RamirezValdez2015(25486586) 	IMGT/V-QUEST	3-30*09 or 3-30*01			18	ARDLDQTIPDLTAPAFEV		10.8	2-28*01 or 2D-28*01		8	MQSLQTWT		4.1	K	Yes	Natural monoclonal	human	0.5 gamma, 0.5gamma, 1C10	 Ramirez-Valdez2015 SHM data are entered for AA, but it's unclear if the data are NT or AA.	31.1443	9.32793	48	498	2475
0PV-a.01	fusion peptide // near gp41-gp120 interface	6MQR(0PV-a.01 in complex with fusion peptide);6OSY(0PV-a.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122)	0PV 		Kong2019(31348886) 	0PV-a.01 neutralization-associated sites;0PV-c.01 contacts	Kong2019(31348886) 	IgBlast IMGT/V-QUEST				15	CARERVVAHNYYGLDLW	10.6				9	CQQYEDFPLTF	10.2		K		Natural monoclonal	macaque		 	57.1033	3.83337	417	820	4510
0PV-b.01	fusion peptide // near gp41-gp120 interface	6N16(0PV-b.01 in complex with HIV fusion peptide)	0PV 		Kong2019(31348886) 	0PV-b.01 neutralization-associated sites	Kong2019(31348886) 	IgBlast IMGT/V-QUEST				14	CVREPVIAAAGTVDVW	7.3				9	CEQTLQIPFTF	2.0		K		Natural monoclonal	macaque		 	70.8693	2.5531	417	821	4511
0PV-c.01	fusion peptide // near gp41-gp120 interface	6MQC(0PV-c.01 in complex with fusion peptide);6NF2(0PV-c.01 in complex with HIV-1 Env BG505 DS-SOSIP and antibodies VRC03 and PGT122)	0PV 		Kong2019(31348886) 		Kong2019(31348886) 	IgBlast IMGT/V-QUEST				17	TSRAKDYRGPSYSRIDVW	14.4				9	CMQFVEFPLTF	4.3		K		Natural monoclonal	macaque		 	59.855	2.84227	417	822	4512
10-1074	gp120 V3 // V3 glycan (V3g)	4FQ2(10-1074 Fab);5T3X(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);5T3Z(Natively Glycosylated BG505 SOSIP.664 in Complex with IOMA and 10-1074);6OKP(SOSIP.664 in complex with SF12 and 10-1074);EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074)	Donor 17 	PGT121	Mouquet2012a(23115339) 	10-1074 contacts;10-1074 contacts;10-1074 neutralization;10-1074 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;mutations affecting 10-1074 binding;V3 Signature Analysis Summary	Klein2013(23540694) 	IgBlast	4-59	3-3	6					3-21	3 or 2					L	Yes	Natural monoclonal	human	10.1074	 	0.71153	60.8902	4396	17	2777
							Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 16	6*03	24	ARRGQRIYGVVSFGEFFYYYSMDV			3-21*02	3*02	12	HMWDSRSGFSWS					
10-1074GM	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 																			Engineered monoclonal	human		 	1.70613	13.0582	26	362	3897
10-1074-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	1.33043	48.2715	238	274	3539
10-1074V	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121		hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary																		Engineered monoclonal	human		 	0.44827	76.4079	600	243	3283
10-1121	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 3-10	6*03	24	ALHGKRIYGIVALGELFTYFYMDV			3-21*02	3*02	12	HIWDSRRPTNWV			L		Natural monoclonal	human		 			20	369	2803
10-1130	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-10 or 3-3	6*03	24	ALHGKRIYGIVALGELFTYFYMDV			3-21*02	3*02	12	HIWDSRRPTNWV			L		Natural monoclonal	human		 			20	368	2804
10-1146	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	10 or 3	6*03	24	AQQGKRIYGIVSFGEFFYYYYMDA			3-21*02	3*02	12	HYWDSRSPISWV			L		Natural monoclonal	human		 			20	370	2806
10-1341	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3 or 16	6*03	24	ARRGQRIYGVVSFGEFFYYYSMDV			3-21*02	3*02	12	HMWDSRSGFSWS			L		Natural monoclonal	human		 			20	371	2813
10-1369	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 16	6*03	24	TKHGRRIYGVVAFGEWFTYFYMDV			3-21*02	3*02	12	HIYDARRPTNWV			L		Natural monoclonal	human		 			20	364	2815
10-259	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01		6*03	24	TKHGRRIYGIVAFNEWFTYFYMDV			3-21*02	3*02	12	HIYDARGGTNWV			L		Natural monoclonal	human		 			20	365	2782
10-303	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 9	6*03	24	TLHGRRIYGIVAFNEWFTYFYMDV			3-21*02	3*02	12	HIWDSRVPTKWV			L		Natural monoclonal	human		 			20	366	2785
10-410	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3 or 3-10	6*03	24	ALHGKRIYGIVALGELFTYFYMDV			3-21*02	3*02	12	HIWDSRRPTNWV			L		Natural monoclonal	human		 			20	367	2787
10-847	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 		Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 16	6*03	24	ARRGQRIYGVVSFGEFFYYYSMDV			3-21*02	3*02	12	HMWDSRSGFSWS			L		Natural monoclonal	human		 			20	372	2798
10-996	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 	10-996 signature predictions;Key sites for PGT121-like and 10-1074-like mAbs;V3 Signature Analysis Summary	Mouquet2012a(23115339) 	IgBlast IMGT/V-QUEST	4-59*01	3-3 or 10	6*03	24	TQQGKRIYGVVSFGEFFHYYYMDA			3-21*02	3*02	12	HKWDSRSPLSWV			L		Natural monoclonal	human		 	1.64005	44.6236	360	16	2800
10A3	gp120 V3 // V3 glycan (V3g)		uncoded_rabbit 		Qin2015(26039641) 	10A3 epitope																		Natural monoclonal	rabbit		rabbit antibody 	14.4323	20.4026	22	323	3863
10A37	gp120 V3 // V3 glycan (V3g)		uncoded_rabbit 		Qin2015(26039641) 	10A37 epitope																		Natural monoclonal	rabbit		rabbit antibody 	6.98787	20.2343	22	324	3864
10E8	gp41 MPER (membrane proximal external region)	4G6F(Fab 10E8 complexed with gp41 peptide);4U6G(10E8 Fab in complex with a hydrocarbon-stapled HIV-1 gp41 MPER peptide);5GHW(10E8 with long epitope bound);5IQ7(10E8-S74W Fab in complex with an HIV-1 gp41 peptide);5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);5SY8(10E8 Fab light chain mutant1 and T117v2 HIV-1 MPER scaffold);5T29(10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2);5T5B(10E8 FAB LIGHT CHAIN MUTANT5 AND T117V2 HIV-1 MPER SCAFFOLD);5T6L(10E8 Fab in complex with the MPER epitope scaffold T117v2);5T80(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidic acid);5T85(10E8 Fab in complex with the MPER epitope scaffold T117v2 and phosphatidylglycerol);5TFW(10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold)	Donor N152 	10E8	Huang2012a(23151583) 	10E8 contacts;10E8 contacts;10E8 residue prediction;10E8 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;mutations affecting 10E8 binding;Mutations affect neutralization by 10E8;Q563R affects binding and neutralization of MPER mAbs;Residues important for 10E8 binding;Signature Analysis Summary	Huang2012a(23151583) 	IMGT/V-QUEST	3-15*05	3-3*01	1*01	20	TGKYYDFWSGYPPGEEYFQD	21		3-19*01	3*02	12	SSRDKSGSRLSV	14		L	Yes	Natural monoclonal	human		 	0.49996	6.42963	5646	12	2708
10E8-0fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	3.87858	5.20716	21	121	3080
10E8-0fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	1.19809	5.99976	21	120	3079
10E8-10fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.9675	5.65735	21	116	3075
10E8-10fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.56558	7.15275	21	115	3074
10E8-10fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	2.37887	6.84055	21	117	3076
10E8-19fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.44926	8.98017	21	114	3073
10E8-19fH/16fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.39459	7.48086	21	113	3072
10E8-2fH/0fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	7.97449	5.97822	21	122	3081
10E8-2fH/10fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.94299	6.20129	21	118	3077
10E8-2fH/4fL	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	5.13723	5.59785	21	119	3078
10E8-3R	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Rujas2018(29386285) 																	L		Engineered monoclonal	human	10E8i	 	0.015334	5.19071	17	862	4658
10E8 IgG mutant 1	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Irimia2017(28225819) 																			Engineered monoclonal	human		 	0.25918	11.6142	108	448	4018
10E8 IgG mutant 2	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Irimia2017(28225819) 																			Engineered monoclonal	human		 	2.70736	9.48824	108	449	4019
10E8 IgG mutant 3	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Irimia2017(28225819) 																			Engineered monoclonal	human		 	52.1608	2.81275	108	450	4020
10E8 IgG mutant 5	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Irimia2017(28225819) 																			Engineered monoclonal	human	10E8d, 10E8 mutant 5	 	33.6953	4.18346	110	452	4022
10E8/N6	gp120 CD4bs;gp41 MPER (membrane proximal external region)		Donor N152 Z258 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8fv-N6fv	bispecific 	0.049453	8.40368	108	427	3978
10E8/PGDM1400/PRO-140	gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region);non-HIV: host CCR5		Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human;humanized mouse	10E8Fab-PGDM1400fv-PRO140fv	trispecific 	0.012252	6.91922	105	425	3992
10E8/PGT121/PGDM1400.V1	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V1	trispecific 	0.52481	21.1939	28	428	3981
10E8/PGT121/PGDM1400.V2	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V2	trispecific 	1.53708	26.254	28	429	3982
10E8/PGT121/PGDM1400.V3	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V3	trispecific 	0.20382	20.0096	28	430	3984
10E8/PGT121/PGDM1400.V4	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V4	trispecific 	1.23307	32.5067	28	431	3983
10E8/PGT121/PGDM1400.V5	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V5	trispecific 	0.21034	19.1657	28	432	3985
10E8/PGT121/PGDM1400.V6	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V6	trispecific 	0.63234	24.5142	28	433	3986
10E8/PGT121/PGDM1400.V7	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V7	trispecific 	0.42434	17.4206	28	434	3987
10E8/PGT121/PGDM1400.V8	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V8	trispecific 	0.023348	12.7172	171	421	3988
10E8/PGT121/PGDM1400.V8.4DS	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V8.4DS	trispecific 			9	437	3991
10E8/PGT121/PGDM1400.V8Fc	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V8Fc	trispecific 	0.18638	13.9596	27	435	3989
10E8/PGT121/PGDM1400.V8LL	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor 84 Donor N152 		Khan2018(29976677) 																			Engineered monoclonal	human	10E8Fab-PGT121fv-PGDM1400fv.V8LL	trispecific 			12	436	3990
10E8V1.1/P140	gp41 MPER (membrane proximal external region);non-HIV: host CCR5		Donor N152 		Huang2016(27315479) 																			Engineered monoclonal	human;humanized mouse		bispecific 	0.0025529	7.94089	236	256	3471
10E8V2.0/iMab	gp41 MPER (membrane proximal external region);non-HIV: host CD4R		Donor N152 		Huang2016(27315479) 																			Engineered monoclonal	human;humanized mouse	10E08-iMab, 10E8-iMAb, 10E8/iMAb	bispecific 	0.002227	5.6643	340	257	3472
10E8v4	gp41 MPER (membrane proximal external region)	5IQ9(10E8v4 Fab in complex with an HIV-1 gp41 peptide);6X58(MPER-Fluc-Ec2 bound to 10E8v4 antibody);7MF7(Crystal structure of antibody 10E8v4-P100gA Fab);7MFB(10E8v4 Fab - light chain H31F variant)	Donor N152 	10E8	Kwon2016(27053554) 																	L	Yes	Engineered monoclonal	human		 	0.43791	6.17434	877	387	3508
10E8v4-5R-100cF	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Kwon2018(29444432) 																			Engineered monoclonal	human	10E8v4-5R+100cF 10E8v4-V5R-100cF 10E8v4-V5F-100cF	 	0.05102	5.58738	416	438	4002
10E8v4-DS	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Kwon2016(27053554) 																	L		Engineered monoclonal	human		 			9	632	4263
10J4	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	160	3150
10M6	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	164	3154
11F1F	gp41 MPER (membrane proximal external region)		llama#9 																					Fab or heavy-chain-only	llama		llama VHH 	28.2747	2.712	45	762	4475
12A12	gp120 CD4bs		Patient 12 	12A12	Scheid2011(21764753) 	12A12 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary	Klein2013(23540694) 	IgBlast	1-2	3-10 or 1-26 or 5-24	5					1-33	1					K	No	Natural monoclonal	human	12A12 d57	 	0.22938	10.2566	849	43	2581
							Scheid2011(21764753) 		1-2	1-26 or 3-10	4 or 5	13	DGSGDDTSWHLDP			1D-33	3	5	AVLEF					
12A21	gp120 CD4bs	4JPW(12a21 in complex with 93th057 gp120 mutant)	Patient 12 	12A12	Scheid2011(21764753) 	12A21 alanine scanning;12A21 contacts;Mutations allowing binding of germline Abs	Klein2013(23540694) 	IgBlast	1-2	6-19 or 3-10	5 or 4					1D-33	3					K		Natural monoclonal	human	12A21 d57	 12A21 is a close clonal relative of 12A10 and 12A4, and the germline repertoir is as shown for 12A4 in Scheid2011.	0.42263	21.6335	323	93	2627
							Scheid2011(21764753) 		1-2	5-12 or 3-10	4 or 5	13	DESGDDLKWHLHP			1D-33	3	5	AVFQW					
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			13	DESGDDLKWHLHP			1-33*01	1*01	5	AVFQW					
1357	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1 		Nyambi1998(9765494) 																			Natural monoclonal	human	1357-D	 	55.2765	3.29435	22	183	955
1361	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1 		Nyambi1998(9765494) 																			Natural monoclonal	human		 	58.917	3.3112	41	181	952
1393A	gp120 V2 // V2 glycan(V2g) // V2 apex		donor_uncoded_1 		Nyambi2000(10888650) 																			Natural monoclonal	human		 	63.231	3.07667	43	182	953
13I10	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGPSTWLPHL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	162	3152
15e	gp120 CD4bs		N70 		Robinson1990c(1694449) 		Gorny2009(18952295) 		4-39*02	2-8	6												Yes	Natural monoclonal	human	15E, 1.5e, 1.5E, N70-1.5e	 	84.951	1.95986	111	53	627
16G6	gp120 V3 // V3 glycan (V3g)		KTS376 		RamirezValdez2015(25486586) 		RamirezValdez2015(25486586) 	IMGT/V-QUEST	5-51*01			7	ARGGGDI			3-19*01		10	NSRDSSDHWV			L	Yes	Natural monoclonal	human		 	60.3847	5.57495	48	529	3259
1-79	gp120 V3 // V3 glycan (V3g)		Patient 1 		Scheid2009(19287373) 		Scheid2009(19287373) 		5-51	3	3	16	SYYDFSIGDGNDAFDV			1-47	1	10	AAWDDSFDYV			K		Natural monoclonal	human		 			18	475	2199
179NC75	gp120 CD4bs	7LLK(Q23.17_DS-SOSIP in complex with 179NC75 Fab)	EB179 		Freund2015(26516768) 	179NC75 binding-associated sites	Freund2015(26516768) 	IgBlast IMGT/V-QUEST	3-21	3-9	5	24	VHAWRYFDWVNRRSPVEKVLSIDL			3-1	2	10	QTWDSKNYVT			L		Natural monoclonal	human		 	12.6804	32.0116	240	226	3317
17b	gp120 CD4i CoRbs (Cluster C)	1G9M(gp120 (HXB2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);1GC1(gp120 core complexed with CD4 and 17b);1RZ8(antibody 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);1YYL(CD4M33, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);1YYM(F23, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I5Y(CD4M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2I60([Phe23]M47, a scorpion-toxin mimic of CD4, in complex with gp120 (YU2) and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NXZ(gp120 (T257S, S334A, S375W) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NY1(gp120 (I109C, T257S, S334A, S375W, Q428C) complexed with CD4 and 17b);2NY2(gp120 (T123C, T257S, S334A, S375W, G431C) complexed with CD4 and 17b);2NY3(gp120 (K231C, T257S, E267C, S334A, S375W) complexed with CD4 and 17b);2NY4(gp120 (K231C, T257S, E268C, S334A, S375W) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b);2NY6(gp120 (M95W, W96C, I109C, T123C, T257S, V275C,S334A, S375W, Q428C, G431C) complexed with CD4 and 17b);4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);4RQS(gp120 core bound to CD4 and 17b Fab);5A7X(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A8H(BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195)	N70 			17b contacts;MPER membrane fusion mutations confer sensitivity;Mutation affects binding to 17b and 412d;Mutation affects neutralization;mutations affecting 17b binding;mutations affecting 17b binding;Mutations at the trimer apex that affect sensitivity	Klein2013(23540694) 	IgBlast	1-69	3-16 or 3-22	5					3-15	2					K	Yes	Natural monoclonal	human	1.7b, 1.7B, sCD4-17b	 	72.4825	3.46118	834	52	658
							Gorny2009(18952295) 		1-69		1													
19b	gp120 V3 // V3 glycan (V3g)		N70 		Robinson1990c(1694449) 																	K	No	Natural monoclonal	human	1.9B, N70-1.9b, N701.9b	 			6	726	457
1B2530	gp120 CD4bs	4YFL(1B2530 in complex with HIV-1 clade AE 93TH057 gp120)	Patient 1 		Scheid2011(21764753) 	1B2530 contacts;Signature Analysis Summary	Scheid2011(21764753) 		1-46	6-13 or 6-19	4 or 5	16	AEAASDSHSRPIMFDH			1-47	3	11	ATYDSDGSIRL			L		Natural monoclonal	human		 1B2530 is a close clonal relative to INC127, and the germline repertoir is as shown for INC127 in Scheid2011.	12.3292	9.01227	318	97	2578
1B5	gp120 CD4i CoRbs (Cluster C)		llama#9 		Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1B5	llama antibody 	22.1425	4.43342	32	230	3250
1C2-llama	gp120 V2-CD4bs				Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1C2	llama antibody 	13.908	6.2962	26	227	3247
1C2-rabbit	gp41-gp120 interface	6P65(HIV Env 16055 NFL TD 2CC+ in complex with antibody 1C2 fragment antigen binding);6PEH(Crystal structure of rabbit monoclonal anti-HIV antibody 1C2);EMD-20260(HIV Env 16055 NFL TD 2CC+ in complex with antibody 1C2 fragment antigen binding);EMD-20274(Negative stain reconstruction of HIV-1 Env 16055 NFL TD 2CC+ trimer in complex with rabbit antibody 1C2 fragment antigen binding)	C3 		Dubrovskaya2019(31732167) 	1C2 contacts																		Natural monoclonal	rabbit		rabbit antibody 	9.32833	4.41968	244	764	4471
1D9	gp120 V3 // V3 glycan (V3g)		KTS376 		RamirezValdez2015(25486586) 		RamirezValdez2015(25486586) 	IMGT/V-QUEST	3-30*09 or 3-30*01			16	AKDGADVDNLGPAFDY			2-28*01 or 2D-28*01		8	MQPLQSWY			K	Yes	Natural monoclonal	human		 	33.5155	9.68867	48	528	3257
1E1	gp120 V2-CD4bs				Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1E1	llama antibody 	70.1952	2.11803	26	229	3249
1E2	gp120 CD4i CoRbs (Cluster C)		llama#9 		Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1E2	llama antibody 	67.1795	2.23987	26	233	3253
1F10	gp120 V3 // V3 glycan (V3g)		llama#9 		Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1F10	llama antibody 	9.64739	7.96383	26	228	3248
1F7	gp120 CD4bs				Buchacher1994(7520721) 		Gach2013(23991039) 		4-59*01			16	GRFDYFRGGHRLIFDS			1D-33*01		9	QQFDSLPPT			K		Natural monoclonal	human	human 1F7	 	36.7319	6.60166	122	165	949
1H9	gp120 CD4i CoRbs (Cluster C)		llama#8 		Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 1H9	llama antibody 	25.1028	4.19244	26	231	3251
1NC9	gp120 CD4bs		Patient 1 		Scheid2011(21764753) 		Klein2013(23540694) 	IgBlast	1-46	2-8 or 5-12	4					1-47	3					L		Natural monoclonal	human		 	3.95204	24.6021	31	96	2900
							Scheid2011(21764753) 		1-46	5-12 or 2-8	4 or 5	19	QDSDFHDGHGHTLRGMFDS			1-47	3	11	AAYDSTFSLPV					
2158	gp120 V2 // V2 glycan(V2g) // V2 apex	4OAW(Fab structure of V2 mAb 2158)				Mutations at the trimer apex that affect sensitivity																		Natural monoclonal	human		 	64.9225	2.87065	43	186	1347
2191	gp120 V3 // V3 glycan (V3g)				Gorny2002(12186887) 																			Natural monoclonal	human		 	45.4818	5.17719	100	77	1092
2219	gp120 V3 // V3 glycan (V3g)	2B0S(antibody 2219 in complex with three different V3 peptides);2B1A(Fab 2219 in complex with UG1033 peptide);2B1H(Fab 2219 in complex with UG29 peptide)			Gorny2002(12186887) 																			Natural monoclonal	human		 	49.8952	4.25128	105	78	1089
2408b	gp120 CD4bs		2408 		Chen2021(33453152) 																			Natural monoclonal	transgenic mouse		 	50.8962	5.22233	416	851	4602
2408c.3	gp120 CD4bs		2408 		Chen2021(33453152) 																			Natural monoclonal	transgenic mouse		 	48.9128	4.83593	416	853	4603
2411a	gp120 CD4bs	7JKS(2411a in complex with HIV-1 gp120 core)	2411 		Chen2021(33453152) 	2411a contacts																		Natural monoclonal	transgenic mouse		 	12.3645	10.3959	416	852	4604
2413a	gp120 CD4bs	7JKT(2413a in complex with HIV-1 gp120 core)	2413 		Chen2021(33453152) 																			Natural monoclonal	transgenic mouse		 	32.2765	6.26601	416	854	4605
2413b	gp120 CD4bs		2413 		Chen2021(33453152) 																			Natural monoclonal	transgenic mouse		 	21.259	5.66918	416	855	4606
2413c	gp120 CD4bs		2413 		Chen2021(33453152) 																			Natural monoclonal	transgenic mouse		 	31.8963	5.25383	416	856	4607
246-D	gp41 cluster I				Xu1991(1714520) 		Gorny2009(18952295) 		1-69*01	6-19	4											K	Yes	Natural monoclonal	human	246, 246D, SZ-246.D	 			4	704	783
2557	gp120 V3 // V3 glycan (V3g)	3MLR(Fab 2557 in complex with a NY5 V3 peptide);3MLS(FAb 2557 in complex with gp120 V3 mimotope);3MLT(Fab 2557 in complex with a UG1033 V3 peptide);3MLU(Fab 2557 in complex with a ZAM18 V3 peptide);3MLV(Fab 2557 in complex with an NOF V3 peptide)			Gorny2004(14963135) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		3*01		TRLYLFEGAQSSNAFDL	14.2		3-1*01	3*02		QAWDASTGV	14		L		Natural monoclonal	human		 	61.1682	3.59128	126	55	1315
2558	gp120 V3 // V3 glycan (V3g)	3UJI(Fab 2558 in complex with MN peptide)			Gorny2004(14963135) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		4*02		ARLGFEGDYSGSFFDY	7.3		3-1*01	2*01 or 3*01		QAWDSTLGVV	5.7		L		Natural monoclonal	human		 	56.18	4.18878	121	54	1317
25C4b	gp120 CD4i		KTS376 		Tanaka2017(28938888) 		Tanaka2017(28938888) 		3-23	3-22	4	28	AKMPLWFAESLDYYDSSGSFWFSNYFDY	10.1		3-20	4	9	QQYGRSPLT	6		K		Natural monoclonal	human		 Tanaka2017 %SHM shown for VH and VL only.	56.3613	3.97586	61	536	4144
2909	quaternary structure	3PIQ(2909 Fab)			Gorny2005(15795308) 																			Natural monoclonal	human		 			12	199	1421
2D4	gp120 V2-CD4bs				Strokappe2012(22438910) 																			Fab or heavy-chain-only	llama	VHH 2D4	llama antibody 	87.3381	1.38607	26	232	3252
2E7	gp41 MPER (membrane proximal external region)	5HM1(Llama VHH 2E7 in complex with gp41)	llama#9 		Strokappe2012(22438910) 	2E7 contacts																		Fab or heavy-chain-only	llama	VHH 2E7	llama antibody 	25.145	2.48845	26	234	3254
2F5	gp41 MPER (membrane proximal external region)	1TJG(2F5 complexed with gp41 7mer epitope);1TJH(2F5 with a gp41 11mer epitope);1TJI(2F5 with a gp41 17mer epitope);1U8H(2F5 with gp41 Peptide ALDKWAS);1U8I(2F5 with gp41 Peptide ELDKWAN);1U8J(2F5 with gp41 Peptide ELDKWAG);1U8O(2F5 with gp41 Peptide ELDKHAS);1U8P(2F5 with gp41 Peptide ECDKWCS);1U8Q(2F5 with gp41 Peptide ELEKWAS);1U91(2F5 with gp41 Peptide Analog ENDKW-[Dap]-S (cyclic));1U92(2F5 with gp41 Peptide Analog E-[Dap]-DKWQS (cyclic));2F5A(Fab 2F5);2F5B(2F5 complexed with gp41 epitope);2P8L(2F5 with gp41 Peptide ELLELDKWASLWN);2P8M(2F5 with gp41 Peptide ELLELDKWASLWN in new crystal form);2P8P(2F5 with gp41 Peptide LELDKWASLW[N-Ac]);2PR4(2F5 Fab);2PW1(2F5 with gp41 Peptide ELDKWNSL);2PW2(2F5 with gp41 Peptide ELDKWKSL);3BQU(2F5 Fab-3H6 Fab Complex);3D0L(2F5 with gp41 FP-MPER Hyb3K construct);3D0V(2F5 with gp41 Peptide LLELDKWASLW);3DRO(2F5 with gp41 peptide ELLELDKWASLWN);3DRQ(2F5 with gp41 FP-MPER Hyb3K construct soaked in PEG/2-propanol);3DRT(2F5 with gp41 scrambledFP-MPER scrHyb3K construct);3EGS(2F5 with gp41 scrambledFP-MPER scrHyb3K construct soaked in ammonium sulfate);3IDG(2F5 with gp41 Peptide ALDKWD);3IDI(2F5 Fab fragment with gp41 Peptide ALDKWNQ);3IDJ(2F5 Fab fragment with gp41 Peptide analog ELD(Orn)WAS);3IDM(2F5 Fab fragment with gp41 Peptide analog ELD(Nrg)WAS);3IDN(2F5 Fab fragment with gp41 Peptide analog ELD(Paf)WAS);3LEV(2F5 with epitope scaffold ES2);3MOA(2F5 Fab fragment with 17 aa gp41 MPER-derived peptide);3MOB(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide);3MOD(2F5 Fab fragment with 11 aa gp41 MPER-derived peptide)			Buchacher1994(7520721) 	2F5 and 4E10 signature sites;2F5 contacts;2F5 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 2F5 binding;Mutation affects neutralization by 2F5 and 4E10;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary	Zhang2019a(31772165) 	IMGT/V-QUEST	2-5*02	3-3*01	6*02	22	RRGPTTSSGVPIARGPVNAMDV	12.1		1D-13*02	4*01	9	QQLHFYPHT	11.8		K	Yes	Natural monoclonal	human	c2F5, IAM 2F5, IAM2F5, IAM-41-2F5	 	15.6953	8.97083	3873	14	815
							Kunert1998(9737583) 		2		6													
2G12	gp120 glycans;gp120 glycosylation sites in C2, C3, C4, and V4	1OM3(Fab 2G12);1OP3(Fab 2G12 bound to disaccharide mannose);1OP5(Fab 2G12 bound to oligosaccharide mannose);1ZLS(Fab 2G12 + Man4);1ZLU(Fab 2G12 + Man5);1ZLV(Fab 2G12 + Man7);1ZLW(Fab 2G12 + Man8);2OQJ(Fab 2G12 with 21-mer peptide ligand);3OAU(2G12 Recognizes Di-Mannose);3OAY(Mimic of the HIV glycan shield);3OAZ(Mimic of the HIV glycan shield);3OB0(Mimic of the HIV glycan shield);4RBP(2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomanose);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03)			Buchacher1994(7520721) 	2G12 contacts;2G12 signature predictions;Mutation affects 2G12 binding;Mutation affects VRC01, PGT151, and 2G12 binding;Mutation increases neutralization sensitivity;mutations affecting 2G12 binding	Huber2010(20702640) 	IMGT/V-QUEST	3-21	6-25	3					1-5	1					K	Yes	Natural monoclonal	human	c2G12, G12	 Wu2011 %SHM calculated for heavy chain = VH and light chain = VL.	50.312	4.82269	2937	41	1370
							Wu2011(21835983) 	IgBlast	3-21*01 or 3-21*02 or 3-21*02 or 3-21*02						30.6	1-5*03					17.7			
2H10	gp41 MPER (membrane proximal external region)	4B50(HIV-1 gp41 MPER-specific llama VHH 2H10)			LutjeHulsik2013(23505368) 																			Fab or heavy-chain-only	llama		Llama VHH 	100	1	33	761	4473
2N5	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	163	3153
3019	gp120 V3 // V3 glycan (V3g)				Gorny2006(16809292) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		3*01		ARVEGDWGALDL	5.9		3-1*01	2*01 or 3*01		QAWDSSSAWGV	9.7		L		Natural monoclonal	human		 	24.59	7.87061	21	56	1797
3074	gp120 V3 // V3 glycan (V3g)	3MLX(Fab 3074 in complex with an MN V3 peptide);3MLY(Fab 3074 in complex with a UR29 V3 peptide);3MLZ(Fab 3074 in complex with a VI191 V3 peptide)			Gorny2006(16809292) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		3*01		ARDFGEYHYDGRGFQCEGFDL	5.9		1-51*02	2*01 or 3*01		ATWDGSLRTV	5.3		L		Natural monoclonal	human	V3-3074	 	53.4046	5.1668	544	65	1798
35O22	gp41-gp41 interface	4TOY(35O22 Fab);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5T3S(gp140 trimer MD39-10MUTA in complex with Fabs PGT124 and 35022);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124);5UTF(DS-SOSIP.6mut BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);5V7J(BG505 SOSIP.664 Prefusion Env Trimer with Four Glycans removed in Complex with Neutralizing Antibodies 3H+109L and 35O22);5W6D(BG505-SOSIP.v4.1-GT1-N137A in complex with Fabs 35022 and 9H/109L);6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128)	Donor N152 	35O22	Huang2014(25186731) 	35O22 contacts;35O22 mutations affecting neutralization;Mutation affects neutralization by 35O22;mutations affecting 35O22 binding	Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*03 or 4*02	16	GLLRDGSSTWLPYL	35		2-14*02 or 2-23*03 or 2-23*02 or 2-23*01	1*01	10	CSYTHNSGCV	24		L		Natural monoclonal	human	35022	 	2.91957	51.8138	1056	157	3147
3694	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		1*01		VRLGHSDIGTSSGDVHN	18.1		3-1*01	2*01 or 3*01		QAWDTNTGVH	11.5		L		Natural monoclonal	human		 	26.6133	6.82383	21	57	2067
3791	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 	MPER membrane fusion mutations confer sensitivity	Andrabi2013(23466102) 	IMGT/V-QUEST	1-18*01		4*02		VRVRDNEQGDYGQLDL	12.2		1-1	4*01		QQYESLPWA	4.3		K		Natural monoclonal	human		 	40.5643	6.75034	23	68	2073
3869	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-f*01		4*02		ATSHCPGGSCSSSFDF	8.3		3-1*01	2*01 or 3*01		QVWDTTTTSYVI	8.6		L		Natural monoclonal	human		 	62.4526	3.65919	130	63	2076
3881	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		3*02		ARISVVVLPAVFPDI	11.2		3-15*01	1*01		QQYHDWLWT	5.4		K		Natural monoclonal	human		 	56.9594	5.03908	21	67	2077
3904	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	3-30*03		4*03		AKAGEGVGVMDA	5.9		1-39*01	3*01		QQSYITIT	5		K		Natural monoclonal	human		 	53.9037	4.7151	21	71	2070
3906	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		3*02		ATMTITIGEEFANAFDI	7.3		3-1*01	2*01 or 3*01		QAWDRISAV	9.7		L		Natural monoclonal	human		 	26.3043	7.41849	21	58	2064
3BC176	gp41-gp41 interface	5AWN(3BC176 Fab)	Patient 3 		Klein2012(22826297) 	3BC176 and 3BC315 key sites;Signature Analysis Summary;Signature Analysis Summary	Klein2012(22826297) 		1-2	5-12	2	19	SMRPVDHGIDYSGLFVFHF			2-23	3	10	CSYASYDRLI			L		Natural monoclonal	human		 	9.41136	12.6386	54	101	2825
							Klein2013(23540694) 	IgBlast	1-2	5-12 or 3-16	3					2-23 or 3								
3BC315	gp41-gp41 interface	5CCK(3BC315 Fab)	Patient 3 		Klein2012(22826297) 	3BC176 and 3BC315 key sites	Klein2012(22826297) 		1-2	5-12	3	19	PMRPVSHGIDYSGLFVFQF			2-23	3	10	CCSYANYDKL			L		Natural monoclonal	human		 	22.9459	5.64128	236	102	2824
3BNC117	gp120 CD4bs	4JPV(3BNC117 complexed with gp120);4LSV(3BNC117 complexed with gp120 (C1086));5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);5V8M(BG505 SOSIP.664 trimer in complex with 3BNC117);7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117)	Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC117 contacts;3BNC117 signature predictions;Altered glycosylation affects neutralization by CD4BS bnAbs;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 3BNC117 neutralization;mutations affecting 3BNC117 binding;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;Sites selected during 3BNC117 immunotherapy	Klein2013(23540694) 	IgBlast	1-2	6-25 or 1-26	6 or 2					1-33	3					K	Yes	Natural monoclonal	human	3BNC117 dRU3	 	0.54326	21.3962	4736	15	2586
							Scheid2011(21764753) 		1-2	6-25 or 2-8	2 or 6	10	QRSDYWDFDV			1D-33	3	5	QVYEF					
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			10	QRSDYWDFDV			1-33*01	3*01	5	QVYEF					
3BNC117/10-1074	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17 Patient 3 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific 	0.3867	8.31339	254	268	3473
3BNC117/10-1074-IgG3C-	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17 Patient 3 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific; IgG3C hinge variant 	0.14654	8.41105	240	269	3537
3BNC117_FR3-03	gp120 CD4bs		Patient 3 	3BNC117	Liu2019(30760721) 																	K		Engineered monoclonal	human	3BNC117 FR3-03	 	0.50979	14.4176	416	797	4573
3BNC117-IgG3C-	gp120 CD4bs		Patient 3 		Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	0.46648	15.5814	238	276	3538
3BNC117/PGT135-IgG3C-	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 39 Patient 3 		Bournazos2016(27315478) 																			Engineered monoclonal	human	3BNC117-PGT135	bispecific; IgG3C hinge variant 	0.069889	11.0323	327	278	3534
3BNC55	gp120 CD4bs	5I9Q(3BNC55 Fab in complex with 426c.TM4deltaV1-3 gp120)	Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC55 signature predictions;Signature Analysis Summary	Scheid2011(21764753) 		1-2	3-3 or 6-19 or 5-12	2 or 6	10	RHSDYCDFDI			1D-33	1 or 3	5	QVYEF			K		Natural monoclonal	human		 	4.68911	15.4342	367	42	2579
3BNC60	gp120 CD4bs	3RPI(Fab 3BNC60);4GW4(3BNC60 Fab with P61A mutation);5FEC(3BNC60 Fab germline precursor in complex with 426c.TM4deltaV1-3 gp120)	Patient 3 	3BNC117	Scheid2011(21764753) 	3BNC60 contacts	Klein2013(23540694) 	IgBlast	1-2	3-3 or 6-25	2					1-33	3					K		Natural monoclonal	human		 3BNC60 is a close clonal relative of 3BNC23, 3BNC128, 3BNC64, 3BNC34, and the germline repertoir is as shown for 3BNC23 in Scheid2011.	0.23941	10.8391	81	94	2582
							Scheid2011(21764753) 		1-2	6-25 or 3-3	2 or 6	10	QRSDFWDFDV			1D-33	3	5	QVYEF					
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST								1-33*01	3*01	5	QVYEF					
3BNC62	gp120 CD4bs		Patient 3 	3BNC117	Scheid2011(21764753) 		Scheid2011(21764753) 		1-2	6-25 or 6-13 or 6-6	2 or 6	10	QRSDYWDFDV			1D-33	3	5	QVYEF			K		Natural monoclonal	human	BNC62	 	0.83201	22.4684	30	95	2584
3E3	gp120 CD4bs		llama#9 		McCoy2014a(25522326) 																			Fab or heavy-chain-only	llama	3E3 VHH	llama antibody 	1.6937	13.0207	71	197	3221
4022	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		5*02		ARTGGPEGGGWFEP	11.8		3-10*01	3*02		YSTDSRGTYGV	7.9		L		Natural monoclonal	human		 	29.5985	7.00816	21	59	2065
4025	gp120 V3 // V3 glycan (V3g)	3UJJ(Fab 4025 in complex with Con A)			Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		6*02		AILGFWGANRGGGGMDV	3.8		3-10*01	1*01		YSTNSGGTFFV	4.7		L		Natural monoclonal	human		 	38.9018	6.75202	21	62	2066
4121	gp120 V3 // V3 glycan (V3g)				Gorny2009(18952295) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-18*01		4*02		AISPLQLERLEDYFDY	5.2		1-44*01	1*01		AAWDDSLNGPFV	1.4		L		Natural monoclonal	human		 	43.5332	4.23385	21	69	2074
412d	gp120 CCR5bs;gp120 CD4i	1RZG(Human anti-HIV-1 GP120 reactive antibody 412d)	AC01 			Mutation affects binding to 17b and 412d;Mutations at the trimer apex that affect sensitivity																K		Natural monoclonal	human	4.12D, 412D	 			6	750	1582
4139	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-8*01		4*02		ARLTVDCDDGGCYGDY	6.6		2-14*01	2*01 or 3*01		NSYRSDTLV	6.6		L		Natural monoclonal	human		 	42.8949	5.76014	21	70	3025
4210	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	1-f*01		3*02		AIGKSVAGTSAYDI	5.6		3-1*01	3*02		QAWDSRAAV	4.3		L		Natural monoclonal	human		 	27.2654	6.72866	21	64	3023
438-B11	gp120 V3 // V3 glycan (V3g)	6UTK(438-B11 Fab in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22);6UUH(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-B11);6UUM(438-B11 DSS mutant (Cys98A-Cys100aA));6V6W(438-B11 DSS mutant (Cys98A-100aA) in complex with an uncleaved prefusion optimized soluble BG505 trimer and Fab 35O22)	CBJC438 	438-B11	Kumar2020(32938661) 	438-B11 contacts	Kumar2020(32938661) 	IMGT/V-QUEST	1-69*01	3-3*01	3*01	21	WRGCGMCPYDTSSYYNDASDV	25.4		3-20*01	3*01	9	QYYGGSFFT	12.7		K		Natural monoclonal	human	B11	 	4.05621	47.0693	272	679	4220
438-D5	gp120 V3 // V3 glycan (V3g)	6UUL(Crystal structure of broad and potent HIV-1 neutralizing antibody 438-D5)	CBJC438 	438-B11	Kumar2020(32938661) 		Kumar2020(32938661) 	IMGT/V-QUEST	1-69*01	3-3*01	3*01	21	WRGCGMCPYDTSSYYNDASDV	24.7		3-20*01	3*01	9	QYYGGSFFT	13.5		K		Natural monoclonal	human	D5	 	1.12934	22.0589	14	680	4240
438-D6	gp120 V3 // V3 glycan (V3g)		CBJC438 		Kumar2020(32938661) 		Kumar2020(32938661) 	IMGT/V-QUEST	3-48*02	1-20*01	4*02	8		8.7		2-11*01	3*02	10		2.6		L		Natural monoclonal	human	D6	 			12	681	4264
438-F11	gp120 V3 // V3 glycan (V3g)		CBJC438 		Kumar2020(32938661) 		Kumar2020(32938661) 	IMGT/V-QUEST	7-4-1*02	2-21*02	6*04	20		10.1		1-40*01	2*01	11		7.8		L		Natural monoclonal	human	F11	 			12	682	4265
447-52D	gp120 V3 // V3 glycan (V3g)	1Q1J(Fab 447-52D in complex with V3 peptide);3C2A(447-52D in complex with UG1033 peptide);3GHB(Fab 447-52D in complex with V3 peptide 92RW020);4M1D(Fab 447-52D with V3 cyclic peptide MN)			Buchbinder1992(1466965) 	447-52D contacts;mutations affecting 447-52D binding;mutations affecting 447-52D binding;Mutations at the trimer apex that affect sensitivity	Klein2013(23540694) 	IgBlast	3-15	3-10 or 3-16	6					1-51	3					L	Yes	Natural monoclonal	human	447, 447-52-D, 447/52-DII, 447d, 447-D, 447D, 447D-52	 	52.1248	6.55412	837	51	500
4487	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*03		4*02		ARLDGNAAAFDY	8.3		1-51*02	2*01 or 3*01		GTWDNNLRAG	5.6		L		Natural monoclonal	human		 	34.0034	5.27528	21	60	3027
4490	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	5-51*01		4*02		ARVGYDSYGYSGSNFDE	4.5		3-1*01	2*01 or 3*01		QAWDTRTVV	5		L		Natural monoclonal	human		 	39.1782	5.0526	21	61	3026
4508	gp120 V3 // V3 glycan (V3g)				Andrabi2013(23466102) 		Andrabi2013(23466102) 	IMGT/V-QUEST	4-59*01		4*02		ARGPLLYFGAPRTHFDY	4.6		4-1*01	3*01		QQYYNTPPT	4.7		K		Natural monoclonal	human		 	34.7707	7.50925	21	66	3024
45-46m2	gp120 CD4bs	4JKP(45-46m2 complexed with gp120)	NIH45 	VRC01	Diskin2013(23712429) 	45-46m2 signature predictions																		Engineered monoclonal	human	m2, NIH45-46 G54W.HC_S28Y.LC	 	0.072729	38.6127	252	3	3161
45-46m25	gp120 CD4bs		NIH45 	VRC01	Diskin2013(23712429) 																			Engineered monoclonal	human	m25, NIH45-46 G54W_W47I.HC_S28Y.LC	 	0.19645	24.9044	252	5	3167
45-46m28	gp120 CD4bs		NIH45 	VRC01	Diskin2013(23712429) 																			Engineered monoclonal	human	m28, NIH45-46 G54W_W47T.HC_S28Y.LC, NIH45-46m28	 	0.13328	26.0761	252	6	3175
45-46m7	gp120 CD4bs		NIH45 	VRC01	Diskin2013(23712429) 	45-46m7 signature predictions																		Engineered monoclonal	human	m7, NIH45-46 G54W_W47V.HC_S28Y.LC	 	0.1706	25.289	252	4	3162
48d	gp120 CD4i	1RZ7(Human anti-HIV-1 GP120-reactive antibody 48d);3JWD(gp120 with gp41-Interactive Region with Fab 48D);3JWO(gp120 with gp41-Interactive Region with Fab 48D);4DVR(YU2 gp120 core in complex with Fab 48d and NBD-557)				Mutations at the trimer apex that affect sensitivity	Gorny2009(18952295) 		1-f*01	1-26	3											K	Yes	Natural monoclonal	human	48D, 4.8d, 4.8D	 	83.8477	2.28492	452	377	659
49G2	gp120 CD4bs		KTS376 		RamirezValdez2015(25486586) 		RamirezValdez2015(25486586) 	IMGT/V-QUEST	1-18*01			22	ARRNYYDSGSYYIRDGDYSMDV			1-44*01		11	ATWDDSLDGWV			L	Yes	Natural monoclonal	human		 	45.4835	6.71738	48	531	3264
4E10	gp41 MPER (membrane proximal external region)	1TZG(Fab 4E10 complexed with gp41 13mer epitope);2FX7(Fab 4E10 complexed with gp41 epitope);2FX8(Fab 4E10 complexed with gp41 Aib-induced peptide);2FX9(Fab 4e10 with 4e10 epitope on gp41);3H3P(Epitope-scaffold 4E10 Fv complex);4LLV(Unbound form of 4E10 Fv);4LRN(Ontogeny of recognition specificity and functionality for 4E10);4M62(Ontogeny of recognition specificity and functionality for 4E10);4M8Q(Ontogeny of recognition specificity and functionality for 4E10);4NGH(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41 and a tethered phosphate moiety);4NHC(4E10 Fab fragment in complex with a hydrocarbon-stapled peptide containing the 4e10 epitope on gp41);4OB5(Ontogeny of recognition specificity and functionality for 4E10);4ODX(4E10 germline encoded precursor no.7 in complex with epitope scaffold T117);4WY7(recombinant 4E10 expressed in Escherichia coli with epitope bound);4XAW(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: Crystals cryoprotected with phosphatidic acid);4XBE(4E10 Fab in complex with its peptide epitope on HIV-1 gp41: crystals cryoprotected with sphingomyelin);4XBG(4E10 Fab in complex with phosphatidic acid: 2.73 A resolution);4XBP(4E10 Fab crystalized in the presence of Phosphatidylethanolamine);4XC1(4E10 Fab in complex with its peptide epitope on HIV-1 GP41: crystals cryoprotected with sn-Glycerol 3-phosphate);4XC3(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with rac-glycerol 1-phosphate);4XCC(4E10 Fab crystalized in the presence of Phosphatidylcholine; I422 space group);4XCE(4E10 Fab crystalized in the presence of Phosphatidylcholine; C2 space group);4XCF(4E10 Fab in complex with its peptide epitope on HIV-1 gp41; crystals cryoprotected with phosphatidylcholine);4XCN(4E10 Fab in complex with phosphatidic acid; 2.9 A resolution);4XCY(4E10 Fab in complex with phosphatidylglycerol);5CIL(non-neutralizing version of 4E10 (WDWD) with epitope bound);5CIN(non-neutralizing version of 4E10 (DeltaLoop) with epitope bound);5CIP(Unbound 4E10);5X08(4E10, mutant Npro, with peptide bound)		4E10	Buchacher1994(7520721) 	2F5 and 4E10 signature sites;4E10 contacts;4E10 contacts;4E10 signature predictions;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 4E10 binding;Mutation affects neutralization;Mutation affects neutralization by 2F5 and 4E10;Mutation affects neutralization by PGZL1, H4K3, or 4E10;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Mutations at the trimer apex that affect sensitivity;Q563R affects binding and neutralization of MPER mAbs;Residues important for neutralization or binding by 4E10;Signature Analysis Summary	Zhang2019a(31772165) 	IMGT/V-QUEST	1-69*10	3-10*01	4*03	18	EGTTGWGWLGKPIGAFAH	6.8		3-20*01	2*01	9	QQYGQSLST	4.7		K	Yes	Natural monoclonal	human		 Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.	2.97937	5.21059	4311	13	846
							Morris2011(21980336) 	SoDA	1-69*10		1*01	18	REGTTGWGWLGKPIGAFA		12.6	3-20*01		9	QQYGQSLST		7			
4E10-3R	gp41 MPER (membrane proximal external region)			4E10	Rujas2018(29386285) 																	K		Engineered monoclonal	human		 			6	863	4659
4E9C	gp120 CD4i		KTS376 		Yoshimura2010(20504942) 	Mutations coupling nAb resistance with ceniciviroc sensitivity	Tanaka2017(28938888) 		1-69	3-22	6	22	VGGRDNDYYDSSDISSYYAMDV	6.3		3-15	2	11	QHYNNWPLLYT	5.4		K	Yes	Natural monoclonal	human		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 4E9C was labeled as 917B11. Tanaka2017 %SHM shown for VH and VL only.	47.2906	4.86788	141	533	2477
							RamirezValdez2015(25486586) 	IMGT/V-QUEST	1-69*01 or 1-69D*01			22				3-15*01		11	QHYNNWPLLYT					
4O20	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	159	3149
561_01_18	gp120 CD4bs	6UDJ(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074);EMD-20739(bNAb 1-18 in complex with BG505 SOSIP.664 and 10-1074)	IDC561 	561_01_18	Schommers2020(32004464) 	561_01_18 contacts;561_01_18 escape mutations	Schommers2020(32004464) 	IgBlast	1-46*01	3-10*01	6*03	18	ARDPFGDRAPHYNYHMDV			3-20*01	3*01	9	QRYGGTPIT			K		Natural monoclonal	human	1-18	 	0.087878	10.0157	439	472	4065
561_01_55	gp120 CD4bs	6UDK(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074);EMD-20740(bNAb 1-55 in complex with modified BG505 SOSIP-based immunogen RC1 and 10-1074)	IDC561 	561_01_18	Schommers2020(32004464) 		Schommers2020(32004464) 	IgBlast	1-46*01	3-10*01	6*03	18	ARDPFGDMYPHYNYHMDV			3-20*01	3*01	9	QRYGGTPIT			K		Natural monoclonal	human	1-55	 	0.15568	11.3586	256	474	4066
561_02_12	gp120 CD4bs		IDC561 		Schommers2020(32004464) 		Schommers2020(32004464) 	IgBlast	1-46*01	3-16*01	6*04	20	ARDPFGETFRGHDQPYRMDV			3-20*01	4*01	10	QSYGSITPLV			K		Natural monoclonal	human	2-12	 	0.23892	26.0208	432	473	4067
5G2	gp120 V3 // V3 glycan (V3g)		KTS376 		RamirezValdez2015(25486586) 		RamirezValdez2015(25486586) 	IMGT/V-QUEST	3-30*09 or 3-30*01			16	AKDGADENNLGPAFDY			2-28*01 or 2D-28*01		8	MQSLHSWT			K		Natural monoclonal	human		 	48.3916	6.65393	48	526	3258
697-D	gp120 V2 // V2 glycan(V2g) // V2 apex	4D9L(Fab structure of V2 mAb 697)			Gorny1994(7525987) 	Mutations at the trimer apex that affect sensitivity																		Natural monoclonal	human	697-30D, 697D	 	72.5628	2.29489	47	184	325
7-107	gp120 glycans		pt7 	7-269	Lorin2022(35230385) 		Lorin2022(35230385) 	IgBlast	3-30	2-2	6	23	DDIVGDCSTGFCYWGYYYQGMDV	10.5		3-15	2	10	QHYNSWPRAT	11.3		K	Yes	Natural monoclonal	human		 	13.7129	21.1528	48	604	4217
7-155	gp120 glycans		pt7 		Lorin2022(35230385) 		Lorin2022(35230385) 	IgBlast	1-69	2-21	6	12	GIWGGHYSPMDV	29.5		1-5	2	9	QHYRENSYT	19.3		K	No	Natural monoclonal	human		 	24.5629	12.0493	48	605	4218
7-176	gp120 glycans		pt7 		Lorin2022(35230385) 		Lorin2022(35230385) 	IgBlast	1-69	4-11 or 3-10	6	13	HRDMGDYHHGMDV	25.9		3-15	4	9	QHYESLPFT	17.6		K	No	Natural monoclonal	human		 	14.6654	16.8089	48	606	4219
717G2	gp120 V3 // V3 glycan (V3g)		KTS376 		RamirezValdez2015(25486586) 		RamirezValdez2015(25486586) 	IMGT/V-QUEST	3-30*09 or 3-30*01			21	AREGPHVYDSSDPDPVLEMDF			2D-29*02		8	MQSLHLWT			K	Yes	Natural monoclonal	human		 	43.461	7.95622	48	527	3260
7-269	gp120 glycans	7PC2(Env in complex with the IgA bNAb 7-269 and 3BNC117);EMD-13316(Env in complex with the IgA bNAb 7-269 and 3BNC117)	pt7 	7-269	Lorin2022(35230385) 	7-269 contacts	Lorin2022(35230385) 	IgBlast	3-30	2-2	6	23	DDILGDCSTSHCYWGYYYQGMDV	9.1		3-15	2	10	YHYNNWPRGS	9.5		K	Yes	Natural monoclonal	human		 	5.6157	37.8576	112	603	4216
7B9	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPYL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	158	3148
7H6	gp41 MPER (membrane proximal external region)		Donor N152 	10E8	Huang2012a(23151583) 	Q563R affects binding and neutralization of MPER mAbs	Huang2012a(23151583) 	IMGT/V-QUEST	3-15*05	3-3*01	1*01	22	TGKYYDFWSGYPPGEEYFQD	21		3-19*01	3*02	12	SSRDKSGSRLSV	14		L		Natural monoclonal	human		 	0.42023	8.13379	26	100	2709
7K3	gp41-gp41 interface		Donor N152 	35O22	Huang2014(25186731) 		Huang2014(25186731) 	IMGT/V-QUEST	1-18*02	5-24*01	4*02 or 4*03	16	GLLRDGSSTWLPHL			2-14*02	1*01	10	CSYTHNSGCV			L		Natural monoclonal	human		 			8	161	3151
830A	gp120 V2 // V2 glycan(V2g) // V2 apex	4YWG(830A in complex with V1V2)			Nyambi2000(10888650) 																			Natural monoclonal	human		 	74.8356	2.7642	41	185	954
8ANC131	gp120 CD4bs	4RWY(8ANC131 in complex with HIV-1 clade B YU2 gp120)	Patient 8 	8ANC131	Scheid2011(21764753) 	8ANC131 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects 8ANC131 neutralization;Signature Analysis Summary	Klein2013(23540694) 	IgBlast	1-46	3-16	6					3-NL5	3					K		Natural monoclonal	human		 	4.59984	11.8678	919	72	2587
							Scheid2011(21764753) 		1-46	3-16	6	16	DGLGEVAPDYRYGIDV			3-11	2 or 3	9	QEYSSTPYN					
							Zhou2015(26004070) 	IMGT/V-QUEST	1-46			16				3-20		9						
8ANC134	gp120 CD4bs	4RX4(8ANC134 in complex with HIV-1 clade A Q842.d12 gp120)	Patient 8 	8ANC131	Scheid2011(21764753) 	8ANC134 contacts	Scheid2011(21764753) 		1-46	D3-16	6	16	DGLGEVAPAYLYGIDA			3-11	2 or 3	9	QEYSSTPYN			K		Natural monoclonal	human		 8ANC134 is a close clonal relative of 8ANC26, and the repertoir is as shown for 8ANC26 in Scheid2011.	8.4335	15.9968	203	98	2588
8ANC195	gp41-gp120 interface	4P9H(8ANC195 Fab in complex with gp120 of 93TH057 HIV-1 and soluble CD4 D1D2);4P9M(8ANC195 Fab);5A7X(negative stain EM of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5A8H(cryo-ET subtomogram averaging of BG505 SOSIP.664 in complex with sCD4, 17b, and 8ANC195);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5CJX(8ANC195 Fab in complex with BG505 SOSIP.664 HIV-1 Env trimer);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195)	Patient 8 		Scheid2011(21764753) 	8ANC195 contacts;8ANC195 contacts;8ANC195 residue prediction;8ANC195 signature predictions;mutation affecting 8ANC195 binding;Mutation affects 8ANC195 neutralization;Signature Analysis Summary	Klein2013(23540694) 	IgBlast	1-69	3-3	5 or 4					1-5	5					K	No	Natural monoclonal	human		 8ANC195 is a close clonal relative of 8ANC142, and the repertoir is shown for 8ANC142 in Scheid2011.	5.9534	12.3504	1426	44	2583
							Scheid2011(21764753) 		1-69	3-3		20	TSTYDQWSGLHHDGVMAFSS			1-5	1 or 5	9	QQYDTYPGT					
8ANC195-IgG3C-	gp41-gp120 interface		Patient 8 		Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	3.67154	15.0125	232	270	3540
8ANC195/PGT128-IgG3C-	gp120 V3 // V3 glycan (V3g);gp41-gp120 interface		Donor 36 Patient 8 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific; IgG3C hinge variant 	0.16412	16.5915	232	272	3532
916B2	gp120 CD4i		KTS376 		RamirezValdez2015(25486586) 		Tanaka2017(28938888) 		1-69	2-15	4	16	ARDSDLYCSGGSCFEI	8.7		7-46	3	9	LLSYSGARV	5.9		L	Yes	Natural monoclonal	human		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 916B2 was labeled as 4E9C. Tanaka2017 %SHM shown for VH and VL only.	48.6996	5.07102	142	534	3268
							RamirezValdez2015(25486586) 	IMGT/V-QUEST	1-69D*01 or 1-69*01			16				7-46*01		9	LLSYSGARV					
917B11	gp120 CD4i		KTS376 		RamirezValdez2015(25486586) 		Tanaka2017(28938888) 		1-69	3-10	6	28	AGRSLEGADYYEAGTPYNVYYYYYVMDD	5.2		1-51	2 or 3	11	GTWDSSLSAVV	2.8		L	Yes	Natural monoclonal	human		Heavy chain sequences for 4E9C, 916B2, and 917B11 are based on CDRH3 data from RamirezValdez2015 Table 1 and Tanaka2017, which suggest that these 3 HC sequences were mislabeled in RamirezValdez2015 Supp Fig 1; the sequence for 917B11 was labeled as 916B2. Tanaka2017 %SHM shown for VH and VL only.	56.6966	5.96678	48	535	3269
							RamirezValdez2015(25486586) 	IMGT/V-QUEST	1-69D*01 or 1-69*01			28				1-51*01		11	GTWDSSLSAVV					
A10	gp41-gp120 interface		C3 		Dubrovskaya2019(31732167) 																			Natural monoclonal	rabbit		rabbit antibody 	41.6656	9.33613	16	766	4479
A12	gp120 CD4bs		llama#44 		Forsman2008(18842738) 																			Fab or heavy-chain-only	llama	VHH A12	llama antibody 	30.7894	9.19053	95	190	1860
A12V163-a.01	fusion peptide // near gp41-gp120 interface	6MQS(A12V163-a.01 in complex with HIV fusion peptide);6N1V(A12V163-a.01 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122)	A12V163 	A12V163-a	Kong2019(31348886) 	A12V163-a.01 neutralization-associated sites	Kong2019(31348886) 	IgBlast IMGT/V-QUEST				14	CVREGVPTEATTGDHW	6.0				11	CQSYDISLGAHVF	4.4		L		Natural monoclonal	macaque		 	93.7334	1.43785	416	826	4516
A12V163-a.02	fusion peptide // near gp41-gp120 interface		A12V163 	A12V163-a	Kong2019(31348886) 																	L		Natural monoclonal	macaque		 	97.8483	1.17193	416	827	4517
A12V163-b.01	fusion peptide // near gp41-gp120 interface	6MPG(A12V163-b.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122)	A12V163 		Kong2019(31348886) 		Kong2019(31348886) 	IgBlast IMGT/V-QUEST				11	CTKESAAAIGHYW	5.7				9	CQQYYTTPLTF	3.0		K		Natural monoclonal	macaque		 	99.399	1.06318	416	828	4518
A14	gp120 CD4bs		llama#1 		McCoy2014a(25522326) 																			Fab or heavy-chain-only	llama	A14 VHH	llama antibody 	1.96465	20.132	61	196	3218
A16	gp120 CD4bs		F524 		Qiao2016(27387828) 	A16 contacts																		Natural monoclonal	human		 	57.3488	3.53445	140	260	3491
A32	gp120 CD4i C1 (Cluster A)	3TNM(A32 Fab);4YBL(stabilized inner domain of clade A/E HIV-1 gp120 in complex with antibody A32);4YC2(stabilized inner domain of clade A/E HIV-1 gp120 in complex with antibody A32)				W69 is important for ADCC																	Yes	Natural monoclonal	human	A-32	 			38	725	660
Ab1271	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1271	macaque antibody 	31.5585	3.35509	21	798	4410
Ab1289	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1289	macaque antibody 	48.8637	2.52122	21	799	4411
Ab1303	gp120 CD4bs	7RYU(Anti-HIV neutralizing antibody Ab1303 Fab isolated from sequentially immunized mcaques);7TFN(Cryo-EM structure of CD4bs antibody Ab1303 in complex with HIV-1 Env trimer BG505 SOSIP.664)			Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1303	macaque antibody 	44.3951	3.40851	21	800	4417
Ab1368	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1368	macaque antibody 	83.4315	1.32121	21	801	4412
Ab1415	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1415	macaque antibody 	33.5022	5.1997	21	802	4413
Ab1456	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1456	macaque antibody 	36.61	7.64892	21	803	4414
Ab1457	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1457	macaque antibody 	41.0283	7.18878	21	804	4415
Ab1461	gp120 V3 // V3 glycan (V3g)				Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1461	macaque antibody 	39.0173	6.32325	21	805	4416
Ab1485	gp120 V3 // V3 glycan (V3g)	7KDE(BG505 SOSIP.664 with macaque mAb Ab1485 and human mAb 8ANC195)	CE8J 		Wang2020(33084569) 	Ab1485 contacts																L		Natural monoclonal	macaque		macaque antibody 	4.39027	63.7904	42	686	4252
Ab1573	gp120 CD4bs	7RYV(Anti-HIV neutralizing antibody Ab1573 Fab isolated from sequentially immunized macaques)			Escolano2021(34818054) 																	L		Natural monoclonal	macaque	1573	macaque antibody 	65.278	2.58613	21	806	4418
ACS101	gp120 CD4bs	7U04(antibody ACS101);7Z3A(AMC009 SOSIPv5.2 in complex with Fabs ACS101 and ACS124)	H18877 		vanSchooten2022a(35922441) 	ACS101 contacts	vanSchooten2022a(35922441) 	IMGT/V-QUEST	1-02*02	1-26*01	5*02	19	ARGGRGYDEPWGAYTWLDP	48	27	2-23*02	2*01	8	YSYDDMII	31	18	L		Natural monoclonal	human		 	25.9514	7.44959	283	752	4468
ACS114	gp120 silent face		H18877 		vanSchooten2022(36395347) 	ACS114 contacts;Mutation affects ACS114 neutralization	vanSchooten2022(36395347) 	IMGT/V-QUEST	4-34*08		4*02 or 4*01	14	VRVGPGPHMAALDY	36	21	2-24*01	1*01	9	VQGTQFPWT	24	8	K		Natural monoclonal	human		 	49.4151	7.94023	243	753	4484
ACS117	gp120 silent face		H18877 		vanSchooten2022(36395347) 		vanSchooten2022(36395347) 	IMGT/V-QUEST	4-34*01		4*02	13	ARSWGPTGPAPNS	48	24	2-24*01	2*02	9	MQATHEPRT	23	11	K		Natural monoclonal	human		 	34.3591	8.08321	243	754	4487
ACS122	gp41-gp120 interface	7U5G(ACS122 Fab)	H18877 		vanSchooten2022(36395347) 	ACS122 contacts	vanSchooten2022(36395347) 	IMGT/V-QUEST	4-59*03 or 4-59*11		5*02	18	AREKSVVEPDNMVRWFDP	24	15	3-21*04	1*01	11	QVWDSSRDHCV	10	3	L		Natural monoclonal	human		 	85.7538	1.85158	243	755	4490
ACS125	gp41-gp120 interface		H18877 		vanSchooten2022(36395347) 		vanSchooten2022(36395347) 	IMGT/V-QUEST	4-59		5*02	18	VQEKSIAEEDNMVRWFGP	30	15	3-21*04	1*01	11	QLWDSSLDQCV	18	7	L		Natural monoclonal	human		 	90.1082	1.53998	243	756	4493
ACS130	gp120 V3 // V3 glycan (V3g)		H18877 		vanSchooten2022(36395347) 		vanSchooten2022(36395347) 	IMGT/V-QUEST	5-51*01		4*02	12	ARLNGDYAQFDY	23	11	1-51*01	2*01 or 3*01	10	GTWDNSLNAL	21	12	L		Natural monoclonal	human		 	75.5775	2.44419	243	757	4495
ACS202	fusion peptide // near gp41-gp120 interface	6NC2(Env trimer in complex with fusion peptide targeting antibody ACS202 fragment antigen binding);6NCP(structure of HIV-1 broadly neutralizing antibody ACS202);EMD-0433(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody ACS202 fragment antigen binding);EMD-8299(AMC011 SOSIP trimer in complex with autologous antibody ACS202)	D12950 		vanGils2016(27841852) 	ACS202 contacts;Mutation affects ACS202 neutralization or binding	vanGils2016(27841852) 	IMGT/V-QUEST	3-30*03	2-8*02	6*02	24	CARDRLGRPWNIGGRLVYYYYGMDVW			1-33*01	3*01	9	QEYENLQFT			K		Natural monoclonal	human		 	14.5742	20.5094	578	303	3545
AIIMS-P01	gp120 V3 // V3 glycan (V3g)		AIIMS_330 		Kumar2019(30429339) 																			Natural monoclonal	human		 	3.64015	27.933	127	453	4035
b12	gp120 CD4bs	1HZH(B12 unliganded);1N0X(B12 complexed with mimotope);2NY7(gp120 complexed with Fab b12);3RU8(Fab b12 with epitope scaffold);5VN8(B41 SOSIP.664 in complex with fragment antigen binding variable domain of b12)	Donor b 		Burton1991(1719545) 	b12 contacts;b12 signature predictions;b12 signature sites;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Mutation increases neutralization sensitivity;mutation increases sensitivity to MPER nAbs;Signature Analysis Summary	Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-03*01	3-10*02	6*03	20		13		3-20*01	2*01	9		13		K	Yes	Natural monoclonal	human	1b12, b4/12, Fab b12, Ib12, IgG1 b12, IgG1-b12, IgGB12, MAb IgG1b12	 Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011: %SHM calculated for VH gene IGHV1-3*01 and VL gene IGKV3-20*01 by IMGT/V-QUEST on nt sequences.	29.5033	7.05754	4380	40	633
							Zhang2013(24100711) 	IMGT/V-QUEST	1-03*01	2-21*01	6*03	20				3-20	2	9						
							Barbas1993(8478936) 				6	18	VGPYSWDDSPQDNYYMDV				2	9	QVYGASSYT					
							Wu2011(21835983) 							12.5	20.4					15.5	22.7			
b13	gp120 CD4bs	3IDX(gp120 core in complex with b13);3IDY(gp120 core in complex with b13)	Donor b 		Burton1991(1719545) 	Mutations at the trimer apex that affect sensitivity	Barbas1993(8478936) 				4	19	DIGLKGEHYDILTAYGPDY				4	9	QQHQNVPLT			K		Natural monoclonal	human		 	71.9753	3.28219	181	76	642
B21	gp120 CD4bs		llama#3 		McCoy2014a(25522326) 																			Fab or heavy-chain-only	llama	B21 VHH	llama antibody 	2.9596	17.6827	61	195	3220
b6	gp120 CD4bs		Donor b 		Burton1991(1719545) 	MPER membrane fusion mutations confer sensitivity;Mutation decreases binding to CD4BS mAbs;Mutation increases neutralization sensitivity	Barbas1993(8478936) 				3	22	QKPRYFDLLSGQYRRVAGAFDV				2	9	QQYGTSPYT			K	Yes	Natural monoclonal	human	IgG1b6	 			87	476	641
B9	gp120 CD4bs		llama#1 		McCoy2014a(25522326) 																			Fab or heavy-chain-only	llama	B9 VHH	llama antibody 	1.76635	20.2176	61	194	3219
BE10			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	3-23*04	3-16*02	6*02	21	VKGLQASVHDWLWDGYRSPGA	19.44		1-16*01	1*01	9	QQDKYYPWT	10.61		K		Natural monoclonal	human		 	100	1	14	568	4178
BE7			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*11	3-22*01	3*01	17	ARAYYYDTTTGLGAMDV	16.32		4-1*01	3*01	9	HQFHSSPIT	7.8		K		Natural monoclonal	human		 	29.3592	17.219	14	566	4176
BF520.1	gp120 V3 // V3 glycan (V3g)	6MN7(BG505.SOSIP.664 in complex with BF520.1 antigen binding fragment)	BF520 	BF520	Simonich2016(27345369) 		Simonich2016(27345369) 	IMGT/V-QUEST	1-2	3-10	4	20	ARGPFPNYYGPGSYWGGLDF	6.6	11.2	3-15	3	11	QQYNNWPSPFT	5	11.6	K		Natural monoclonal	human		 Simonich2016 %SHM calculated for VH and VL only.	17.1989	7.78369	76	373	3398
BF520.1-A52N(HC)	gp120 V3 // V3 glycan (V3g)		BF520 	BF520	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	20.9761	5.02805	13	745	4434
BF8			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*01	3-22*01	3*01	17	ARDLYYDTTTGLGAMDV	14.24		4-1*01	3*01	9	QQYHSDPLT	10.64		K		Natural monoclonal	human		 	31.9421	12.6671	14	563	4173
BG1	gp120 V1-V2	5VIY(BG505 SOSIP.664 in complex with antibodies BG1 and 8ANC195);5VVF(BG1 Fab)	EB354 		Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	3-49			22	EQRNKDYRYGQEGFGYSYGMDV	27.2		1-39				19.9		K		Natural monoclonal	human	354BG1	 Freund2017 %SHM calculated for VH and VL only.	16.3123	16.1097	242	306	3622
BG18	gp120 V3 // V3 glycan (V3g)	6CH7(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH8(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CH9(A natively-glycosylated B41 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and 35O22);6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA)	EB354 	BG18	Freund2017(28100831) 	BG18 contacts;BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Freund2017(28100831) 	IMGT/V-QUEST	4-4			21	NAIRIYGVVALGEWFHYGMDV	21.2		3-25		11	QSSDTSDSYKM	17.7		L		Natural monoclonal	human	354BG18	 Freund2017 %SHM calculated for VH and VL only.	0.66662	95.1206	289	308	3623
BG24	gp120 CD4bs	7UCE(BG24 Fab fragment);7UCF(BG505 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);7UCG(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);7UGM(BG24-iGL CDR3mat Fab);7UGN(BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UGO(BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);7UGP(BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan);7UGQ(BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664);EMD-26443(DU422 SOSIP.664 trimer in complex with neutralizing antibody Fab fragments 10-1074 and BG24);EMD-26490(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 1);EMD-26491(Cryo-EM structure of BG24 inferred germline Fabs with germline CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 - Class 2);EMD-26492(Cryo-EM structure of BG24 inferred germline Fabs with mature CDR3s and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1);EMD-26493(Cryo-EM structure of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 1);EMD-26494(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 2);EMD-26495(Cryo-EM map of BG24 Fabs with an inferred germline light chain and 10-1074 Fabs in complex with HIV-1 Env immunogen BG505-SOSIPv4.1-GT1 containing the N276 gp120 glycan- Class 3);EMD-26496(Cryo-EM structure of BG24 Fabs with an inferred germline CDRL1 and 10-1074 Fabs in complex with HIV-1 Env 6405-SOSIP.664)	391370 	BG24	Barnes2022(35960796) 	BG24 contacts;Mutation abrogates BG24 OR VRC01 neutralization;Mutations associated with immunotherapy with BG24 or VRC01	Barnes2022(35960796) 	IgBlast IMGT/V-QUEST	1-02*02			16	ATQVKLDSSAGYPFDI	13.4	22.7	2-11*01		5	SAFEY	8.0	19.5	L		Natural monoclonal	human		 	0.75835	12.2741	316	633	4243
BG24-CDR2-v1	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 																	L		Engineered monoclonal	human	BG24-PG20-CDR2-v1	 	0.22486	10.727	254	638	4248
BG24-CDR2-v2	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 																	L		Engineered monoclonal	human	BG24-PG20-CDR2-v2	 	0.23641	9.44785	254	639	4249
BG24-G54W	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 																	L		Engineered monoclonal	human		 	0.31771	12.7243	254	637	4247
BG24-Y100DW	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 																	L		Engineered monoclonal	human		 	3.0299	17.5689	252	640	4250
BG33	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 		Barnes2022(35960796) 	IgBlast IMGT/V-QUEST	1-02*02			16	ASQVAVGDSTHYPFDV	14.7	26.8	2-11*01		5	SAFEF	6.9	12.8	L		Natural monoclonal	human		 	8.17514	15.7693	30	635	4245
BG38	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 		Barnes2022(35960796) 	IgBlast IMGT/V-QUEST	1-02*02			16	ATQVAVAASTGWAFDV	18.2	28.9	2-11*01		5	SAFEY	10.7	17.2	L		Natural monoclonal	human		 	1.7106	24.7647	40	636	4246
BG5	gp120 CD4bs		391370 	BG24	Barnes2022(35960796) 		Barnes2022(35960796) 	IgBlast IMGT/V-QUEST	1-02*02			16	ATRVKLPSSDDYGFDV	17.6	32.3	2-11*01		5	SSYEF	7.1	13.5	L		Natural monoclonal	human		 	6.22045	30.5647	30	634	4244
BG8	gp120 V3 // V3 glycan (V3g)		EB354 	BG18	Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	4-4			21	NVIRVFGFISLGEWFHYGMDV	25.4		3-25		11	QSSDTSDSYKM	20.5		L		Natural monoclonal	human	354BG8	 Freund2017 %SHM calculated for VH and VL only.	1.84643	43.5005	234	307	3629
BiIA-DG	gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R		Donor 36 		Wu2018(29461979) 																			Engineered monoclonal	human		An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin 	0.44461	16.383	40	375	3915
BiIA-SG	gp120 V3 // V3 glycan (V3g);non-HIV: host CD4R		Donor 36 		Wu2018(29461979) 																			Engineered monoclonal	human		An engineered tandem bispecific bnAb composed from PGT128, iMab, and ImmunoAdhesin 	0.016005	9.66693	129	374	3907
Bi-NAb	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17 NIH45 		Steinhardt2018(29491415) 																			Engineered monoclonal	human	Bi-NAb dVRC01-5X-PGT121	bispecific involving VRC01 and PGT121 	0.39295	7.9911	416	384	3921
BISC-1A	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		CAP256 Donor 17 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of VRC26.25 scFv and 10-1074 	0.022901	9.61404	30	767	4519
BISC-1B	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		CAP256 Donor 17 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of VRC26.25 scFv and PGT121 	0.024083	6.91222	30	768	4520
BISC-1C	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		CAP256 Donor 36 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of VRC26.25 scFv and PGT128 	0.012858	3.94184	30	769	4521
BISC-2A	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17 Donor 84 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of PGT145 scFv and 10-1074 			18	770	4522
BISC-2B	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17 Donor 84 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of PGT145 scFv and PGT121 			18	771	4523
BISC-2C	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 36 Donor 84 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		bispecific composed of PGT145 scFv and PGT128 			18	772	4524
Bi-ScFv	gp120 CD4bs;gp120 V3 // V3 glycan (V3g)		Donor 17 NIH45 		Steinhardt2018(29491415) 																			Engineered monoclonal	human	Bi-ScFv dVRC01-5X-PGT121	bispecific involving VRC01 and PGT121 	0.14478	11.9134	416	385	3958
C8	gp120 CD4bs		llama#44 		Forsman2008(18842738) 																			Fab or heavy-chain-only	llama	VHH C8	llama antibody 	52.7405	3.87312	89	192	1862
CAP228-16H	gp120 V2 // V2 glycan(V2g) // V2 apex	6FY1(CAP228-16H in complex with a scaffolded autologous V1V2);6FY2(CAP228-16H in complex with a heterologous CAP225 V1V2)	CAP228 	CAP228-16H	vanEeden2018(30540944) 	Contacts of IGHV5-51 V2 antibodies	vanEeden2018(30540944) 	IMGT/V-QUEST	5-51*03	10*01	3*02	16	ARHGRGVREVINAFDI	4.9		3-21*01	2*01	11	QVWHSTSAVVF	8.3		L	Yes	Natural monoclonal	human		 			12	626	4026
CAP228-19F	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP228 	CAP228-16H	vanEeden2018(30540944) 		vanEeden2018(30540944) 	IMGT/V-QUEST	5-51*03	10*01	3*02	16	ARHGRGVREVINAFDI	4.9		3-21*01	2*01	11	QVWHSTSAVVF	8.3		L	Yes	Natural monoclonal	human		 			12	627	4027
CAP228-3D	gp120 V2 // V2 glycan(V2g) // V2 apex	6FY3(CAP228-3D bound to a heterologous V2 peptide)	CAP228 		vanEeden2018(30540944) 	Contacts of IGHV5-51 V2 antibodies	vanEeden2018(30540944) 	IMGT/V-QUEST	5-51*03	3-22*01	2*01	19	ARLLNNYDSSGFLYWYLDL	3.9		6-57*01	3*02	11	ADYYCQSYDMT	2.1		L	Yes	Natural monoclonal	human		 			14	628	4028
CAP248-2B	fusion peptide // near gp41-gp120 interface	5F89(Unliganded Fab from CAP248-2B);5MP6(Unliganded Fab from CAP248-2B)	CAP248 		Wibmer2017(28076415) 	Mutation affects neutralization by CAP248-2B	Wibmer2017(28076415) 	IMGT/V-QUEST	4-31*05	6-13*01	3*02 or 3*01	15	EASTKITDDGGAFDF	13.54		2-14*01	1*01	19	SSYTTKKTSFFGPATRAYV	9.72		L		Natural monoclonal	human		 	44.1122	10.1748	19	570	3639
CAP256.J3LS	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex	8FIS(Bispecific CAP256V2LS-J3 Fab in complex with BG505 DS-SOSIP.664)	CAP256 llama#8 		Zhang2023(36729903) 																			Engineered monoclonal	human;llama	CAP256V2LS-J3	Bispecific involving VRC26.25 and llama antibody J3 	0.017457	14.4059	616	760	4497
CAP256V2LS	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 		Zhang2022(36284200) 																			Engineered monoclonal	human		 	0.11433	207.014	616	550	4153
CAP256V2LS-J3-3	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 llama#8 		Zhang2023(36729903) 																			Engineered monoclonal	human;llama		 	0.012141	12.4808	416	763	4499
CAP257-RH1	gp120 CD4bs	5T33(CAP257-RH1 in complex with strain RHPA gp120 core with an oligomannose N276 glycan)	CAP257 		Wibmer2016(27581986) 	CAP257-RH1 contacts;Mutation affects CAP257-RH1 neutralization	Wibmer2016(27581986) 	IMGT/V-QUEST	3-33*03		6*03	11	AGGGKYDYLDV	8.68		3-10*01	3*02	11	FSTDSSGQTWV	8.96		L		Natural monoclonal	human		 	96.2519	1.70482	196	304	3544
CD4-Ig																											 	2.31306	7.65452	1061	22	
CH01	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CH0219 	CH01	Bonsignori2011(21795340) 	CH01 signature sites;Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary	Andrabi2015(26588781) 	IMGT/V-QUEST	3-20*01	3-10*01	2*01	26		17		3-20*01	1*01	9		11		K		Natural monoclonal	human		 	11.7528	10.6929	1029	84	2655
							Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24			13.3	3-20	1	9			10			
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01							3-20*01								
CH01_UA3	gp120 V2 // V2 glycan(V2g) // V2 apex		CH0219 	CH01	Liao2013b(23313589) 																	K		UCA or intermediate	human	CH01_RUA	Named CH01_RUA in Bibollet-Ruche2023 (referenced to the CH01_UA3 sequence from Liao2013b). 			6	746	4460
CH02	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24			14.3	3-20	1	9			13.7	K		Natural monoclonal	human		 	12.23	16.0314	250	85	2656
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01							3-20*01								
CH03	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5ESV(CH03 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from Clade C Superinfecting Strain of Donor CAP256)	CH0219 	CH01	Bonsignori2011(21795340) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24			12	3-20	1	9			10.6	K		Natural monoclonal	human		 	9.22651	20.6749	102	86	2657
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01							3-20*01								
CH04	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	3TCL(Antibody CH04);5ESZ(CH04 in Complex with Scaffolded Trimeric HIV-1 Env V1V2 Domain from the Clade AE Strain A244)	CH0219 	CH01	Bonsignori2011(21795340) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Andrabi2015(26588781) 	IMGT/V-QUEST	3-20*01	3-10*01	2*01	26		14		3-20*01	1*01	9		11		K		Natural monoclonal	human		 	18.6072	12.7275	253	87	2654
							Bonsignori2011(21795340) 	SoDA	3-20	3-10	2	24			11.5	3-20	1	9			9.4			
							Doria-Rose2014(24590074) 	IMGT/V-QUEST	3-20*01							3-20*01								
CH103	gp120 CD4bs	4JAM(antibody CH103);4JAN(CH103 in complex with HIV-1 gp120)	Donor CH505 	CH103	Liao2013(23552890) 	Antibody-driven selection in donor CH505;CH103 and CH235 evolution;CH103 contacts;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;Signature Analysis Summary	Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		16.8		3-1*01	1*01	10		10.6		L		Natural monoclonal	human		 	4.15305	11.0261	1455	50	2861
CH104	gp120 CD4bs		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		14.9		3-1*01	1*01	10		10.6		L		Natural monoclonal	human		 			8	187	2862
CH105	gp120 CD4bs		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		12.7		3-1*01	1*01	10		10		L		Natural monoclonal	human		 			8	188	2863
CH106	gp120 CD4bs		Donor CH505 	CH103	Liao2013(23552890) 		Liao2013(23552890) 	IMGT/V-QUEST	4-59*01	3-16*01	4*02	15		16		3-1*01	1*01	10		11.2		L		Natural monoclonal	human		 			19	189	2864
CH12	gp41 MPER (membrane proximal external region)		CAP206 		Morris2011(21980336) 		Morris2011(21980336) 	SoDA	1-69*04		6*03	17			11.9	3-20*01		11			5.2	L		Natural monoclonal	human	CAP206-CH12	 Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.	82.4473	2.16309	446	282	2854
CH13	gp120 CD4bs		CH0457 	CH13	Moody2015(26355218) 	Mutation decreases binding to CD4BS mAbs																		Natural monoclonal	human		 	29.0118	10.8032	37	248	3236
CH14	gp120 V3 // V3 glycan (V3g)		CH0457 		Moody2015(26355218) 																			Natural monoclonal	human		 	48.3679	8.7145	52	249	3244
CH16	gp120 CD4bs		CH0457 	CH13	Moody2015(26355218) 																			Natural monoclonal	human		 	43.7543	7.61358	48	250	3237
CH17	gp120 CD4bs		CH0457 	CH13	Moody2015(26355218) 																			Natural monoclonal	human		 	43.9701	8.29155	48	251	3238
CH18	gp120 CD4bs		CH0457 	CH13	Moody2015(26355218) 																			Natural monoclonal	human		 	46.2777	7.03121	48	252	3239
CH235	gp120 CD4bs	5F9W(CH235 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8082(BG505 SOSIP.664 in complex with CH235 Fab);EMD-8083(B41 SOSIP.664 trimer in complex with CH235 Fab)	Donor CH505 	CH235	Gao2014(25065977) 	Antibody-driven selection in donor CH505;CH103 and CH235 evolution	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CARNVATEGSLLHYDYW	7.9		3-15*01	1*01	8	QYNNWWTF	3.8		K		Natural monoclonal	human		 	58.5985	3.3291	230	223	3185
CH235.12	gp120 CD4bs	5F96(CH235.12 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8078(BG505 SOSIP.664 trimer in complex with CH235.12 Fab);EMD-8079(B41 SOSIP.664 trimer in complex with CH235.12 Fab)	Donor CH505 	CH235	Bonsignori2016(26949186) 	Antibody-driven selection in donor CH505;Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CVRNVGTAGSLLHYDHW	25.7		3-15*01	1*01	8		12.9		K	Yes	Natural monoclonal	human	CH557	 	1.00319	6.97703	819	225	3292
CH235.9	gp120 CD4bs	5F9O(CH235.09 in complex with HIV-1 clade AE 93TH057 gp120);EMD-8080(B41 SOSIP.664 trimer in complex with CH235.9 Fab);EMD-8081(BG505 SOSIP.664 trimer in complex with CH235.9 Fab)	Donor CH505 	CH235	Bonsignori2016(26949186) 	Antibody-driven selection in donor CH505;Electrostatic interactions with D368	Bonsignori2016(26949186) 	Cloanalyst	1-46*01	3-10*01	4*02	15	CVRNVGTAGSLLHYDHW	19.6		3-15*01	1*01	8		2.8		K		Natural monoclonal	human	CH235.09, CH493	 	6.24706	6.05784	199	224	3291
CH235-L47W(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	68.2638	3.75302	13	732	4421
CH235-Q23K(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	37.0384	5.53909	13	734	4423
CH235-Q46E(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	33.8719	5.91156	13	735	4424
CH235-R57S(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	80.6445	2.10685	13	736	4425
CH235-T19K(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	41.0872	4.97077	16	731	4420
CH235-W55G(HC)	gp120 CD4bs		Donor CH505 	CH235	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 	72.9702	2.97905	13	733	4422
CH27	gp120 CD4bs		CH0457 	CH27	Moody2015(26355218) 																			Natural monoclonal	human		 	32.1877	9.71576	52	245	3242
CH28	gp120 CD4bs		CH0457 	CH27	Moody2015(26355218) 	Mutation decreases binding to CD4BS mAbs																		Natural monoclonal	human		 	10.2164	18.223	48	246	3243
CH44	gp120 CD4bs		CH0457 	CH27	Moody2015(26355218) 	Signature Analysis Summary																		Natural monoclonal	human		 	12.6426	13.6918	48	247	3245
CH45	gp120 CD4bs		CH0457 	CH13	Moody2015(26355218) 																			Natural monoclonal	human		 	65.2365	3.88002	48	253	3240
CH48	gp120 V3 // V3 glycan (V3g)		CH0457 		Moody2015(26355218) 																			Natural monoclonal	human		 	42.3533	9.47883	52	255	3246
CH58	gp120 V2 // V2 glycan(V2g) // V2 apex	4HPO(RV144-elicited antibody CH58 in complex with V2 peptide);4HQQ(RV144-elicited antibody CH58)	347759 		Liao2013b(23313589) 	Contacts and binding of CH58 and CH59;Contacts of IGHV5-51 V2 antibodies	Liao2013b(23313589) 		5-51	3-22	4	19		1.9		6-57	3	9		1.9		L	Yes	Natural monoclonal	human		 	87.5168	1.61731	18	622	3019
CH59	gp120 V2 // V2 glycan(V2g) // V2 apex	4HPY(RV144-elicited antibody CH59 in complex with V2 peptide)	347759 		Liao2013b(23313589) 	Contacts and binding of CH58 and CH59	Liao2013b(23313589) 		3-9	1-26	4	13		2.8		3-10	3	11		0.9		L	Yes	Natural monoclonal	human		 			10	623	3020
CH98	gp120 CD4bs		CH5329 		Bonsignori2014(24614107) 	Mutation decreases binding to CD4BS mAbs	Bonsignori2014(24614107) 	SoDA	3-20	1-IR1	4	21		25.3		2-23	3	12		15.8		L		Natural monoclonal	human		 	10.0009	10.7667	42	99	3052
D5	gp41 five-helix bundle (one CHR of six helix bundle missing);gp41 NHR (N-heptad repeat);gp41 six-helix bundle	2CMR(HIV-1 neutralizing antibody D5 Fab bound to the gp41 inner-core mimetic 5-helix)			Miller2005(16203977) 																			Natural monoclonal	human	5H/I1-BMV-D5	 	82.7424	1.76199	19	864	1710
D5_AR	gp41 NHR (N-heptad repeat)				Rubio2021(33980592) 																			Engineered monoclonal	human	D5_H011_L0	 	31.0966	2.70808	21	865	4657
D7	gp120 CD4bs		llama#44 		Forsman2008(18842738) 																			Fab or heavy-chain-only	llama	VHH D7	 	45.9572	6.12633	63	191	1861
DF1W-a.01	fusion peptide // near gp41-gp120 interface	6MPH(DF1W-a.01, elicited by vaccination of Rhesus macaques, in complex with stabilized HIV-1 Env BG505 DS-SOSIP, which was also bound to antibodies VRC03 and PGT122);6MQM(DF1W-a.01 in complex with HIV fusion peptide)	DF1W 	DF1W-a	Kong2019(31348886) 	DF1W-a.01 neutralization-associated sites	Kong2019(31348886) 	IgBlast IMGT/V-QUEST				10	CAREGPEDFDVW	13.7				9	CGQGVHLPRTF	4.3		K		Natural monoclonal	macaque		 	37.9045	6.84128	417	818	4508
DF1W-a.02	fusion peptide // near gp41-gp120 interface		DF1W 	DF1W-a	Kong2019(31348886) 																	K		Natural monoclonal	macaque		 	46.2556	5.38634	417	819	4509
DFPH-a.01	fusion peptide // near gp41-gp120 interface		DFPH 	DFPH-a	Kong2019(31348886) 	DFPH-a.01 neutralization-associated sites	Kong2019(31348886) 	IgBlast IMGT/V-QUEST				20	CSSRAKIYFAVGYDSGGRIDVW	10.7				9	CQQDYSFPLTF	4.9		K		Natural monoclonal	macaque		 	12.9771	7.07928	417	823	4513
DFPH-a.03	fusion peptide // near gp41-gp120 interface		DFPH 	DFPH-a	Kong2019(31348886) 																	K		Natural monoclonal	macaque		 	23.1555	6.55029	417	824	4514
DFPH-a.15	fusion peptide // near gp41-gp120 interface	6MQE(DFPH-a.15 in complex with HIV fusion peptide);6N1W(DFPH-a.15 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122)	DFPH 	DFPH-a	Kong2019(31348886) 	DFPH-a.15 contacts;DFPH-a.15 neutralization-associated sites																K		Natural monoclonal	macaque		 	23.7362	6.48896	417	825	4515
DH270.1	gp120 V3 // V3 glycan (V3g)	5U0U(DH270.1 (unliganded, single-chain Fv))	CH848 	DH270	Bonsignori2017(28298420) 	V3 Signature Analysis Summary	Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	TTGGWIGLYSDTSGYPNFDY	5.5	14.2	2-23*02	2*01	10	CSYAGSSIIF	6.3	10	L		Natural monoclonal	human	DH270	 	10.6907	17.4537	415	293	3643
DH270.2	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	AKAGYIALYVDYSGYPNFNS	12.1	21.3	2-23*02	2*01	10	CSYAGSSTVI	3.9	6.4	L		Natural monoclonal	human	DH473	 	1.87215	24.245	38	296	3649
DH270.3	gp120 V3 // V3 glycan (V3g)	5TPL(DH270.3 unliganded);6CBJ(DH270.3 Fab in complex with Man9)	CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWISLYVDYSYYPNFDS	12.6	21.3	2-23*02	2*01	10	SSSTNSATVI	8.2	14.5	L		Natural monoclonal	human	DH391	 	14.1611	14.7117	27	297	3650
DH270.4	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGGWISPYYDSSYYPNFDH	11.6	22	2-23*02	2*01	10	CSFGGSATVV	8.8	14.5	L		Natural monoclonal	human	DH429	 	0.73671	31.5641	48	298	3651
DH270.5	gp120 V3 // V3 glycan (V3g)	5TPP(DH270.5 (unliganded))	CH848 	DH270	Bonsignori2017(28298420) 	V3 Signature Analysis Summary	Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGAWISDYYDSSYYPNFDH	11.8	20.5	2-23*02	2*01	10	CSFGGSAAVV	12.4	20	L		Natural monoclonal	human	DH471	 	5.93299	24.2443	415	294	3652
DH270.6	gp120 V3 // V3 glycan (V3g)	5TQA(DH270.6 (unliganded));6CBP(DH270.6 bnAb in complex with the Man9-V3 glycopeptide)	CH848 	DH270	Bonsignori2017(28298420) 	hypervariable loop characteristic correlations with bNAb sensitivity;V3 Signature Analysis Summary	Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	TTGGWISGYYDSSYYPNFDH	12.3	22	2-23*02	2*01	10	CSFGGSATVV	11.8	15.5	L		Natural monoclonal	human	DH542	 	2.71164	35.2194	428	295	3922
DH270 IA1	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	VTGGWISPYYDSSYYPNFDH	8.7	17.3	2-23*02	2*01	10	CSFGGSATVV	7.9	12.7	L		UCA or intermediate	human	DH270 I1	 	0.79309	34.2106	27	299	3645
DH270 IA2	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ATGGWIGLYYDSSGYPNFDY	1.8	5.5	2-23*02	2*01	10	CSYAGSSTVI	1.8	2.7	L		UCA or intermediate	human	DH270 I2	 	8.21191	19.2654	38	300	3646
DH270 IA3	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWIGLYVDYSGYPNFDS	4.2	8.7	2-23*02	2*01	10	CSYAGSSTVI	1.2	1.8	L		UCA or intermediate	human	DH270 I3	 	19.1294	10.6103	27	301	3647
DH270 IA4	gp120 V3 // V3 glycan (V3g)		CH848 	DH270	Bonsignori2017(28298420) 		Bonsignori2017(28298420) 	Cloanalyst	1-2*02	3-22*01	4*02	20	ARGGWIGLYYDSSGYPNFDY	1	3.1	2-23*02	2*01	10	CSYAGSSTVI	0.6	0.9	L		UCA or intermediate	human	Dh270 I4	 	62.349	3.85642	27	302	3648
DH511.1	gp41 MPER (membrane proximal external region)	5U3J(DH511.1 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*04	24	TADLGEPVVSRFFEWGSYYYYMDL	15.7	17.7	1-39*01	2*01	11	QEAYSSTPTLT	16.3	17.6	K		Natural monoclonal	human	DH511	 	0.62322	6.66116	73	314	3847
DH511.11P	gp41 MPER (membrane proximal external region)	5U3M(DH511.11P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TADEGAPILRFFEWGYYNYYMDV	10.6	20.7	1-39*01	2*01	11	QESYSSVPMYI	15.5	18.2	K		Natural monoclonal	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.	0.64487	5.30457	433	319	3856
DH511.12P	gp41 MPER (membrane proximal external region)	5U3N(DH511.12P Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TADEGAPILRFFEWGYYNYYMDV	11.2	21.8							K		Natural monoclonal	human		 DH511.12P heavy chain was paired with the DH511.11P light chain.  Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.	0.5949	5.17193	433	320	3857
DH511.2	gp41 MPER (membrane proximal external region)	5U3K(DH511.2 Fab in Complex with HIV-1 gp41 MPER 662-683 Peptide);5U3L(DH511.2 Fab in Complex with HIV-1 gp41 MPER 670-683 Peptide)	CH0210 	DH511	Williams2017(28783671) 	DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary	Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	4-4*01	6*03	23	TMDEGTPVTRFLEWGYFYYYMAV	17.6	27.5	1-39*01	2*03	11	QENYNTIPSLS	14	20.7	K		Natural monoclonal	human	Ab510049, DH512	 	1.01851	6.03869	1742	313	3656
DH511.2_K3	gp41 MPER (membrane proximal external region)	5U3O(DH511.2_K3 Fab in Complex with HIV-1 gp41 MPER Peptide)	CH0210 	DH511	Williams2017(28783671) 	DH511.2 and DH511.2_K3 contacts;Signature Analysis Summary	Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	4-4*01	6*03	23	TMDEGTPVTRFLEWGYFYYYMAV			1-39*01	2*01	11	QESYSSTPTHI			K		Engineered monoclonal	human	DH511.2 K3, DH511 K3	chimeric: heavy chain from DH511.2 + light chain from DH511.8P 	0.34124	5.79184	832	321	3657
DH511.3	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TADLGEAVVSRFFEWGSYYYYMDF	16	18.7	1-39*01	2*01	11	QEAYSSTPTLT	17.1	19.6	K		Natural monoclonal	human	DH513	 	1.28786	6.73283	73	315	3848
DH511.4	gp41 MPER (membrane proximal external region)	5U3P(DH511.4 Fab)	CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TRDEGAPVTRFLEWGSYYYYMAV	21.4	26.5	1-39*01	2*01	11	QEAYNTNPTLS	15.9	21.7	K		Natural monoclonal	human	DH514	 	1.78849	4.40134	73	316	3849
DH511.5	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TRDEGAPVTRFLEWGSYYYYMAV	21.8	29.5	1-39*01	2*01	11	QEAYNTYPTLS	17.1	22.7	K		Natural monoclonal	human	DH515	 	1.52602	5.60216	73	317	3850
DH511.6	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	ARGTGVVVGGSWTVPPGMAYYLDV	16	17.7	1-39*01	2*03	11	QEAYSSTPTLS	17.6	21.7	K		Natural monoclonal	human	DH516	 	1.34659	8.10451	73	318	3851
DH511_I1	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TRDEGAPVTRFLEWGSYYYYMAV	17	23.6	1-39*01	2*01	11	QEAYNTNPTLS	14	18.6	K		UCA or intermediate	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	573	4185
DH511_I2	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	23	TTDEGAPVTRFLEWGYYYYYMAV	6.1	13.8	1-39*01	2*01	11	QETYNTTPTLT	7.2	12.4	K		UCA or intermediate	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	574	4186
DH511_I3	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TADLGEAVVSRFFEWGSYYYYMDF	15.6	17.7	1-39*01	2*01	11	QEAYSSTPTLT	16.7	19.6	K		UCA or intermediate	human		 bSomatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	575	4187
DH511_I4	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TADLGEAVVSRFFEWGSYYYYMDF	15.6	17.7	1-39*01	2*01	11	QEAYSSTPTLT	16.7	19.6	K		UCA or intermediate	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	576	4188
DH511_I5	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TADLGEAVVSRFFEWGSYYYYMDF	15.3	16.7	1-39*01	2*01	11	QEAYSSTPTLT	15.5	17.6	K		UCA or intermediate	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	577	4189
DH511_I6	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TTDLEGAPVSRFLEWGYYYYYMDV	12	4.1	1-39*01	2*01	11	QETYSTTPTFT	3.8	6.2	K		UCA or intermediate	human		 Somatic mutations were determined over the entire variable region and are reported as the number/frequency of nucleotides or amino acids that differed from the putative germ line V-gene sequence.			12	578	4190
DH511_UCA	gp41 MPER (membrane proximal external region)		CH0210 	DH511	Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	24	TTDLEGAPVLRFLEWGYYYYYMDV	0	0	1-39*01	2*01	11	QQSYSTPPTCT	0		K		UCA or intermediate	human		 Unmutated Common Ancestor of DH511 lineage.  Other lineage members are compared to this Ab's germline sequence.			12	572	4191
DH517	gp41 MPER (membrane proximal external region)		CH0210 		Williams2017(28783671) 		Williams2017(28783671) 	IMGT/V-QUEST	4-34*01	3-16*01	6*01	24	ARGTGVVVGGSWTVPPGMAYYLDV	18.1	35.1	3-39*01	2*01	12	ASRDRSGDRLGV	13.4	23	L		Natural monoclonal	human	Ab510053	 	17.394	9.28817	64	322	3665
DH563	gp120 V3 // V3 glycan (V3g)		CH765 	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		21		3-20	4	9		14		K		Natural monoclonal	human	CH765-DH563	 	28.4967	3.61814	30	310	3821
DH576	gp120 CD4bs	5UIX(DH576 CD4bs Fab)	3043 		Easterhoff2017(28235027) 		Easterhoff2017(28235027) 	Cloanalyst	3-30	3	6	23	ARDRARSTGYFGGIYYYYYGMDV	7.33		1-33	2			3.79		K	No	Natural monoclonal	human		 			9	748	3837
DH583	gp120 CD4bs		3070 		Easterhoff2017(28235027) 		Easterhoff2017(28235027) 	Cloanalyst	5-51		6	23	AVYYCQQYYATPYTFGQGTKVEI	4.68		4-1	2					K	Yes	Natural monoclonal	human		 			11	749	3807
DH650.8	gp120 CD4bs	6XCJ(DH650 Fab from a Rhesus Macaque in Complex with HIV-1 gp120 Core)	RM6072 		Roark2021(33214287) 		Roark2021(33214287) 	IMGT/V-QUEST				14	CARGQLELTASRFDK	4.9				9	CMQGLAFPYSF	4.6		K		Natural monoclonal	macaque		Macaque antibody 	97.4902	1.32261	123	816	4555
DH651.1	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	670	4268
DH651.2	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			36	671	4269
DH651.3	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	672	4270
DH651.4	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			36	673	4271
DH651.5	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	674	4272
DH651.6	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	675	4273
DH651.7	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	676	4274
DH651.8	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	677	4275
DH651.9	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Bonsignori2018(30552024) 																	K		Natural monoclonal	human		 			24	678	4276
DRVIA1	gp120 CD4bs		DRVI01 	DRVIA1-6b	Kong2016(27067056) 		Kong2016(27067056) 	IMGT/V-QUEST	1-18*01	3-22*01	4*02	19		3.8		1-39*01	4*01	9		3.6		K		Natural monoclonal	human		 			8	488	3492
DRVIA3	gp120 CD4bs		DRVI01 	DRVIA1-6b	Kong2016(27067056) 		Kong2016(27067056) 	IMGT/V-QUEST	1-18*01	3-22*01	4*02	19		3.1		1-39*01	4*01	9		4		K		Natural monoclonal	human		 	78.3911	3.21425	24	489	3493
DRVIA4	gp120 CD4bs		DRVI01 	DRVIA1-6b	Kong2016(27067056) 		Kong2016(27067056) 	IMGT/V-QUEST	1-18*01	3-22*01	4*02	19		6.3		1-39*01	4*01	9		4.8		K		Natural monoclonal	human		 			8	490	3494
DRVIA6b	gp120 CD4bs		DRVI01 	DRVIA1-6b	Kong2016(27067056) 		Kong2016(27067056) 	IMGT/V-QUEST	1-18*01	3-22*01	4*02	19		3.8		1-39*01	4*01	9		3.6		K		Natural monoclonal	human		 			8	491	3495
DRVIA7	gp120 CD4bs	5CD3(Immature DRVIA7);5CD5(Immature DRVIA7 bound to clade A/E HIV-1 gp120 core);EMD-6372(JRFL Env SOSIP.664 in complex with DRVIA7);EMD-6373(JRFL Env SOSIP.664 in complex with hybrid antibody DRVIA7/VRC01)	DRVI01 		Kong2016(27067056) 	DRVIA7 contacts	Kong2016(27067056) 	IMGT/V-QUEST	1-2*02	1-7*01	5*02	11	SRTKDYDWDFV	19		1-5*03	1*01	5	QQFEE	17		K		Natural monoclonal	human	A7	 	30.9708	9.14724	85	258	3489
DRVIA7H-VRC01L	gp120 CD4bs		DRVI01 NIH45 		Kong2016(27067056) 																	K		Engineered monoclonal	human	DRVIA7H+ VRC01L	 	4.07941	9.45761	51	486	4091
E51	gp120 CCR5bs;gp120 CD4i	1RZF(Human anti-HIV-1 GP120-reactive antibody E51)	AC01 		Xiang2003(14592765) 																	L	Yes	Natural monoclonal	human		 			4	751	1254
E70	gp41-gp120 interface	6P62(HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding);EMD-20259(HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding);EMD-20273(Negative-stain reconstruction of HIV-1 Env BG505 NFL CC+ trimer in complex with rabbit antibody E70 fragment antigen binding)	C3 		Dubrovskaya2019(31732167) 	E70 contacts																K		Natural monoclonal	rabbit		 	24.9172	13.3709	40	765	4478
F105	gp120 CD4bs	1U6A(Fab F105);3HI1(gp120 (core with V3) complex with F105)			Posner1991(1710248) 	mutations affecting F105 binding;mutations affecting F105 binding;Mutations at the trimer apex that affect sensitivity	Gach2013(23991039) 		4-59*01			15	GPVPAVFYGDYRLDP			3-20*01		9	QQYDNSVCT			K	Yes	Natural monoclonal	human	F-105	 	75.1169	3.12222	672	74	631
F2			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*01	3-22*01	3*01	17	TRAYHYDTTIGLGAMDV	18.06		4-1*01	3*01	9	HQYHSTPIS	9.93		K		Natural monoclonal	human		 	39.5362	9.9704	14	561	4171
F4			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*11	3-22*01	3*01	17	ARAYYYDSTIGLGAMDV	16.32		4-1*01	3*01	9	HQFHSTPVT	8.87		K		Natural monoclonal	human		 	27.6318	16.9226	14	564	4174
F425 B4e8	gp120 V3 // V3 glycan (V3g)	2QSC(Fab F425-B4e8 in complex with a V3-peptide)			Cavacini2003(12646791) 	Mutations at the trimer apex that affect sensitivity																		Natural monoclonal	human	B4e8, F425, F425b, F425-B4e8, F425B4e8	 			21	548	1379
F6	gp120		GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	4-34*01	2-8*01	6*01	18	ARWRLMMVDEVTRHGMDV	16.14		2-28*01	2*02	9	LQTRQGAFT	11.83		K		Natural monoclonal	human		 	30.2306	3.85063	37	567	4177
F8			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*11	3-22*01	3*01	17	ARAYYYDTSIGLGAMDV	14.58		4-1*01	3*01	9	HQFHSSPVT	7.8		K		Natural monoclonal	human		 	32.9787	15.9841	14	565	4175
gVRC-H1dC38/VRC01L	gp120 CD4bs		C38 NIH45 		Zhu2013a(24106303) 		Zhu2013a(24106303) 	IMGT/V-QUEST	1-02*02	2-21*01	5*02	12	ARGFGGSDWSFL									K		Engineered monoclonal	human		chimeric 	1.52584	11.0448	306	150	3118
H6			GX2016EU04 		Ju2018(30382080) 		Ju2018(30382080) 	IMGT/V-QUEST	1-69*01	3-22*01	3*01	17	ARAYYYDTATGLGSMDV	17.01		4-1*01	3*01	9	HQYHSTPIS	11.7		K		Natural monoclonal	human		 	47.919	6.13045	14	562	4172
HG107	gp120 V2 // V2 glycan(V2g) // V2 apex		200134 		Liao2013b(23313589) 		Liao2013b(23313589) 		3-9	2-2	4	14		2.3		3-10	1	10		0.9		L	Yes	Natural monoclonal	human		 			2	624	3021
HG120	gp120 V2 // V2 glycan(V2g) // V2 apex		302689 		Liao2013b(23313589) 		Liao2013b(23313589) 		3-23	5-5	4	13		1.6		3-10	2	10		0.3		L	Yes	Natural monoclonal	human		 			2	625	3022
HGN194	gp120 V3 // V3 glycan (V3g)		VI3265 		Corti2010(20098712) 	HGN194 epitope																		Natural monoclonal	human		 	41.2735	8.6293	106	89	2459
HJ16	gp120 CD4bs	4YE4(Neutralizing Antibody HJ16 in Complex with HIV-1 gp120)	VI3208 		Corti2010(20098712) 	HJ16 binding requires N276;HJ16 contacts;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary	Klein2013(23540694) 	IgBlast	3-30	3-3	2					4-1	4					K		Natural monoclonal	human	HJ16_22	 Wu2011 %SHM calculated for heavy chain = VH and light chain = VL.	18.844	15.5049	1078	88	2460
							Wu2011(21835983) 	IgBlast	3-30*18						45.9	4-1*01					30.4			
							Zhu2011(21880764) 					19												
HK20	gp41 NHR (N-heptad repeat)	2XRA(HK20 Fab in complex with a gp41 mimetic 5-Helix)	VI3081 		Corti2010(20098712) 	HK20 contacts																	Yes	Natural monoclonal	human		 	94.9494	1.2932	141	90	2461
IA-Hu5A8	non-HIV: host CD4R				Wu2018(29461979) 																			Engineered monoclonal	human	IA-iMab	iMab variant that includes ImmunoAdhesin 	0.08637	7.42203	40	618	3914
IA-PGT128	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128																				Engineered monoclonal			Engineered form of PGT128 that includes ImmunoAdhesin 	0.91676	32.6088	40	617	3913
iMab	non-HIV: host CD4R	3O2D(CD4 in complex with a potent antiviral antibody)																							humanized mouse	5A8, Hu5A8, ibalizumab, TMB-355, TNX-335	iMab is an anti-CD4 receptor antibody (not anti-HIV) 	0.094634	9.33202	295	376	3410
iMab-CAP256	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		CAP256 		Moshoette2019(31703699) 																			Engineered monoclonal	human;humanized mouse		bispecific 	0.0017699	14.8957	20	698	4293
iMab-N6	gp120 CD4bs;non-HIV: host CD4R		Z258 		Moshoette2022(36071449) 																			Engineered monoclonal	human;humanized mouse		bispecific 	0.047116	3.13508	21	699	4294
IOMA	gp120 CD4bs	5T3X(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);5T3Z(Fully and Natively Glycosylated BG505 SOSIP.664 HIV-1 Env Trimer in Complex with Antibodies IOMA and 10-1074);6CHB(A natively-glycosylated BG505 SOSIP.664 HIV-1 Envelope Trimer in complex with the broadly-neutralizing antibodies BG18 and IOMA)	R1 		Gristick2016(27617431) 	IOMA contacts	Gristick2016(27617431) 	IgBlast	1-2*02			16	EMFDSSADWSPWRGMVA			2-23*02		8	YSYADGVAF			L		Natural monoclonal	human	IOMA.25	 	12.8509	10.7645	654	309	3720
J3	gp120 CD4bs	7LPN(llama J3 VHH antibody in complex with HIV-1 Env BG505 DS-SOSIP.664);7RI1(llama VHH antibody J3 in complex with HIV-1 C1086 gp120)	llama#8 		McCoy2012(22641382) 																			Fab or heavy-chain-only	llama	J3 VHH, L8CJ3	llama antibody 	0.45597	9.69278	574	193	3216
JM2	gp120 CD4bs				Matz2013(23152508) 																			Fab or heavy-chain-only	llama		llama antibody 	41.385	5.39358	20	131	3055
JM3	gp120-CD4 complex				Matz2013(23152508) 																			Fab or heavy-chain-only	llama		llama antibody 	17.5591	5.39603	22	132	3056
JM4	gp120 CD4bs;gp120 CD4i	4LAJ(JM4 in complex with YU2 gp120 and CD4-mimetic miniprotein M48U1)			Matz2013(23152508) 																			Fab or heavy-chain-only	llama	JM4sdAb, JM4SdAb	llama antibody 	15.086	9.38502	67	133	3053
JM4-IgG2b	gp120 CD4bs;gp120 CD4i				Acharya2013(23843638) 																			Fab or heavy-chain-only	llama		llama antibody 	0.27111	11.9335	195	135	3105
JM4-IgG3	gp120 CD4bs;gp120 CD4i				Acharya2013(23843638) 																			Fab or heavy-chain-only	llama		llama antibody 	0.71993	8.96791	30	136	3106
JM5	gp120-CD4 complex				Matz2013(23152508) 																			Fab or heavy-chain-only	llama		llama antibody 	44.7172	4.30427	21	134	3057
KD-247	gp120 V3 // V3 glycan (V3g)	3NTC(KD-247 Fab)			Eda2006a(16699036) 	KD-247 epitope																	Yes	Natural monoclonal	humanized mouse		mouse antibody 	43.4529	7.05055	48	198	1593
LM52	non-HIV: host CD4R				Song2013(24097413) 																				humanized mouse		LM52 is a variant form of iMab (anti-CD4 receptor antibody, not anti-HIV). 	0.013633	1.82765	236	747	4472
LN01	gp41 MPER (membrane proximal external region)	6SNC(LN01 Fab in complex with an HIV-1 gp41 peptide);6SND(LN01 Fab in complex with an HIV-1 gp41 peptide);6SNE(LN01 Fab in complex with an HIV-1 gp41 peptide)	SA003 		Pinto2019(31653484) 	LN01 contacts	Pinto2019(31653484) 	IMGT/V-QUEST	4-39*07	3-3*01	2*01	20	VRMPSHGFWSGYFSYWYFDL		28	1-39*01	1*01	9	QQSYSTPWT		27	K	Yes	Natural monoclonal	human		 	1.36778	7.16531	236	497	4140
LSEVh-LS-F	gp120 CD4bs;gp120 CD4i CoRbs (Cluster C)				Kong2018(29762173) 																		Yes	Other	human		 			7	850	4595
M1214_N1	gp120 V2V5 corridor	6VU2(M1214_N1 Fab structure);6VY2(M1214_N1 Fab in complex with CH505 TF chimeric SOSIP.664 Env trimer);EMD-21456(Cryo-EM structure of M1214_N1 Fab in complex with CH505 TF chimeric SOSIP.664 Env trimer)	M1214 	M1214-lin1	Jia2020(32315598) 	M1214_N1 contacts	Jia2020(32315598) 	IMGT/V-QUEST	3-66			18	ELREAWYGDLRDYSGLDV	35		2-11		11	AVYAGGFTFPR	24		L		Natural monoclonal	human		 	3.52279	33.9676	120	777	4536
M1214_N1.2	gp120 V2V5 corridor		M1214 	M1214-lin1	Jia2020(32315598) 																	L		Natural monoclonal	human		 	5.89386	20.38	120	778	4537
M1214_N2	gp120 V3 // V3 glycan (V3g)		M1214 	M1214-lin2	Jia2020(32315598) 		Jia2020(32315598) 	IMGT/V-QUEST	4-34			11	IVSQVWGTLDL	30		2-24		9	MQGSEFPWT	17		K		Natural monoclonal	human		 	19.5062	20.9704	120	779	4538
M1214_N2.2	gp120 V3 // V3 glycan (V3g)		M1214 	M1214-lin2	Jia2020(32315598) 		Jia2020(32315598) 	IMGT/V-QUEST	4-34			11	VDPSRGGSFDL	27		2-24		9	MQGSQFPWT	20		K		Natural monoclonal	human		 	28.5335	15.8577	120	780	4539
M36/PRO-140	gp120 CD4i;non-HIV: host CCR5				Khan2018(29976677) 																			Engineered monoclonal	human;mouse	m36.4fv-PRO-140fv	bispecific 	0.011253	6.26089	107	422	3980
M4008_N1	gp120 V3 // V3 glycan (V3g)		M4008 	M4008	Jia2020(32315598) 	M4000_N1 contacts;Mutation affects M4008_N1 neutralization	Jia2020(32315598) 	IMGT/V-QUEST	1-69			17	LQCAGFSCEMDSGPFDLWGQGTQVTVPS	28		1-5		9	QQYYDSRET	24		K		Natural monoclonal	human		 	16.5467	14.4629	120	775	4527
M4008_N1.3_dIgA2	gp120 V3 // V3 glycan (V3g)		M4008 	M4008	Jia2020(32315598) 																	K		Engineered monoclonal	human		 	32.1582	8.89098	120	776	4528
m66	gp41 MPER (membrane proximal external region)	4NRX(m66 in complex with gp41 MPER peptide);4NRY(Antibody m66)	SC44 		Zhu2011(21880764) 	Mutation decreases binding of m66 and m66.6	Zhu2011(21880764) 		5-51*01	3-10*01	6*02	21	QNHYGSGSYFYRTAYYYAMD			1-39*01	3*01	9	QQSYNTPFT			K		Natural monoclonal	human		 	95.5721	1.41734	211	92	2663
m66.6	gp41 MPER (membrane proximal external region)	4NRZ(Antibody m66.6)	SC44 		Zhu2011(21880764) 	Mutation decreases binding of m66 and m66.6	Zhu2011(21880764) 		5-51*01	3-10*01	6*02	21	QNHYGSGSYFYRTAYYYAMD			1-39*01	3*01	9	QQSYSTPFT			K		Natural monoclonal	human	M66.6	 	60.0523	2.79623	335	91	2664
m66 G30(LC)K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66-G30K, m66 G30 LCK, m66G30 LCK, m66G30LCK	 	38.1883	3.21715	47	152	3120
m66 S28(LC)H	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66-S28H, m66 S28 LCH, m66S28 LCH, m66S28LCH	 	92.8194	1.38582	40	151	3119
m66 S28(LC)H-G30(LC)K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66-S28H-G30K, m66 S28 LCH-G30 LCK, m66S28 LCH-G30 LCK, m66S28LCH-G30LCK	 	33.5914	4.54709	40	154	3123
m66 S28(LC)H-G30(LC)K-S31(LC)K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66-S28H-G30K-S31K, m66 S28 LCH-G30 LCK-S31 LCK, m66S28 LCH-G30 LCK-S31 LCK, m66S28LCH-G30LCK-S31LCK	 	18.3974	4.06931	47	155	3124
m66 S31(LC)K	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66-S31K, m66 S31 LCK, m66S31 LCK, m66S31LCK	 	81.7427	1.64876	40	153	3121
m66 Y100e(HC)W	gp41 MPER (membrane proximal external region)		SC44 		Ofek2014(24335316) 																			Engineered monoclonal	human	m66 Y100e HCW, m66Y100e HCW, m66Y100eHCW, m66-Y100eW	 	50.6663	3.78111	47	156	3122
MEL-1842	gp120 CD4bs		Cow #1 		Heydarchi2022(35584627) 																	L		Fab or heavy-chain-only	cow		The light chain gene of MEL-1842 was not rescued, so it was produced using the MEL-2129 light chain. 	0.34016	108.455	94	601	4212
MEL-1872	gp120 CD4bs		Cow #1 		Heydarchi2022(35584627) 	Mutation affects binding or neutralization of MEL-1872																L		Fab or heavy-chain-only	cow		The light chain gene of MEL-1872 was not rescued, so it was produced using the MEL-2129 light chain. 	0.21885	113.074	94	600	4197
MEL-2129	gp120 CD4bs		Cow #1 		Heydarchi2022(35584627) 																	L		Natural monoclonal	cow		 	2.89666	54.3181	92	602	4213
Min12A21	gp120 CD4bs		Patient 12 	12A12	Jardine2016a(27560183) 		Jardine2016a(27560183) 		1-02*02			12	GKNCDYNWDFQH			1-33*01		5	QQYEF			K		Engineered monoclonal	human		 	3.99524	22.412	224	830	4181
Minimal BF520.1	gp120 V3 // V3 glycan (V3g)		BF520 	BF520	Simonich2019(31097697) 																	K		Engineered monoclonal	human	Minimal VH Minimal VK	 			13	710	4328
MinVRC01	gp120 CD4bs		NIH45 	VRC01	Jardine2016a(27560183) 		Jardine2016a(27560183) 		1-02*02			13	DESGDDLKWHLHP			3-11*01		5	AVFQW			K		Engineered monoclonal	human		 	0.75346	20.3587	230	829	4180
N49P11	gp120 CD4bs;gp120 CD4i		N49 	N49P6	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						35	2-11		5			30	L		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	1.19929	5.72401	234	507	4093
N49P18.1	gp120 CD4bs;gp120 CD4i		N49 	N49P6	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2							2-11						L		Natural monoclonal	human		Unpublished N49P18.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi	14.146	4.03303	234	510	4115
N49P19	gp120 CD4bs;gp120 CD4i		N49 	N49P6	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2							2-11						L		Natural monoclonal	human		Unpublished N49P19 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi	4.97479	10.9474	234	511	4116
N49P22			N49 		Sajadi2018(29731169) 																			Natural monoclonal	human		Unpublished N49P22 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) 	10.0963	11.606	234	513	4119
N49P23			N49 		Sajadi2018(29731169) 																			Natural monoclonal	human		Unpublished N49P23 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) 	0.89302	40.7691	234	512	4118
N49P6	gp120 CD4bs;gp120 CD4i;quaternary structure	6OZ2(N49P6 with HIV-1 strain 93TH057 gp120 core);6OZ4(N49P6 with HIV-1 BG505 SOSIP.664 Env trimer ectodomain)	N49 	N49P6	Sajadi2018(29731169) 	N49P6 contacts	Sajadi2018(29731169) 	SoDA	1-2			20	DRANGSGRRRFESVNWFLDL		42	2-11		5	WAFEN		28	L		Natural monoclonal	human		Structural analysis from Tolbert2021 (PMID 34281393) Sajadi2018 %SHM calculated for VH and VL+JL.	0.5532	8.55265	234	504	4090
N49P7	gp120 CD4bs;gp120 CD4i	6BCK(N49P7 with HIV-1 strain 93TH057 gp120 core)	N49 	N49P6	Sajadi2018(29731169) 	N49P7 contacts	Sajadi2018(29731169) 	SoDA	1-2			19	DRSNGSGKRFESSNWFLDL		38	2-11		5	WAYEA		31	L		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	0.32151	8.64383	889	505	3951
N49P7.1	gp120 CD4bs;gp120 CD4i		N49 	N49P6	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						38	2-11		5			31	L		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	0.20684	5.99105	234	506	4092
N49P7.2	gp120 CD4bs;gp120 CD4i		N49 	N49P6	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2							2-11						L		Natural monoclonal	human		Unpublished N49P7.2 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi	0.44283	11.4521	234	509	4112
N49P7.v2	gp120 CD4bs		N49 	N49P6	Kwon2021(34328065) 																	L		Engineered monoclonal	human		 	0.10327	5.71933	428	612	4234
N49P9	gp120 CD4bs		N49 	N49P9	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						38	2-23		5			42	L		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	0.28921	11.5878	234	508	4094
N49P9.1	gp120 CD4bs	6OZ3(N49P9.1 with HIV-1 strain 93TH057 gp120 core)	N49 	N49P9	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2							2-23						L		Natural monoclonal	human		Unpublished N49P9.1 info via personal communication (M. Sajadi) but isolated as described in Sajadi2018 (PMID 29731169) Unpublished germline gene usage provided by M. Sajadi	0.42484	12.5522	234	514	4117
N6	gp120 CD4bs	5TE4(N6 in Complex with HIV-1 Clade G Strain X2088 gp120 Core);5TE5(N6 in Complex with HIV-1 Clade AE Strain 93TH057 gp120 Core);5TE6(N6 in Complex with HIV-1 Clade C Strain DU172.17 gp120 Core)	Z258 	N6	Huang2016a(27851912) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects N6 neutralization;N6 alanine scanning;N6 contacts;Signature Analysis Summary	Huang2016a(27851912) 	IMGT/V-QUEST	1-2*02	2-21*02	6*01	13	CARDRSYGDSSWALDAWGQGTTVVVSA	31		1-33*01 or 1D-33*01	5*01	5	QVLQF	25		K		Natural monoclonal	human		 	0.075722	5.96311	1779	280	3509
N60P1.1	gp120 CD4bs	5WB9(N60P23 with 93TH057 gp120 core (N60P23 differs from N60P1.1 by 1 AA))	N60 	N60 lineage 1	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						36	1-5		5			26	K		Natural monoclonal	human		Structure 5WB9 is for mAb N60P23 which differs from N60P1.1 by 1 AA Sajadi2018 %SHM calculated for VH and VL+JL.	5.85446	11.1567	73	499	4095
N60P2.1	gp120 CD4bs		N60 	N60 lineage 1	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						38	1-5		5			29	K		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	9.93875	13.3704	73	500	4097
N60P22	gp120 CD4bs		N60 	N60 lineage 2	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	4-31						9	3-20		9			11	K		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	88.7001	1.78535	73	503	4100
N60P25.1	gp120 CD4bs		N60 	N60 lineage 1	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						33	1-5		5			26	K		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	3.49384	13.6202	72	501	4098
N60P31.1	gp120 CD4bs		N60 	N60 lineage 1	Sajadi2018(29731169) 		Sajadi2018(29731169) 	SoDA	1-2						42	1-5		5			35	K		Natural monoclonal	human		 Sajadi2018 %SHM calculated for VH and VL+JL.	43.0735	7.3424	73	502	4099
N6/10E8v4-PGDM1400	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84 Donor N152 Z258 		Xu2017(28931639) 																			Engineered monoclonal	human		trispecific involving N6, PGDM1400, and 10E8 	0.043305	6.74707	416	390	3957
N6_FR3-03	gp120 CD4bs	6NM6(BG505 SOSIP.664 Prefusion Env Trimer Bound to N6 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv)	Z258 	N6	Liu2019(30760721) 	Mutation affects neutralization by N6_FR3-03																K		Engineered monoclonal	human	N6-FR3 03	 	0.080594	7.24838	416	796	4572
N6-LS	gp120 CD4bs		Z258 	N6	Julg2017(28539448) 																	K		Engineered monoclonal	human		 	0.082206	5.06056	442	551	4162
N6-LS-N72Q-R18D	gp120 CD4bs		Z258 	N6	Chuang2020(33121334) 																	K		Engineered monoclonal	human		 	0.095107	5.33541	416	807	4575
N6/PGDM1400-10E8v4	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84 Donor N152 Z258 		Xu2017(28931639) 																			Engineered monoclonal	human	N6-LS/PGDM1400-10E8v4, N6/PGDM1400x10E8, PGDM1400/N6x10E8v4	trispecific involving N6, PGDM1400, and 10E8 	0.022389	6.53997	430	389	3956
NC37	quaternary structure		EB354 		Freund2017(28100831) 		Freund2017(28100831) 	IMGT/V-QUEST	1-2 or 1-46			19	DNFGTRPVPGRGYYYGMDV	28.8		3-20				27.9		K		Natural monoclonal	human	354NC37	 Freund2017 %SHM calculated for VH and VL only.	18.5195	15.2635	237	305	3621
NC-Cow1	gp120 CD4bs	6OO0(bovine Fab NC-Cow1);6OPA(NC-Cow1 Fab in complex with HIV-1 BG505 SOSIP.664 and human Fabs 35022 and PGT128);6PW6(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab);EMD-20500(BG505 SOSIP.664 in complex with 3 copies of NC-Cow1 Fab)	Cow #26 		Sok2017(28726771) 	Mutation affects NC-Cow1 binding or neutralization																		Natural monoclonal	cow		 	0.52253	44.4645	216	586	4198
NC-Cow10			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	0.46565	53.6086	23	595	4207
NC-Cow2	gp120 CD4bs		Cow #26 		Sok2017(28726771) 																			Fab or heavy-chain-only	cow		NC-Cow2 is an orphan heavy chain, paired with a germline light chain 	0.049206	13.527	23	587	4199
NC-Cow3			Cow #26 		Sok2017(28726771) 																			Fab or heavy-chain-only	cow		NC-Cow3 is an orphan heavy chain, paired with a germline light chain 	69.1312	2.84003	23	588	4200
NC-Cow4			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	33.0331	11.8105	23	589	4201
NC-Cow5			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	79.3854	2.11641	23	590	4202
NC-Cow6			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	35.7453	9.61165	23	591	4203
NC-Cow7			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	1.0281	62.7872	23	592	4204
NC-Cow8			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	1.0671	43.4132	23	593	4205
NC-Cow9			Cow #26 		Sok2017(28726771) 																			Natural monoclonal	cow		 	2.77506	21.5423	23	594	4206
NIH45-46	gp120 CD4bs	3U7W(Fab NIH45-46);3U7Y(Fab NIH45-46 complexed with gp120);4JDT(chimeric germ-line precursor of NIH45-46 Fab in complex with gp120 (93TH057));4JDV(germ-line precursor of NIH45-46 Fab);5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);5IGX(NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120)	NIH45 	VRC01	Scheid2011(21764753) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutations allowing binding of germline Abs;NIH45-46 contacts;NIH45-46 signature predictions;Signature Analysis Summary;Signature Analysis Summary	Klein2013(23540694) 	IgBlast	1-2	2-8 or 3-9	1					3-11	2					K	Yes	Natural monoclonal	human	45, 45-46	 	0.31734	15.5088	2300	1	2580
							Zhang2013(24100711) 	IMGT/V-QUEST	1-2*02	1-26	2*01	18				3D-15	2	5						
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			16	GKYCTARDYYNWDFEH			3-20*01	2*01	5	QQYEF					
							Scheid2011(21764753) 		1-2							3-11								
NIH45-46G54F	gp120 CD4bs		NIH45 	VRC01	Diskin2011(22033520) 																	K		Engineered monoclonal	human	45-46F	 	0.13264	26.3472	164	168	3165
NIH45-46G54W	gp120 CD4bs		NIH45 	VRC01	Diskin2011(22033520) 	NIH45-46G54W mutations causing resistance;NIH45-46(G54W) signature predictions;Signature Analysis Summary																K		Engineered monoclonal	human	45-46W, NIH45-46 G54W, NIH45-46W	 	0.080624	45.0024	646	2	2821
NIH45-46G54Y	gp120 CD4bs		NIH45 	VRC01	Diskin2011(22033520) 																	K		Engineered monoclonal	human	45-46Y	 	0.1378	23.9373	164	169	3166
NIH45-46WPY	gp120 CD4bs		NIH45 	VRC01		Signature Analysis Summary																K		Engineered monoclonal	human	NIH45-46-WPY	 	0.026926	16.037	118	439	4011
NIH45-46WY	gp120 CD4bs		NIH45 	VRC01		Signature Analysis Summary																K		Engineered monoclonal	human	NIH45-46-WY	 	0.028743	15.8862	118	440	4012
PCDN-33A	gp120 V3 // V3 glycan (V3g)		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs																		Natural monoclonal	human	33A	 	6.08665	25.6639	133	240	3388
PCDN-38A	gp120 V3 // V3 glycan (V3g)		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs	Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*01		5*01	22	ARGGRKICYDYWCGYVNNCFDT	16		3-20*01	1*01	8	QQCGSSPT	11		K		Natural monoclonal	human	38A, PCDN38A	 	13.1102	20.1397	133	241	3389
PCDN-38B	gp120 V3 // V3 glycan (V3g)		PC76 		MacLeod2016(27192579) 	Sites affecting neutralization of PCDN lineage mAbs																		Natural monoclonal	human	38B	 	7.50007	22.2127	133	242	3390
PCIN66B	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRRDTNWWLDP	9.59	18.42	1-5*03	1*01	5	QVLET	12.71	17.71	K		Natural monoclonal	human		 	4.65387	12.9274	145	831	4111
PCIN71B	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TTHSSSRDFQWSLDP	9.88	16.67	1-5*03	1*01	5	QVLET	11.04	16.67	K		Natural monoclonal	human		 	81.8744	3.43076	40	832	4123
PCIN71C	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRRDTNWWLDP	10.76	20.18	1-5*03	1*01	5	QVLET	12.37	18.75	K		Natural monoclonal	human		 	0.85957	11.6015	40	833	4124
PCIN71D2b	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRRDTNWWLDP	10.47	21.05	1-5*03	1*01	5	QVLET	12.71	19.79	K		Natural monoclonal	human		 	1.56612	12.0412	40	834	4125
PCIN71F	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRQQRDWWLDP	12.50	21.05	1-5*03	1*01	5	QVYES	11.04	18.75	K		Natural monoclonal	human		 	68.4587	3.95584	40	835	4126
PCIN71G	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDASRDDRAWRLDP	13.08	21.05	1-5*03	1*01	5	QVVEW	12.37	15.63	K		Natural monoclonal	human		 	1.20328	8.88337	145	836	4127
PCIN71H	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	ARDSSREETNWWLDP	13.08	21.93	1-5*03	1*01	5	QVLET	13.04	20.83	K		Natural monoclonal	human		 	1.25022	14.1086	40	837	4128
PCIN71I1a	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDASRDDRAWRLDP	13.66	21.05	1-5*03	1*01	5	QVFEW	13.04	17.71	K		Natural monoclonal	human	PCIN71I	 	0.79599	10.0571	145	838	4129
PCIN71J2a	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDASRDDRAWRLDP	10.76	20.18	1-5*03	1*01	5	QVLET	12.71	18.75	K		Natural monoclonal	human		 	0.97592	9.89338	40	839	4130
PCIN71K	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRDETNWWLDP	14.24	23.68	1-5*03	1*01	5	QVLET	13.04	18.75	K		Natural monoclonal	human		 	0.74257	11.9003	40	840	4131
PCIN71L	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRDETNWWLDP	14.24	24.56	1-5*03	1*01	5	QVLET	13.04	18.75	K		Natural monoclonal	human		 	1.04471	15.5751	145	841	4132
PCIN71M1a	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	ARDSSRDETNWWLDP	14.53	21.05	1-5*03	1*01	5	QVLET	12.37	18.75	K		Natural monoclonal	human		 	1.05043	12.8066	40	842	4133
PCIN71N1a	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRGNTEWRLDP	14.53	21.05	1-5*03	1*01	5	QVYQT	12.71	18.75	K		Natural monoclonal	human		 	100	1	40	843	4134
PCIN71O	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRDNLEWRLDP	15.99	23.68	1-5*03	1*01	5	QVFEW	12.71	15.63	K		Natural monoclonal	human		 	0.82024	6.53472	40	844	4135
PCIN71P	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRGDTEWRLDP	15.99	23.68	1-5*03	1*01	5	QVFEW	13.04	16.67	K		Natural monoclonal	human		 	1.36988	7.71059	40	845	4136
PCIN77B1b	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRDETNWWLDP	11.34	23.68	1-5*03	1*01	5	QVLET	12.71	19.79	K		Natural monoclonal	human		 	12.2046	10.3554	40	846	4137
PCIN77C	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	TRDSSRRDLEWRLDP	11.92	21.05	1-5*03	1*01	5	QVLET	13.71	19.79	K		Natural monoclonal	human		 	6.24267	16.5622	40	847	4138
PCIN77D	gp120 CD4bs		PC063 	PCIN63			Umotoy2019(31315032) 	IMGT/V-QUEST	1-02*02		5*02	15	ARDSSRDETNWWLDP	13.08	20.18	1-5*03	1*01	5	QAYES	12.37	19.79	K		Natural monoclonal	human		 	39.9006	7.23709	145	848	4139
PCT64-18B	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETKDFWGDDYGDYYDHYFIDV	8.62	16.38	3-20*01	3*01	8	RQYDTSFT	5.3	11.21	K		Natural monoclonal	human	PCT64 18B	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	44.1335	8.39332	37	339	3873
PCT64-18C	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYANYYDPYLIDV	9.77	15.52	3-20*01	3*01	8	RQYGTSFT	3.12	6.54	K		Natural monoclonal	human	PCT64 18C	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	77.3056	2.91181	37	340	3874
PCT64-18D	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDYYAQYYDPYLIDV	9.77	17.24	3-20*01	3*01	8	RQYGTSFT	4.36	8.41	K		Natural monoclonal	human	PCT64 18D	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	21.5607	17.099	146	341	3875
PCT64-18F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDYYAQYYDPYLIDV	10.63	17.24	3-20*01	3*01	8	RQYGTSFT	4.67	9.35	K		Natural monoclonal	human	PCT64 18F	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	34.8927	10.6058	37	342	3876
PCT64-24A	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYQYKYFWDV	9.48	17.24	3-20*01	3*01	8	QQYTSSCT	4.67	9.35	K		Natural monoclonal	human	PCT64 24A	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	44.5511	7.00016	37	343	3877
PCT64-24B	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYQYKYFWDV	9.48	17.24	3-20*01	3*01	8	QQYTSSCT	4.67	9.35	K		Natural monoclonal	human	PCT64 24B	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	48.978	6.20823	37	344	3878
PCT64-24E	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVESYDFWSDDYSQYDYTYLSDV	10.63	18.1	3-20*01	3*01	8	QQYSSSCT	4.36	8.41	K		Natural monoclonal	human	PCT64 24E	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	21.4424	16.4408	145	345	3879
PCT64-24F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDEYSQHYDPYLIDV	10.92	17.24	3-20*01	3*01	8	RQYDRSFT	6.54	11.21	K		Natural monoclonal	human	PCT64 24F	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	23.3356	17.7261	143	346	3880
PCT64-24G	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYSQHYNSYLIDV	11.21	18.97	3-20*01	3*01	8	RQYDTSFT	4.67	11.21	K		Natural monoclonal	human	PCT64 24G	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	36.6103	9.57143	37	347	3881
PCT64-24H	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVETGDFWSDDYSQHYNSYLIDV	11.21	18.97	3-20*01	3*01	8	RQYDTSFT	5.3	12.15	K		Natural monoclonal	human	PCT64 24H	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	48.4913	6.57433	37	348	3882
PCT64-35B	gp120 V2 // V2 glycan(V2g) // V2 apex	5FEH(PCT64_35B, a broadly neutralizing anti-HIV antibody)	PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.49	18.1	3-20*01	3*01	8	RQYETSFS	9.35	17.76	K		Natural monoclonal	human	PCT64 35B	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	22.2694	12.2215	145	349	3884
PCT64-35C	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.49	18.1	3-20*01	3*01	8	RQYETSFT	9.35	16.82	K		Natural monoclonal	human	PCT64 35C	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	28.4326	12.8153	37	350	3885
PCT64-35D	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.49	18.1	3-20*01	3*01	8	RQYETSFT	9.35	16.82	K		Natural monoclonal	human	PCT64 35D	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	19.795	12.9663	145	351	3886
PCT64-35E	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.49	18.1	3-20*01	3*01	8	RQYETSFT	9.35	16.82	K		Natural monoclonal	human	PCT64 35E	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	27.6653	13.9691	37	352	3887
PCT64-35F	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.78	18.97	3-20*01	3*01	8	RQYDTSFT	7.48	14.02	K		Natural monoclonal	human	PCT64 35F	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	34.1535	10.208	37	353	3888
PCT64-35G	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEKGDFWSDDYSQHYNTYLIDV	11.78	18.97	3-20*01	3*01	8	RQYETSFS	8.41	16.82	K		Natural monoclonal	human	PCT64 35G	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	26.0402	10.2531	145	354	3889
PCT64-35H	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGDFWSDDYSQHYNTYLIDV	12.07	18.97	3-20*01	3*01	8	RQYDTSFT	8.41	14.95	K		Natural monoclonal	human	PCT64 35H	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	41.4128	6.6585	37	355	3890
PCT64-35I	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGGFWSDEYSQHWDPYLIDV	12.07	19.83	3-20*01	3*01	8	RQYDTSFT	9.03	14.95	K		Natural monoclonal	human	PCT64 35I	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	85.5159	1.92827	37	356	3891
PCT64-35K	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	12.07	20.69	3-20*01	3*01	8	RQYETSFT	9.35	16.82	K		Natural monoclonal	human	PCT64 35K	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	39.2351	9.58151	37	357	3892
PCT64-35M	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 	PCT64-35M signature sites	Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	NTGVEWYDFWSDEYSQEETKYFKDV	12.36	19.83	3-20*01	3*01	8	QQYTRSCT	6.85	10.28	K		Natural monoclonal	human	PCT64 35M	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	7.43376	29.4003	353	358	3893
PCT64-35N	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	12.36	20.69	3-20*01	3*01	8	RQYDTSFT	7.48	14.02	K		Natural monoclonal	human	PCT64 35N	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	45.7088	7.35153	37	359	3894
PCT64-35O	gp120 V2 // V2 glycan(V2g) // V2 apex		PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVEAGDFWSDEYSQHYNTYLIDV	12.36	20.69	3-20*01	3*01	8	RQYDTSFT	7.79	13.08	K		Natural monoclonal	human	PCT64 35O	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	29.9539	10.9467	145	360	3895
PCT64-35S	gp120 V2 // V2 glycan(V2g) // V2 apex	6CA6(Crystal structure of PCT64_35S, a broadly neutralizing anti-HIV antibody.);EMD-7865(PC64M4C054.SOSIP in complex with PCT64-35S Fab)	PC64 	PCT64	Landais2017(29166592) 		Landais2017(29166592) 	IMGT/V-QUEST	3-15*01	3-3*01	6*03	25	MTGVERGDFWSDDYSQHYNTYLIDV	13.22	20.69	3-20*01	3*01	8	RQYETSFT	7.48	14.02	K		Natural monoclonal	human	PCT64 35S	 Landais2017 %SHM calculated for heavy chain = VH+JH; light chain = Vk+Jk..	19.0401	15.5769	146	361	3896
PG16	gp120 V2 // V2 glycan(V2g) // V2 apex	3LRS(Structure of PG16);3MME(Structure and functional dissection of PG16);3MUG(PG16 Fab);4DQO(Fab PG16 complexed with V1V2 region (ZM109))	Donor 24 	PG9	Walker2009a(19729618) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization of PGDM1400 and PG16;Mutation affects PG9-like Ab sensitivity;Mutations at the trimer apex that affect sensitivity;PG16 signature predictions;PG9-like antibodies require N160 for neutralization;PG9-like contacts;V2 Signature Analysis Summary	Klein2013(23540694) 	IgBlast	3-33	3-3	6					2-14	3					L	Yes	Natural monoclonal	human		 Wu2011: %SHM calculated for VH gene IGHV3-33*05 and VL gene IGLV2-14*01by IMGT/V-QUEST on nt sequences.	0.68333	39.3136	3506	10	2125
							Pancera2010(20538861) 	IMGT/V-QUEST JoinSolver	3-33*05	3-3*01	6*03					2-14*01	3*02							
							Walker2009a(19729618) 	IMGT/V-QUEST	3-33*05				EAGGPIWHDDVKYYDFNDGYYNYHYMDV			2-14*01			SSLTDRSHRIF					
							Wu2011(21835983) 							14.5	21.4					12.5	21.2			
PG16/10-1074	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17 Donor 24 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific 	0.26292	14.491	46	267	3514
PG16-iMab	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		Donor 24 		Pace2013a(23878231) 																			Engineered monoclonal	human;humanized mouse	PG16-ibalizumab	bispecific 	0.0047604	15.7096	252	201	3278
PG16/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 17 Donor 24 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific 	0.30227	19.4428	130	265	3512
PG16/PGT128	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g)		Donor 24 Donor 36 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific 	0.30595	20.1815	131	264	3513
PG9	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	3MUH(PG9 light chain);3U2S(Fab PG9 complexed with V1V2 region (ZM109));3U36(Fab PG9);3U4E(Fab PG9 complexed with V1V2 region (CAP45));5VJ6(BG505 SOSIP.664 in complex with PG9 and 8ANC195)	Donor 24 	PG9	Walker2009a(19729618) 	Disulfide bond introduced in V1V2 affects binding;Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;mutations affecting PG9 binding;Mutations at the trimer apex that affect sensitivity;PG9 contacts;PG9 contacts;PG9 escape mutations;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PG9 residue prediction;PG9 signature predictions;PG9 signature sites;V2 Signature Analysis Summary	Pancera2010(20538861) 	IMGT/V-QUEST JoinSolver	3-33*05	3-3*01	6*03					2-14*01	3*02					L	Yes	Natural monoclonal	human		 Wu2100: %SHM calculated for VH gene IGHV3-33*05 and VL gene IGLV2-14*01by IMGT/V-QUEST on nt sequences.	0.83952	23.0883	6586	9	2124
							Zhou2013a(23911655) 	IMGT/V-QUEST	3-33*05	1-1*01	6*03	30				2-14	3	10						
							Walker2009a(19729618) 	IMGT/V-QUEST	3-33*05				EAGGPDYRNGYNYYDFYDGYYNYHYMDV			2-14*01			KSLTSTRRRVF					
							Wu2011(21835983) 							14.9	18.8					10.1	14.1			
PG9/aplaviroc	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5		Donor 24 		Gavrilyuk2013(23427154) 																			Engineered monoclonal	human	PG9-aplaviroc	Conjugation of PG9 with aplaviroc, a small molecule that blocks CCR5. 	0.33288	7.99799	234	549	4161
PG9-iMab	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CD4R		Donor 24 		Pace2013a(23878231) 																			Engineered monoclonal	human;humanized mouse	PG9-ibalizumab	bispecific 	0.0073056	8.86025	266	200	3277
PG9-PG16-RSH	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 24 	PG9	Pancera2013(23708607) 		Pancera2010(20538861) 	IMGT/V-QUEST	3-33*05	3-3*01	6*03					2-14*01	3*02					L		Engineered monoclonal	human	PG9-16, PG916, PG9-16-RSH	chimeric 	0.2509	50.5214	440	103	3037
PGC14	gp120		Donor 24 		Walker2009a(19729618) 		Walker2009a(19729618) 	IMGT/V-QUEST	1-24*01				GAVGADSGSWFDP			3-1*01			AWETTTTTFVFF			L		Natural monoclonal	human		 	76.5847	2.73307	162	79	2128
PGDM11	gp120 V3 // V3 glycan (V3g)		Donor 14 		Sok2016(27438765) 																			Natural monoclonal	human		 	7.71323	21.8645	110	261	3502
PGDM12	gp120 V3 // V3 glycan (V3g)		Donor 14 		Sok2016(27438765) 																			Natural monoclonal	human		 	2.84353	33.9304	134	262	3503
PGDM1400	gp120 V2 // V2 glycan(V2g) // V2 apex	4RQQ(Fab PGDM1400)	Donor 84 	PGDM1400	Sok2014(25422458) 	Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization of PGDM1400 and PG16;Mutation causes resistance to V2 bnAbs;PGDM1400 lineage requires N160;PGDM signature sites;V2 Signature Analysis Summary	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFW			2-28	1	9	CMQGRESPWTF			K		Natural monoclonal	human		 	0.18886	61.1388	4788	174	3201
PGDM1400-LS	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 	PGDM1400																		K		Engineered monoclonal	human		 	0.13842	55.316	416	553	4164
PGDM1400/PRO-140	gp120 V2 // V2 glycan(V2g) // V2 apex;non-HIV: host CCR5		Donor 84 		Khan2018(29976677) 																			Engineered monoclonal	human;mouse	PGDM1400fv-PRO-140fv	 	0.032683	19.2107	107	423	3979
PGDM1401	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CARGSKHRLRDYVMYDDYGALQWAVYVDYLSNLDVW			2-28	1	9	CMQGRESPWTF			K		Natural monoclonal	human		 	0.29088	116.019	108	175	3203
PGDM1402	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CAKGSKHRLRDYALYDDIGALQWAVDVDYLSTLEFW			2-28	1	9	CMQGRESPWTF			K		Natural monoclonal	human		 	10.0606	17.8356	102	176	3204
PGDM1403	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	33	CVKGSKFRLREWADYNEWGLVSAQHGDYVTQLGIW			2-28	1	9	CMQGLQSPTTF			K		Natural monoclonal	human		 	6.3626	43.7463	98	177	3205
PGDM1404	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CVRGAKFRLRHDATYDYWNDLLWADDRDYVTQLDLW			2-28	1	9	CMQGRHIPLTF			K		Natural monoclonal	human		 	8.06011	47.5202	89	178	3206
PGDM1405	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		6	34	CVRGAKFRLRHDATYDYYNDLLWADDRDYVTQLDLW			2-28	1	9	CMQGRHIPLTF			K		Natural monoclonal	human		 	11.3345	50.3411	98	179	3207
PGDM1406	gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 84 		Sok2014(25422458) 	PGDM1400 lineage requires N160	Sok2014(25422458) 	IMGT/V-QUEST	1-8		1	33	CVKGQKFRLTEWADYNEFGLVAAQKGDYVTQLDVW			2-28	1	9	CMQGLRTPMTF			K		Natural monoclonal	human		 	53.9685	5.52324	89	180	3208
PGDM21	gp120 V3 // V3 glycan (V3g)	EMD-8182(PGDM21 in complex with BG505 SOSIP.664 trimer)	Donor 82 		Sok2016(27438765) 																			Natural monoclonal	human		 	4.44153	34.488	134	263	3506
PGT121	gp120 V3 // V3 glycan (V3g)	4FQ1(PGT121 Fab);4FQC(PGT121 Fab bound to a complex-type sialylated N-glycan);4FQQ(germline antibody PGT121-GL Fab);4JY4(Fab PGT121);5CEZ(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with an early putative precursor of the PGT121 family)	Donor 17 	PGT121	Walker2011(21849977) 	Disulfide bond introduced in V1V2 affects binding;hypervariable loop characteristic correlations with bNAb sensitivity;Key sites for PGT121-like and 10-1074-like mAbs;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT121 neutralization;mutations affecting neutralization by PGT121;mutations affecting PGT121 binding;mutations affecting PGT121 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 contacts;PGT121 contacts;PGT121 family and N137 glycan;PGT121 resistance;PGT121 signature predictions;V3 Signature Summary	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CARTLHGRRIYGIVAFNEWFTYFYMDVW	18	23	3-21	3*02	15	DYYCHIWDSRVPTKWVF	22	28	L	Yes	Natural monoclonal	human	PGT-121	 	0.65256	52.7237	7503	18	2635
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	TLHGRRIYGIVAFNEWFTYFYMDV	17	21	3-21*02	3*02	12	HIWDSRVPTKWV	18	30			
PGT121.414.LS	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121																				Engineered monoclonal	human		 	1.16397	66.6423	416	554	4165
PGT121GM	gp120 V3 // V3 glycan (V3g)		Donor 17 	PGT121	Mouquet2012a(23115339) 																			Engineered monoclonal	human		 	41.818	6.17672	26	363	3898
PGT122	gp120 V3 // V3 glycan (V3g)	4JY5(Fab PGT122);4NCO(BG505 in complex with Fab PGT122);4TVP(Env Trimer Ectodomain in Complex with Antibodies PGT122 and 35O22);5D9Q(BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46);5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYL(Clade A BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 and 35O22);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);5U7M(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-378806 in Complex with Human Antibodies PGT122 and 35O22);5U7O(BG505 SOSIP.664 Prefusion Env Trimer Bound to Small Molecule HIV-1 Entry Inhibitor BMS-626529 in Complex with Human Antibodies PGT122 and 35O22);5UTF(BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M in Complex with Human Antibodies PGT122 and 35O22);5UTY(DS-SOSIP.mut4 BG505 gp140 HIV-1 Env Trimer, Containing Mutations I201C-P433C (DS), L154M, N300M, N302M, T320L in Complex with Human Antibodies PGT122 and 35O22);6B0N(clade A BG505 isolate in complex with Fabs PGT122 and PGV19);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122)	Donor 17 	PGT121	Walker2011(21849977) 	mutations affecting PGT122 binding;mutations affecting PGT122 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;PGT122 glycan contacts;PGT122 neutralization	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CATTKHGRRIYGVVAFKEWFTYFYMDVW	19	25	3-21	3*02	15	DYYCHIWDSRRPTNWVF	18	26	L		Natural monoclonal	human	PGT-122	 	1.2886	45.8654	164	25	2636
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	TKHGRRIYGVVAFKEWFTYFYMDV	18	24	3-21*02	3*02	12	HIWDSRRPTNWV	19	26			
PGT123	gp120 V3 // V3 glycan (V3g)	4JY6(Fab PGT123)	Donor 17 	PGT121	Walker2011(21849977) 	Mutation greatly reduces PGT123 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT121 family and N137 glycan;V3 Signature Analysis Summary	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CARALHGKRIYGIVALGELFTYFYMDVW	20	27	3-21	3*02	15	DYYCHIYDARGGTNWVF	22	34	L		Natural monoclonal	human	PGT-123	 	0.99835	65.0371	455	26	2637
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-59*01		6*03	24	ALHGKRIYGIVALGELFTYFYMDV	21	27	3-21*02	3*02	12	HIYDARGGTNWV	24	38			
PGT124	gp120 V3 // V3 glycan (V3g)	4R2G(PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4);5T3S(trimer MD39-10MUTA in complex with Fabs PGT124 and 35022);5UM8(trimer 16055 NFL TD CC (T569G) in complex with Fabs 35022 and PGT124)	Donor 17 	PGT121	Walker2011(21849977) 	PGT121 family and N137 glycan	Sok2013(24278016) 	IMGT/V-QUEST	4-59		6*03	26	CATARRGWRIYGVVSFGEFFYYYYMDVW	15	21	3-21	3*02	15	DYYCHMWDSRSGFSWSF	19	35	L		Natural monoclonal	human	PGT-124	 	0.14027	19.4097	86	149	3115
PGT125	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT125 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT125 signature sites;V3 Signature Analysis Summary	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FDGEVLVYNHWPKPAWVDL	20	27	2-8*01	2*01 or 3*01	10	GSLVGNWDV	15	22	L		Natural monoclonal	human	PGT-125	 	3.1199	60.4455	421	27	2639
PGT126	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT126 and PGT127 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FDGEVLVYHDWPKPAWVDL	17	23	2-8*01	2*01 or 3*01	10	SSLVGNWDVI	9	13	L	Yes	Natural monoclonal	human	PGT-126	 	0.95081	46.7839	604	28	2640
PGT127	gp120 V3 // V3 glycan (V3g)	3TWC(PGT127 complexed with Man(9))	Donor 36 	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT126 and PGT127 neutralization;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;V3 Signature Analysis Summary	Zhang2013(24100711) 	IMGT/V-QUEST	4-61*05	3-16*02	5*02	25				2-8	3 or 2	10				L		Natural monoclonal	human	PGT-127	 	4.87851	37.5113	420	24	2641
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FGGEVLVYRDWPKPAWVDL	15	23	2-8*01	2*01 or 3*01	10	SSLVGNWDV	9	12			
PGT128	gp120 V3 // V3 glycan (V3g)	3TV3(PGT128 complexed with Man(9));3TYG(PGT128 complexed with glycosylated gp120);5ACO(PGT128 Fab in complex with BG505 SOSIP.664 Env trimer);5C7K(BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT128 and 8ANC195);5JS9(gp140 trimer with an engineered 8-residue HR1 turn bound to 8ANC195 and PGT128);5JSA(gp140 trimer with an engineered 10-residue HR1 turn bound to 8ANC195 and PGT128);6B3D(PGT128 in complex with a bacterially derived synthetic mimetic of Man9);6OPA(bovine Fab NC-Cow1 in complex with BG505 SOSIP.664 and human Fabs 35022 and PGT128)	Donor 36 	PGT128	Walker2011(21849977) 	hypervariable loop characteristic correlations with bNAb sensitivity;Mutation affects neutralization of V3 mAbs;Mutation greatly reduces PGT128 neutralization;mutations affecting PGT128 binding;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;PGT127, PGT128 contacts;PGT128 contacts;PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO);V3 Signature Analysis Summary	Klein2013(23540694) 	IgBlast	4-39	4-11 or 5-24 or 1-26	5					2-8	2 or 3					L		Natural monoclonal	human	PGT-128	 	0.84897	59.7007	3964	23	2642
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	FGGEVLRYTDWPKPAWVDL	19	28	2-8*01	2*01 or 3*01	10	GSLVGNWDVI	9	14			
PGT128-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128	Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	0.84187	53.0508	232	271	3541
PGT130	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128	Walker2011(21849977) 	Mutation greatly reduces PGT130 neutralization;Mutations at the trimer apex that affect sensitivity;PGT121-123, 125-128, 130, 131 sites important for neutralization;V3 Signature Analysis Summary	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	SGGDILYYYEWQKPHWFSP	22	34	2-8*01	2*01 or 3*01	10	SSLFGRWDVV	12	19	L		Natural monoclonal	human	PGT-130	 	3.20269	36.1893	601	29	2643
PGT131	gp120 V3 // V3 glycan (V3g)		Donor 36 	PGT128	Walker2011(21849977) 	PGT121-123, 125-128, 130, 131 sites important for neutralization	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	19	SGGDILYYIEWQKPHWFYP	23	33	2-8*01	2*01 or 3*01	10	SSLSGRWDIV	13	23	L		Natural monoclonal	human	PGT-131	 	11.0186	21.2576	162	30	2644
PGT135	gp120 V3 // V3 glycan (V3g)	4JM2(PGT 135 Fab in complex with gp120 core (JR-FL) bound to CD4 and 17b Fab);4JM4(Fab PGT135)	Donor 39 	PGT135	Walker2011(21849977) 	Mutation greatly reduces PGT135 neutralization;Mutations at the trimer apex that affect sensitivity;PGT135 contacts and sites;V3 Signature Analysis Summary	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HRHHDVFMLVPIAGWFDV	17	29	3-15*01	1*01	9	QQYEEWPRT	16	28	K		Natural monoclonal	human	PGT-135	 	14.8308	19.4218	1285	31	2645
PGT135-IgG3C-	gp120 V3 // V3 glycan (V3g)		Donor 39 	PGT135	Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	19.8045	16.7842	238	277	3543
PGT136	gp120 V3 // V3 glycan (V3g)		Donor 39 	PGT135	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HKYHDIFRVVPVAGWFDP	15	25	3-15*01	1*01	9	QQYEEWPRT	12	21	K		Natural monoclonal	human	PGT-136	 	54.5814	5.82733	164	32	2646
PGT137	gp120 V3 // V3 glycan (V3g)		Donor 39 	PGT135	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	4-39*07		5*02	18	HKYHDIVMVVPIAGWFDP	20	29	3-15*01	1*01	9	QQYEEWPRT	11	18	K		Natural monoclonal	human	PGT-137	 	40.3483	8.18728	162	33	2647
PGT141	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 	Mutation affects PG9-like Ab sensitivity;PG9-like contacts	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	12	21	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	14	21	K		Natural monoclonal	human	PGT-141	 	4.13098	34.5902	196	34	2648
PGT142	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		Donor 84 	PGT145	Walker2011(21849977) 	hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary;V2 Signature Analysis Summary	Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	12	23	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	14	21	K		Natural monoclonal	human	PGT-142	 	1.78526	70.1417	592	35	2649
PGT143	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5UXQ(Structure of PGT143)	Donor 84 	PGT145	Walker2011(21849977) 	Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT143 neutralization;V2 Signature Analysis Summary	Andrabi2015(26588781) 	IMGT/V-QUEST	1-8*01	4-17*01	6*02	34		16		2-28*01	1*01	9		15		K		Natural monoclonal	human	PGT-143	 	3.55651	38.5754	611	36	2650
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINYQEWNDYLEFLDV	12	21	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	14	22			
PGT144	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5UY3(Structure of human Fab PGT144)	Donor 84 	PGT145	Walker2011(21849977) 		Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	32	GSKHRLRDYVLYDDYGLINQQEWNDYLEFLDV	14	24	2-28*01 or 2D-28*01	1*01	9	MQGLNRPWT	13	23	K		Natural monoclonal	human	PGT-144	 	20.9877	10.5939	162	37	2652
PGT145	gp120 V2 // V2 glycan(V2g) // V2 apex	3U1S(Fab PGT145);5U1F(BG505 DS-SOSIP trimer in complex with CD4 and antibody PGT145);5V8L(BG505 SOSIP.664 trimer in complex with 3BNC117 and PGT145);6NIJ(PGT145 Fab in complex with full length AMC011 Env)	Donor 84 	PGT145	Walker2011(21849977) 	Disulfide bond introduced in V1V2 affects binding and neutralization;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;Mutation affects neutralization by V1V2 glycan mAbs;Mutation affects PG9-like Ab sensitivity;Mutation causes resistance to V2 bnAbs;Mutation greatly reduces PGT145 neutralization;mutations affecting PGT145 binding;mutations affecting PGT145 binding;mutations affecting PGT145 binding;PG9-like antibodies require N160 for neutralization;PG9-like contacts;PGT145 contacts;PGT145 contacts;PGT145 epitope;PGT145 escape mutations;Signature Analysis Summary;V2 Signature Analysis Summary	Andrabi2015(26588781) 	IMGT/V-QUEST	1-8*01	4-17*01	6*02	33		17		2-28*01	1*01	9		17		K		Natural monoclonal	human	PGT-145	 	0.9682	39.5196	2646	38	2651
							Walker2011(21849977) 	IMGT/V-QUEST SoDA2	1-8*01		6*02	31	GSKHRLRDYFLYNEYGPNYEEWGDYLATLDV	18	29	2-28*01 or 2D-28*01	1*01	9	MQGLHSPWT	16	24			
PGT145-scFv-Fc	gp120 V3 // V3 glycan (V3g)		Donor 84 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		 			18	774	4526
PGT151	fusion peptide // near gp41-gp120 interface	4NUG(Antibody PGT151);5FUU(JR-FL EnvdCT trimer in complex with PGT151 Fab);6DCQ(Wild type HIV-1 glycoprotein PC64M18C043 in complex with PGT151 Fab);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab)	Donor 31 		Falkowska2014(24768347) 	mutation affecting PGT151 binding;Mutation affects PGT151 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;mutations affecting PGT151 binding;mutations affecting PGT151 binding;PGT151 contacts;PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARMFQESGPPRLDRWSGRNYYYYSGMDV	20	28	2D-29*02	4*01	9	MQSKDFPLT	12	15	K	Yes	Natural monoclonal	human	PGT-151	 	0.25538	75.163	2749	123	3107
PGT151/10-1074-IgG3C-	fusion peptide // near gp41-gp120 interface;gp120 V3 // V3 glycan (V3g)		Donor 17 Donor 31 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific; IgG3C hinge variant 	0.12608	23.6649	238	275	3533
PGT151/35O22	fusion peptide // near gp41-gp120 interface;gp41-gp120 interface		Donor 31 Donor N152 		Bournazos2016(27315478) 																			Engineered monoclonal	human		bispecific 	1.18454	26.2946	120	266	3518
PGT151-IgG3C-	fusion peptide // near gp41-gp120 interface		Donor 31 		Bournazos2016(27315478) 																			Engineered monoclonal	human		IgG3C hinge variant 	0.42059	65.6104	238	273	3542
PGT152	fusion peptide // near gp41-gp120 interface	4NUJ(Antibody PGT152)	Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARMFQESGPPRFDSWSGRNYYYYSGMDV	19	29	2D-29*02	4*01	9	MQSKDFPLT	12	14	K	Yes	Natural monoclonal	human	PGT-152	 	0.47199	75.5425	232	124	3108
PGT153	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARDRDGYGPPQIQTWSGRYLHLYSGIDA	22	27	2D-29*02	4*01	9	MQSKDFPLT	13	18	K		Natural monoclonal	human	PGT-153	 	6.87459	34.5845	50	125	3109
PGT154	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	ARNIEEFSVPQFDSWSGRSYYHYFGMDV	18	26	2D-29*02	4*01	9	MQSRDFPIT	17	22	K		Natural monoclonal	human	PGT-154	 	4.0906	44.6074	50	126	3110
PGT155	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHKVPQLHSWSGRNLYHYTGFDV	21	30	2D-29*02	4*01	9	LQTKDFPLT	17	20	K		Natural monoclonal	human	PGT-155	 	4.88956	47.1451	50	127	3111
PGT156	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHKVPQLHSWSGRNLYHYTGFDV	21	31	2D-29*02	4*01	9	LQTKDFPLT	17	21	K		Natural monoclonal	human	PGT-156	 	3.83441	62.2493	50	128	3112
PGT157	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHEVPQLHSWSGRNLYHYTGVDI	20	29	2D-29*02	4*01	9	MQTKDFPLT	14	17	K		Natural monoclonal	human	PGT-157	 	9.82692	30.9537	50	129	3113
PGT158	gp41		Donor 31 		Falkowska2014(24768347) 	PGT151-PGT158 sites of interaction	Falkowska2014(24768347) 		3-30*04		6*02	28	AKDGEEHEVPQLHSWSGRNLYHYTGVDV	21	31	2D-29*02	4*01	9	MQTKDFPLT	14	19	K		Natural monoclonal	human	PGT-158	 	4.88464	50.9387	50	130	3114
PGZL1	gp41 MPER (membrane proximal external region)	6O3D(Fab fragment of PGZL1);6O3G(Fab fragment of PGZL1 in complex with its MPER peptide epitope);6O3J(Fab fragment of PGZL1 in complex with its MPER peptide epitope and phosphatidic acid);EMD-0620(Full length HIV-1 Envelope glycoprotein AMC011 in complex with PGT151 Fab and PGZL1 Fab)	PG13 	PGZL1	Zhang2019a(31772165) 	Mutation affects neutralization by PGZL1, H4K3, or 4E10;PGZL1 contacts	Zhang2019a(31772165) 	IMGT/V-QUEST	1-69*06	3-10*01	3*01	15	EGEGWFGKPLRAFEF	20.9		3-20*01	5*01	9	QQYGTSQST	12.6		K		Natural monoclonal	human		 	9.59677	6.16393	260	492	4120
PGZL1_gVmDmJ	gp41 MPER (membrane proximal external region)	6O41(PGZL1 germline Fab fragment PGZL1_gVmDmJ);6O42(germline PGZL1 (PGZL1_gVmDmJ) Fab in complex with MPER peptide epitope)	PG13 	PGZL1	Zhang2019a(31772165) 		Zhang2019a(31772165) 	IMGT/V-QUEST	1-69*06	3-10*01	4*03	17	CAREGEGWFGKPLRAFEFW			3-20*01	5*01					K		UCA or intermediate	human	PGZL1 gVmDmJ	 	75.6029	2.38435	260	494	4122
PGZL1.H4K3	gp41 MPER (membrane proximal external region)	6O3K(Fab fragment of PGZL1.H4K3);6O3L(Fab fragment of PGZL1.H4K3 in complex with its MPER peptide epitope);6O3U(Fab fragment of PGZL1.H4K3 in complex with 06:0 PA)	PG13 	PGZL1	Zhang2019a(31772165) 	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a(31772165) 	IMGT/V-QUEST	1-69*06	3-10*01	3*01	15	EGEGWFGRPLRAFEF			3-20*01	5*01	9	QQYGTSQST			K		Engineered monoclonal	human	H4K3	 	1.4267	4.66656	260	493	4121
polyclonal 391370	gp120 CD4bs		391370 		Barnes2022(35960796) 																			Polyclonal	human		 	90.2876	1.2914	42	641	4251
polyclonal Donor 27845			27845 		Schoofs2019(31126879) 																			Polyclonal	human		 	84.0426	1.28112	31	545	4151
polyclonal EB179	gp120 CD4bs		EB179 		Freund2015(26516768) 																			Polyclonal	human		 	79.9672	1.54648	14	703	4288
polyclonal IDC561			IDC561 		Schommers2020(32004464) 																			Polyclonal	human		 	56.2654	1.93335	38	629	4239
polyclonal NIH45			NIH45 		Wu2010(20616233) 																			Polyclonal	human		 	73.2555	1.74608	278	411	3967
polyclonal Patient 1			Patient 1 		Scheid2011(21764753) 																			Polyclonal	human		 	79.7209	1.6126	21	413	3972
polyclonal Patient 12			Patient 12 		Scheid2011(21764753) 																			Polyclonal	human		 			6	416	3975
polyclonal Patient 3			Patient 3 		Scheid2011(21764753) 																			Polyclonal	human		 	65.8404	2.00908	61	414	3973
polyclonal Patient 8			Patient 8 		Scheid2011(21764753) 																			Polyclonal	human		 	59.3104	2.33271	21	415	3974
polyclonal pt7 IgA			pt7 		Lorin2022(35230385) 																			Polyclonal	human		 	61.5825	3.41285	24	608	4222
polyclonal pt7 IgG			pt7 		Lorin2022(35230385) 																			Polyclonal	human		 	59.3504	3.30053	24	607	4221
polyclonal R1			R1 		Gristick2016(27617431) 																			Polyclonal	human		 	70.0696	1.84216	18	724	4368
PRO-140	non-HIV: host CCR5				Olson1999(10196311) 																				mouse	P140, PA14, PRO 140, PRO140	 	0.33411	4.05364	106	583	4157
PRO-140/PGDM1400/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5		Donor 17 Donor 84 		Khan2018(29976677) 																			Engineered monoclonal	human;humanized mouse	PRO140Fab-PGDM1400fv-PGT121fv	trispecific 	0.054149	16.0618	105	424	3993
QA013.19	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		1-46	4-17	4	20	GRSLRLSPNAFTMRTPPPDY	15	21.4	2-23	2	10	CSYGGASTLI	11.5	19.4	L		Natural monoclonal	human		 	37.6701	5.78481	19	391	3920
QA013.2	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		3-7	6-6	5	21	AREAYHLVYDDRIPRGNWFDP	21.2	31.6	1-40	3	11	QSYDTTLTASV	11.5	17.2	L		Natural monoclonal	human		 	10.861	16.0538	33	392	3923
QA013.3	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		1-46	6-13	4	10	ATYGATGEVY	8.7	15.6	3-25	3	10	QSSDSSAIWV	6.1	7.5	L		Natural monoclonal	human		 	34.6598	10.6183	19	394	3925
QA013.32	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		1-46	4-17	4	20	GRARRLSPVSSTMRTPPPDS	17	28.6	2-23	2	10	CSYGGASTLV	9.7	14.3	L		Natural monoclonal	human		 	30.6613	8.13293	19	393	3924
QA013.4	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		1-18	3-10	6	21	ARDGLWAGSQNNLFSYYGMDV	8.7	9.2	3-25	3	10	QSADSSGHWV	4.7	7.4	L		Natural monoclonal	human		 	31.8265	7.69202	19	395	3926
QA013.53	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		QA013 		Williams2018(29669274) 		Williams2018(29669274) 		1-46	6-13	4	10	ATYGATGEVY	9.4	16.5	3-25	3	10	QSADSSATWV	6.8	10.8	L		Natural monoclonal	human		 	29.6894	12.3924	18	396	3927
QA255.087			QA255 		Williams2015(26629541) 		Williams2015(26629541) 	IMGT/V-QUEST	1-69	4-11	6	28		6.94		3-20	2	9		5.32		K	No	Natural monoclonal	human		 Williams2015 %SHM was calculated for V genes only.			9	705	4295
QA255.105	gp120 V3 // V3 glycan (V3g)		QA255 		Williams2015(26629541) 	QA255.105 epitope	Williams2015(26629541) 	IMGT/V-QUEST	3-15	2-21	6	17		9.18		3-20	2	9		7.45		K	Yes	Natural monoclonal	human		 Williams2015 %SHM was calculated for V genes only.			9	706	4296
QA255.187			QA255 		Williams2015(26629541) 		Williams2015(26629541) 	IMGT/V-QUEST	1-69	2-2	5	18		8.74		1-39	3	9		9.24		K	No	Natural monoclonal	human		 Williams2015 %SHM was calculated for V genes only.			9	708	4298
RHA1.V2.01	gp120 V2 // V2 glycan(V2g) // V2 apex	6XRT(SHIV-elicited RHA1.V2.01 in complex with HIV-1 Env BG505 DS-SOSIP.664);EMD-22295(SHIV-elicited RHA1.V2.01 in complex with HIV-1 Env BG505 DS-SOSIP.664)	RM5695 	RHA1.V2	Roark2021(33214287) 	RHA1.V2.01 contacts;RHA1.V2.01 signatures	Roark2021(33214287) 	IMGT/V-QUEST				24	CARKGEDFYEDDYGQYFTAGWFFDLW	8.5				8	CQCYDSSVLF	6.2		L		Natural monoclonal	macaque		Macaque antibody 	6.954	26.1731	232	809	4544
RHA1.V2.02	gp120 V2 // V2 glycan(V2g) // V2 apex		RM5695 	RHA1.V2	Roark2021(33214287) 		Roark2021(33214287) 	IMGT/V-QUEST				24	CARKGEDFYEDDYGQYFTAGWYFDLW	8.5				8	CQCYDTTVLF	6.6		L		Natural monoclonal	macaque		Macaque antibody 	0.55556	14.6803	18	810	4545
RHA1.V2.03	gp120 V2 // V2 glycan(V2g) // V2 apex		RM5695 	RHA1.V2	Roark2021(33214287) 		Roark2021(33214287) 	IMGT/V-QUEST				24	CARKGEDFYEDDYGQYFTAGWYFDLW	7.5				8	CQCYDSNVLF	6.6		L		Natural monoclonal	macaque		Macaque antibody 	1.31063	21.0412	24	811	4546
RHA1.V2.04	gp120 V2 // V2 glycan(V2g) // V2 apex		RM5695 	RHA1.V2	Roark2021(33214287) 		Roark2021(33214287) 	IMGT/V-QUEST				24	CARKGEDFYEDDYGQYFTAGWFFDLW	7.1				8	CQCYDTTVLF	6.2		L		Natural monoclonal	macaque		Macaque antibody 	0.98814	24.8588	24	812	4547
RoAb13	non-HIV: host CCR5				Ji2007(17166600) 																				mouse	ROAb13	 	0.30728	9.45136	106	584	4159
RoAb13/PGDM1400/PGT121	gp120 V2 // V2 glycan(V2g) // V2 apex;gp120 V3 // V3 glycan (V3g);non-HIV: host CCR5		Donor 17 Donor 84 		Khan2018(29976677) 																			Engineered monoclonal	human;mouse	RoAb13Fab-PGDM1400fv-PGT121fv	 	0.094815	24.9301	107	426	3997
RoAb13/PRO-140	non-HIV: host CCR5				Khan2018(29976677) 																			Engineered monoclonal		RoAb13/PRO 140	bispecific 	0.2401	2.55389	106	585	4160
sCD4		1CDJ(glycoprotein CD4);1G9M(gp120 (HXB2) complexed with CD4 and 17b);1G9N(gp120 (YU2) complexed with CD4 and 17b);1GC1(gp120 core complexed with CD4 and 17b);1RZJ(gp120 (HXB2) complexed with CD4 and 17b);1RZK(gp120 (YU2) complexed with CD4 and 17b);2NXY(gp120 (S334A) complexed with CD4 and 17b);2NY0(gp120 (M95W, W96C, T257S, V275C, S334A, S375W, A433M) complexed with CD4 and 17b);2NY5(gp120 (M95W, W96C, I109C, T257S, V275C, S334A, S375W, Q428C, A433M) complexed with CD4 and 17b)																									 	7.27906	5.02791	601	39	
SF10	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	GRVGPGGLFDRWTGYHGHKWVDA	25.3	37.1	3-20*01		6	QQYGRT	19.9	29	K		Natural monoclonal	human		 	3.33066	43.1113	31	544	4150
SF12	gp120 silent face	6OKP(SOSIP.664 in complex with SF12 and 10-1074);6OKQ(SF12 Fab);EMD-20100(B41 SOSIP.664 in complex with SF12 and 10-1074);EMD-20101(B41 SOSIP.664 trimer in complex with 2 Fab fragments of SF12 and 1 Fab fragment of 10-1074)	27845 	SF12	Schoofs2019(31126879) 	SF12 interaction sites	Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	ARLGPGGIFDRWTGHYGDKWLDP	17	21.4	3-20*01		6	QLSGRR	14.6	20.4	K		Natural monoclonal	human		 	2.12886	26.5461	271	538	4063
SF2	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	ARLGPGGLFDRYTGYHGRKWLDA	24.4	32	3-20*01		6	QQYGRT	18	23.9	K		Natural monoclonal	human	SF02	 	21.2102	16.2415	31	539	4146
SF3	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	GRVGPGGLFDRWRGYHGHKWVDA	25.3	39.2	3-20*01		6	QQYGRT	21.4	29	K		Natural monoclonal	human	SF03	 	16.7942	20.2421	31	540	4147
SF5	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	ARLGPGGIFDRWTGHYGDKWLDP	19	25.5	3-20*01		6	QLSGRR	16	21.5	K		Natural monoclonal	human	SF05	 	3.17704	30.2375	269	541	4064
SF7	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	GRVGPGGLFDRWRGYHGHKWVDA	25.3	39.2	3-20*01		6	QQYGRT	21.4	29	K		Natural monoclonal	human	SF07	 	16.1502	21.7268	31	542	4148
SF8	gp120 silent face		27845 	SF12	Schoofs2019(31126879) 		Schoofs2019(31126879) 	IgBlast IMGT/V-QUEST	4-59*01			23	ARLGPGGLFDRYTGYHGRKWLDA	24.4	32	3-20*01		6	QQYGRT	16.5	21.7	K		Natural monoclonal	human	SF08	 	21.3329	17.876	31	543	4149
T-01 MB	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)				Rujas2022(35064083) 																			Other	human		 	0.044983	28.5222	261	857	4653
T-01 MB.v2	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)				Rujas2022(35064083) 																			Other	human		 	0.0022159	18.1969	261	859	4654
T-02 MB	gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region);non-HIV: host CD4R				Rujas2022(35064083) 																			Other	human		 	0.037258	16.9794	14	860	4655
Tri-NAb	gp120 CD4bs;gp120 V3 // V3 glycan (V3g);gp41 MPER (membrane proximal external region)		Donor 17 Donor N152 NIH45 		Steinhardt2018(29491415) 																			Engineered monoclonal	human		trispecific involving VRC01, PGT121, and 10E8 	0.071679	6.29224	416	386	3959
vFP1.01	gp41 fusion domain	5TKJ(vFP1.01 in complex with HIV-1 fusion peptide residue 512-519)	1868 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	1868-vFP1.01	mouse Ab 	78.9308	2.30044	436	378	3937
vFP16.02	gp41 fusion domain	6CDI(antibody vFP16.02 in complex with HIV-1 Env BG505 DS-SOSIP, and antibodies VRC03 and PGT122);6CDO(vFP16.02 in complex with HIV-1 fusion peptide residue 512-519)	2712 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	2712-vFP16.02	mouse Ab 	37.5988	5.70298	852	382	3949
vFP20.01	gp41 fusion domain	6CDP(vFP20.01 in complex with HIV-1 fusion peptide residue 512-519)	2716 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	2716-vFP20.01	mouse Ab 	44.3829	4.52989	436	383	3950
vFP5.01	gp41 fusion domain	5TKK(vFP5.01 in complex with HIV-1 fusion peptide residue 512-519)	1868 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	1868-vFP5.01	mouse Ab 	98.4733	1.14622	416	379	3944
vFP7.04	gp41 fusion domain	6CDM(vFP7.04 in complex with HIV-1 fusion peptide residue 512-519);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122)	2586 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	2586-vFP7.04	mouse Ab 	78.8731	2.2905	416	380	3938
vFP7.05	gp41 fusion domain		2586 		Xu2018(29867235) 	Mutation reduces binding/neutralization of fusion peptide mAbs																		Natural monoclonal	mouse	2586-vFP7.05	mouse Ab 	83.1511	2.09128	416	381	3939
VRC01	gp120 CD4bs	3NGB(VRC01 complexed with gp120);4JPI(Fab VRC01 germline precursor);4JPK(VRC01 germline precursor Fab complexed with gp120 outer domain);4LSS(VRC01 complexed with gp120 (KER2008));4LST(VRC01 complexed with gp120 (ZM176));5FYJ(Clade G X1193.c1 SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5FYK(SOSIP.664 Prefusion Env Trimer in Complex with PGT122, 35O22 and VRC01);5KZC(gp120 engineered outer domain with a Man9 glycan at position N276, in complex with VRC01);6MYY(Germline VRC01 antibody recognition of a modified clade C envelope trimer);6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv)	NIH45 	VRC01	Wu2010(20616233) 	3BNC117 contacts;Electrostatic interactions with D368;hypervariable loop characteristic correlations with bNAb sensitivity;Mutation abrogates BG24 OR VRC01 neutralization;Mutation affects neutralization;Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation affects VRC01 neutralization;Mutation affects VRC01, PGT151, and 2G12 binding;Mutation decreases binding to CD4BS mAbs;mutations affecting VRC01 binding;mutations affecting VRC01 binding;Mutations allowing binding of germline Abs;Mutations associated with immunotherapy with BG24 or VRC01;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01;Sequence changes after immunotherapy with VRC01;Signature Analysis Summary;VRC01 contacts;VRC01 contacts;VRC01 residue prediction;VRC01 signature predictions	Klein2013(23540694) 	IgBlast	1-2	3-16 or 5-24	1					3-11	2					K	Yes	Natural monoclonal	human	VRC01 d45, VRC-HIVMAB060-00-AB	 Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.	0.86261	9.95782	10750	7	2163
							Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3-16*01 or 3-16*02	1*01 or 2*01	14		32		3-11*01	2*01	5		17				
							Zhang2013(24100711) 	IMGT/V-QUEST	1-02*02	2-21*01	2*01	14				3D-15	2	5						
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			12	GKNCDYNWDFEH			3-20*01	2*01	5	QQYEF					
VRC01-0fH/0fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	100	1	21	112	3071
VRC01.23LS	gp120 CD4bs	6VI0(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP);EMD-21208(VRC01.23 in complex with HIV-1 Env BG505 DS.SOSIP)	NIH45 	VRC01	Kwon2021(34328065) 	VRC01.23LS primary contacts																K		Engineered monoclonal	human		 	0.058173	7.34675	428	609	4223
VRC01-30fH/10fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.116	6.59213	21	105	3063
VRC01-30fH/19fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.24418	6.15972	21	104	3062
VRC01-5fH/0fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	48.8246	6.57282	21	111	3070
VRC01-5fH/10fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.47302	7.52701	21	109	3068
VRC01-5fH/6fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.4139	9.21114	21	110	3069
VRC01-8fH/10fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.48875	8.77056	21	107	3066
VRC01-8fH/19fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.95145	7.28841	21	106	3065
VRC01-8fH/6fL	gp120 CD4bs		NIH45 	VRC01	Georgiev2014(24391217) 																			Engineered monoclonal	human		 	0.86517	7.89262	21	108	3067
VRC01b	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	642	3338
VRC01c	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	643	3339
VRC01d	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	644	3341
VRC01e	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	645	3342
VRC01-E16A(HC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	738	4427
VRC01-E28T(HC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	737	4426
VRC01f	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	646	3343
VRC01_FR3-03	gp120 CD4bs	6NNF(BG505 SOSIP.664 Prefusion Env Trimer Bound to VRC01 FR3-03 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22)	NIH45 	VRC01	Liu2019(30760721) 	Mutation affects neutralization by VRC01_FR3-03																K		Engineered monoclonal	human	VRC01 FR3-03	 	0.43466	11.3898	416	793	4569
VRC01g	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	647	3344
VRC01h	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	648	3345
VRC01H-DRVIA7L	gp120 CD4bs		DRVI01 NIH45 		Kong2016(27067056) 																	K		Engineered monoclonal	human	VRC01H+ DRVIA7L	 	92.7804	1.5677	37	487	4113
VRC01i	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	649	3346
VRC01-I21L(LC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	743	4432
VRC01-LS	gp120 CD4bs		NIH45 	VRC01	Ko2014(25119033) 																	K	Yes	Engineered monoclonal	human	VRC01LS	 	0.46537	9.01353	416	571	3313
VRC01-N73T(LC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	742	4431
VRC01-P63K(HC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	739	4428
VRC01/PGDM1400-10E8v4	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex;gp41 MPER (membrane proximal external region)		Donor 84 Donor N152 NIH45 		Xu2017(28931639) 																			Engineered monoclonal	human	SAR-441236, SAR441236, VRC01-LS/PGDM1400-10E8v4	trispecific involving VRC01, PGDM1400, and 10E8 	0.039266	9.30439	416	388	3955
VRC01 UCA	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		UCA or intermediate	human		 	100	1	14	669	4267
VRC01-W68S(LC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	740	4429
VRC01-Y28S(LC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	744	4433
VRC01-Y72F(LC)	gp120 CD4bs		NIH45 	VRC01	Wiehe2018(29861171) 																	K		Engineered monoclonal	human		 			3	741	4430
VRC02	gp120 CD4bs		NIH45 	VRC01	Wu2010(20616233) 	VRC02 signature predictions	Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3-16*01 or 3-16*02	1*01 or 2*01	14		32		3-11*01	2*01	5		19		K		Natural monoclonal	human		 Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.52135	8.81276	569	45	2164
VRC03	gp120 CD4bs	3SE8(VRC03 complexed with gp120);5JOF(VRC03 gHVgLV antigen-binding fragment);5JXA(Ligand-free VRC03 antigen-binding fragment);6CUE(vFP7.04 in complex with BG505 DS-SOSIP, and antibodies VRC03 and PGT122);6E5P(2G12 bound to HIV-1 Env BG505 DS-SOSIP, which was also bound to VRC03);EMD-8981(2G12 bound to HIV-1 Env BG505 DS-SOSIP which was also bound to VRC03)	NIH45 	VRC01 (VRC03+06 sublineage)	Wu2010(20616233) 	Altered glycosylation affects neutralization by CD4BS bnAbs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary;VRC03 contacts;VRC03 signature predictions;VRC03 signature predictions	Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	3-22*01	1*01	16		29		3-20*01	2*01	5		20		K		Natural monoclonal	human	VRC03 d45	 Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2010 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.Zhou2013 note re-assignment of previously-published germline genes for VRC01 and VRC03.	6.45245	21.9965	1787	21	2165
							Wu2010(20616233) 	IMGT/V-QUEST JoinSolver	1-02*02	3	1*01	16		30		3-20*01	2*01	5		20				
							Zhang2013(24100711) 	IMGT/V-QUEST	1-18*01 or 1-2*02 or 1-2*04	2-21*01	2*01	23				3-NL5	2	5						
							Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			14	RGSCDYCGDFPWQY			3-20*01	2*01	5	QQFEF					
VRC03b	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03b	 			24	650	3353
VRC03d	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03d	 			24	651	3354
VRC03f	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03f	 			24	652	3356
VRC03g	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03g	 			24	653	3357
VRC03h	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03h	 			24	654	3358
VRC03i	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human	VRC03i	 			24	655	3359
VRC06	gp120 CD4bs	4JB9(VRC06 in complex with HIV-1 gp120 core)	NIH45 	VRC01 (VRC03+06 sublineage)	Li2012(22875963) 		Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	4-17*01	1*01	17		29		3-20*01	2*01	5		16		K		Natural monoclonal	human		 	23.8065	9.61119	807	75	2660
VRC06b	gp120 CD4bs	4XNZ(VRC06B in complex with HIV-1 clade A/E strain 93TH057 gp120)	NIH45 	VRC01 (VRC03+06 sublineage)	Li2012(22875963) 	Signature Analysis Summary	Li2012(22875963) 	IMGT/V-QUEST JoinSolver	1-2*02 or 1-2*04	4-17*01	1*01	17		32		3-20*01	2*01	5		18		K		Natural monoclonal	human	VRC06b	 	9.88935	19.7585	673	83	2661
VRC06c	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	656	3360
VRC06d	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	657	3361
VRC06e	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	658	3362
VRC06f	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	659	3363
VRC06g	gp120 CD4bs		NIH45 	VRC01 (VRC03+06 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	660	3364
VRC07	gp120 CD4bs	4OLU(VRC07 in complex with 93TH057 gp120);4OLV(VRC07-G54F in complex with 93TH057 gp120);4OLW(VRC07-G54H in complex with 93TH057 gp120);4OLX(VRC07-G54L in complex with 93TH057 gp120);4OLY(VRC07-G54R in complex with 93TH057 gp120);4OLZ(VRC07-G54W in complex with 93TH057 gp120);4OM0(VRC07-G54Y in complex with 93TH057 gp120);4OM1(VRC07-I30Q, G54W, S58N in complex with 93TH057 gp120)	NIH45 	VRC01	Rudicell2014(25142607) 	hypervariable loop characteristic correlations with bNAb sensitivity;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs;Signature Analysis Summary	Rudicell2014(25142607) 	IMGT/V-QUEST	1-02*02			16	CTRGKYCTARDYYNWDFEH			3-20*01						K		Natural monoclonal	human		 	0.28683	10.5764	2152	166	3059
VRC07-501-LS	gp120 CD4bs		NIH45 	VRC01	Rudicell2014(25142607) 																	K		Engineered monoclonal	human		 	0.058126	10.6101	358	170	3158
VRC07-508-LS	gp120 CD4bs		NIH45 	VRC01	Rudicell2014(25142607) 																	K		Engineered monoclonal	human		 	0.069271	14.2131	358	171	3159
VRC07-523-F54-LS.v3	gp120 CD4bs		NIH45 	VRC01	Kwon2021(34328065) 																	K		Engineered monoclonal	human		 	0.035973	6.70863	416	610	4236
VRC07-523-LS	gp120 CD4bs		NIH45 	VRC01	Rudicell2014(25142607) 	hypervariable loop characteristic correlations with bNAb sensitivity;Signature Analysis Summary;Signature Analysis Summary																K		Engineered monoclonal	human	VRC07-523, VRC07-523LS	 	0.088232	8.53537	2682	172	3156
VRC07-523-LS_FR3-03	gp120 CD4bs		NIH45 	VRC01	Liu2019(30760721) 	Mutation affects neutralization by VRC07-523-LS_FR3-03																K		Engineered monoclonal	human	VRC07-523-LS FR3-03	 	0.074689	6.57062	416	795	4571
VRC07-523-LS-N72Q-R24D	gp120 CD4bs		NIH45 	VRC01	Chuang2020(33121334) 																	K		Engineered monoclonal	human		 	0.11916	8.7012	416	808	4576
VRC07-523-W54-LS.v3	gp120 CD4bs		NIH45 	VRC01	Kwon2021(34328065) 																	K		Engineered monoclonal	human		 	0.030373	6.21709	426	611	4235
VRC07-544-LS	gp120 CD4bs		NIH45 	VRC01	Rudicell2014(25142607) 																	K		Engineered monoclonal	human		 	0.074032	10.9016	358	173	3160
VRC07b	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	661	3348
VRC07c	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	662	3349
VRC07d	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	663	3350
VRC07e	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	664	3351
VRC07f	gp120 CD4bs		NIH45 	VRC01	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	665	3352
VRC07_FR3-03	gp120 CD4bs		NIH45 	VRC01	Liu2019(30760721) 	Mutation affects neutralization by VRC07_FR3-03																K		Engineered monoclonal	human	VRC07 FR3-03	 	0.1813	9.28102	416	794	4570
VRC07xPG9-16	gp120 CD4bs;gp120 V2 // V2 glycan(V2g) // V2 apex		Donor 24 NIH45 		Asokan2015(26446600) 																			Engineered monoclonal	human		bispecific 	0.025853	26.973	34	235	3372
VRC08	gp120 CD4bs	4XMP(VRC08 in complex with HIV-1 clade A strain Q842.d12 gp120)	NIH45 	VRC01 (VRC08 sublineage)	Wu2015(25865483) 		Wu2015(25865483) 	IMGT/V-QUEST JoinSolver	1-02*02		1*01	23	CARGRSCCGGRRHCNGADCFNWDFQHW	27		3-20*01	2*01	5	QCLEA	22		K		Natural monoclonal	human		 	0.25167	11.6464	440	613	3279
VRC08c	gp120 CD4bs		NIH45 	VRC01 (VRC08 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	666	3318
VRC08d	gp120 CD4bs		NIH45 	VRC01 (VRC08 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	667	3366
VRC08e	gp120 CD4bs		NIH45 	VRC01 (VRC08 sublineage)	Wu2015(25865483) 																	K		Natural monoclonal	human		 			24	668	3367
VRC08H/UCAL	gp120 CD4bs		NIH45 	VRC01	Bonsignori2018(30552024) 																	K		Engineered monoclonal	human	VRC08H/UCAL	chimeric: VRC08 HC with VRC01-UCA LC 	9.66349	10.9214	14	684	4289
VRC13	gp120 CD4bs	4YDJ(44-VRC13.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	44 		Zhou2015(26004070) 	Signature Analysis Summary;VRC13 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	1-69							2-14						L		Natural monoclonal	human	44-VRC13.01, VRC13.01	 	0.7001	21.6859	1304	236	3284
VRC16	gp120 CD4bs	4YDK(C38-VRC16.01 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38 		Zhou2015(26004070) 	Signature Analysis Summary;VRC16 contacts;VRC16 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	3-32							1-39						K		Natural monoclonal	human	C38-VRC16.01, VRC16.01	 	10.1831	11.4287	704	237	3286
VRC18	gp120 CD4bs	4YDL(C38-VRC18.02 in complex with HIV-1 clade AE strain 93TH057 gp120)	C38 		Zhou2015(26004070) 	VRC18 contacts	Zhou2015(26004070) 	IMGT/V-QUEST	1-2							3-20						K		Natural monoclonal	human	C38-VRC18.02, VRC18.02	 	4.60778	12.1397	175	238	3287
VRC21.01	gp120 V3 // V3 glycan (V3g)		N170 	VRC21	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	3-30*03		4*02	12	VRGDGENGGTDY	15		6-57*01	3*02	10	QSYDSNYYWV	9		L		Natural monoclonal	human		 	50.5423	6.41227	28	283	3559
VRC21.02	gp120 V3 // V3 glycan (V3g)		N170 	VRC21	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	3-30*03		4*02	12	VRGDGENGGTDY	17		6-57*01	3*02	10	QSYDDTYFWV	10		L		Natural monoclonal	human		 	53.3922	5.01602	28	284	3560
VRC22.01	gp120 V3 // V3 glycan (V3g)		N170 		Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*01		6*02	19	ARAGGMSDWAYPYYYGMDV	7		1-17*01	1*01	9	LQYNTFPRT	6		K		Natural monoclonal	human		 	79.9232	2.32598	444	285	3561
VRC23	gp120 CD4bs	4J6R(VRC23 in complex with HIV-1 gp120)	127/C 		Georgiev2013(23661761) 		Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	1-2*02							3-15*01						K		Natural monoclonal	human		 	9.7537	9.06124	637	11	3012
VRC23b	gp120 CD4bs		127/C 		Georgiev2013(23661761) 		Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	1-2*02							3-15*01						K		Natural monoclonal	human		 	2.36696	10.0325	50	81	3014
VRC24	gp120 V3 // V3 glycan (V3g)		N27 		Georgiev2013(23661761) 	Mutations at the trimer apex that affect sensitivity	Georgiev2013(23661761) 	IMGT/V-QUEST JoinSolver	4-4*07							1-51*02						L		Natural monoclonal	human		 	21.1932	14.2941	76	82	3013
VRC26.01	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCR(Fab CAP256-VRC26.01)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDVGDYKSDEWGTEYYDISISYPIQDPRAMVGAFDLW	8.3		51*02				3.9		L		Natural monoclonal	human	CAP256-VRC26.01	 	45.7262	6.77853	238	137	3038
VRC26.02	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDIREYECEYWTSDYYDFGRPQPCIDSRGVVGTFDVW	8.7		51*02				4.9		L		Natural monoclonal	human	CAP256-VRC26.02	 	24.9844	17.091	102	138	3039
VRC26.03	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OD1(Fab CAP256-VRC26.03)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDGW	8.7		51*02				7.4		L		Natural monoclonal	human	CAP256-VRC26.03	 	5.92568	51.1265	251	139	3040
VRC26.04	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4ORG(Fab CAP256-VRC26.04)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKQLPCRKSRGVAGIFDKW	9		51*02				8.1		L		Natural monoclonal	human	CAP256-VRC26.04	 	11.491	30.2338	118	140	3041
VRC26.05	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDQRYYECEEWASDYYDFGREQPCLDPRGVVGIFDLW	10		51*02				5.6		L		Natural monoclonal	human	CAP256-VRC26.05	 	14.6264	37.7645	102	141	3042
VRC26.06	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCW(Fab CAP256-VRC26.06)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			36	CARDLRELECEEWTLYNYYDFGSRGPCVDPRGVAGSFDVW	11		51*02				7.4		L		Natural monoclonal	human	CAP256-VRC26.06	 	52.2653	6.36854	254	142	3043
VRC26.07	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OD3(Fab CAP256-VRC26.07, a potent V1V2-directed HIV-1 neutralizing antibody)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREDECEEWWSDYYDFGKKLPCRKSRGVAGVFDKW	12		51*02				7.7		L		Natural monoclonal	human	CAP256-VRC26.07	 	42.7516	11.2896	102	143	3044
VRC26.08	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;Mutations at the trimer apex that affect sensitivity;V2 Signature Analysis Summary;VRC26.08 signature sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGRELPCRKFRGLGLAGIFDIW	12		51*02				9.8		L		Natural monoclonal	human	CAP256.26.08, CAP256-VRC26.08	 	0.67925	146.319	1758	144	3045
VRC26.09	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Disulfide bond introduced in V1V2 affects binding and neutralization;mutations affecting VRC26.09 binding;mutations affecting VRC26.09 binding;VRC26.09 escape mutations	Andrabi2015(26588781) 	IMGT/V-QUEST	3-30*18	3-3*01	3*02	39		14		1-51*02	1*01	12		10		L		Natural monoclonal	human	CAP256-09, CAP256.09, CAP256-VRC26.09	 	2.13866	98.1991	455	145	3046
							Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVKDQREDECEEWWSDYYDFGRELPCRKSRGLGLAGIFDMW	14		51*02				9.8				
VRC26.10	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	4OCS(Fab CAP256-VRC26.10)	CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDMREYECEYWTSDYYDFGRPQPCIDRRGVVGIFDMW	12		51*02				3.9		L		Natural monoclonal	human	CAP256-VRC26.10	 	19.9435	18.0649	102	146	3047
VRC26.11	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CVKDMRELECEEWASDYYDFGKPQPCLDRRGVSGISAWW	13		51*02				14		L		Natural monoclonal	human	CAP256-VRC26.11	 	21.0456	16.7775	102	147	3048
VRC26.12	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2014(24590074) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW	15		51*02				8.4		L		Natural monoclonal	human	CAP256-VRC26.12	 	55.1423	6.21408	102	148	3049
VRC26.13	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLRESECEEWESDYYDFGKKGPCVKPRGVAGGLDLW	15		51*02				9.5		L		Natural monoclonal	human	CAP256-VRC26.13	 	57.3671	6.91884	53	202	3296
VRC26.14	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW	10		51*02				7.7		L		Natural monoclonal	human	CAP256-VRC26.14	 	21.2703	21.9103	53	203	3297
VRC26.15	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDLREYECELWASDYYDFGKPQPCEDPRGVVGTSDIW	10		51*02				6.7		L		Natural monoclonal	human	CAP256-VRC26.15	 	17.7778	18.5014	53	204	3298
VRC26.16	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDVREMECEEWASDYYDFGRGGPCRDFRGVVGILDIW	10		51*02				7.7		L		Natural monoclonal	human	CAP256-VRC26.16	 	19.4692	21.7843	53	205	3299
VRC26.17	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDMREMECEEWASDYYDFGRPGPCRDLRGVVGTFDIW	12		51*02				8.1		L		Natural monoclonal	human	CAP256-VRC26.17	 	14.2809	29.361	53	206	3300
VRC26.18	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDMREMECEEWASDYYDFGRSGPCRDFRGVVGVFDIW	12		51*02				7.4		L		Natural monoclonal	human	CAP256-VRC26.18	 	21.2526	18.578	53	207	3301
VRC26.19	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDSREYECELWTSDYYDFGKPQPCIDTRDVGGLFDMW	13		51*02				10		L		Natural monoclonal	human	CAP256-VRC26.19	 	6.25411	30.6226	53	208	3302
VRC26.20	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;Selects for breadth-driven Abs in CAP256 lineages	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEERWSDYYHFGRVLPCRKYRGLGLAGVFDIW	16		51*02				13		L		Natural monoclonal	human	CAP256-VRC26.20	 	92.4725	1.71003	64	209	3315
VRC26.21	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYAFGRGGPCRKYHGQGLAGIFDIW	18		51*02				14		L		Natural monoclonal	human	CAP256-VRC26.21	 	38.5418	15.406	53	210	3303
VRC26.22	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	16		51*02				13		L		Natural monoclonal	human	CAP256-VRC26.22	 	3.40475	67.4206	53	211	3304
VRC26.23	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLREYECEEWRSDYYDFGRDQPCIDSQGVVGILDIW	9.7		51*02				6.3		L		Natural monoclonal	human	CAP256-VRC26.23	 	56.2467	7.82527	53	212	3305
VRC26.24	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CAKDLGGIKNDEWGTDYYDISVSYPVQDPRAVAGIFDVW	4.2		51*02				2.5		L		Natural monoclonal	human	CAP256-VRC26.24	 	63.1294	5.52389	48	213	3306
VRC26.25	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure	5DT1(Fab CAP256-VRC26.25);6VTT(CAP256-VRC26.25 Fab bound to HIV-1 Env trimer CAP256.wk34.c80 SOSIP.RnS2)	CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;L184F escapes V2-targeting bnAbs;V2 Signature Analysis Summary;VRC26.25 contacts;VRC26.25 neutralization associated sites;VRC26.25 signature sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			36	CAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNW	12		51*02				9.8		L		Natural monoclonal	human	CAP256.26.25, CAP256-VRC26.25	 	0.090707	227.384	1970	214	3285
VRC26.25 D99E	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.028692	48.6146	16	712	4317
VRC26.25 D99E/E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.021264	33.6076	16	716	4321
VRC26.25 D99E/E100bV/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.016252	29.2692	16	719	4324
VRC26.25 D99E/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.024566	39.1178	16	717	4322
VRC26.25 E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.020886	38.8285	16	713	4318
VRC26.25 E100bV/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.015004	28.5054	16	718	4323
VRC26.25 E100bV/K100sR/L:S95bD	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.010432	44.5503	16	722	4327
VRC26.25 E100bV/Q100nE/K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.0057805	37.8161	16	721	4326
VRC26.25.K100mA	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Zhang2022(36284200) 																	L		Engineered monoclonal	human	CAP256-VRC26.25.K100mA	 	0.36168	154.443	416	552	4163
VRC26.25 K100sR	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.026497	38.644	16	714	4319
VRC26.25 R97G/D99V/E100bV	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 	VRC26	Yin2021(34261793) 																	L		Engineered monoclonal	human		 	0.019888	39.5049	16	715	4320
VRC26.25-scFv-Fc	gp120 V2 // V2 glycan(V2g) // V2 apex		CAP256 		Davis-Gardner2020(31937648) 																			Engineered monoclonal	human		 	0.10458	58.7531	30	773	4525
VRC26.26	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites;hypervariable loop characteristic correlations with bNAb sensitivity;V2 Signature Analysis Summary	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDVW	17		51*02				9.8		L		Natural monoclonal	human	CAP256-VRC26.26	 	1.28959	87.6356	722	215	3289
VRC26.27	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDQREDECEEWWSDYYDFGKELPCRKFRGLGLAGIFDIW	16		51*02				9.5		L		Natural monoclonal	human	CAP256-VRC26.27	 	0.78118	138.474	417	216	3290
VRC26.28	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	15		51*02				12		L		Natural monoclonal	human	CAP256-VRC26.28	 	2.56895	82.5635	53	217	3307
VRC26.29	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECVEWWSDYYNFGRELPCSKFRGLGLAGIFDIW	15		51*02				13		L		Natural monoclonal	human	CAP256-VRC26.29	 	2.81206	69.3584	53	218	3308
VRC26.30	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYNFGRELPCRKFRGQGLAGIFDIW	16		51*02				13		L		Natural monoclonal	human	CAP256-VRC26.30	 	10.0708	41.409	53	219	3309
VRC26.31	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			37	CVRDRQEDECEEWWSDYYNFGRELPCRKFRGPGLAGIFDIW	15		51*02				10		L		Natural monoclonal	human	CAP256-VRC26.31	 	21.3807	27.306	53	220	3310
VRC26.32	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CVKDLRELECEEWTSDYYDFGRPQPCIDPRGVSGISAMW	11		51*02				15		L		Natural monoclonal	human	CAP256-VRC26.32	 	24.7511	20.5688	53	221	3311
VRC26.33	gp120 V2 // V2 glycan(V2g) // V2 apex;quaternary structure		CAP256 	VRC26	Doria-Rose2016(26468542) 	CAP256-VRC26 lineage epitope;CAP256-VRC26 lineage escape mutations;CAP256-VRC26 lineage neutralization-associated sites	Doria-Rose2016(26468542) 	IMGT/V-QUEST	3-30*18			35	CARDQRYYECEEWASDYYDFGREQPCQDPRGVVGIFDIW	9.4		51*02				6.5		L		Natural monoclonal	human	CAP256-VRC26.33	 	23.192	20.9109	53	222	3312
VRC27	gp120 CD4bs	4YDI(Z258-VRC27.01 in complex with HIV-1 gp120 from clade A strain Q23.17)	Z258 		Zhou2015(26004070) 	VRC27 alanine scanning;VRC27 contacts	Huang2016a(27851912) 	IMGT/V-QUEST	1-2*02			13	CARDRLYDGSSWRLDPWGQGTRVVVSS			1-33*01		5	QVLES			K		Natural monoclonal	human	VRC27.01, Z258-VRC27.01	 	1.08003	21.5606	365	239	3288
VRC28.01	gp120 V3 // V3 glycan (V3g)		N170 		Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-34*03		4*02	26	VRGHLSRDRLGQYAFWSGALIDYLDP	19		2-28*01	1*01	9	MQGIDTPRT	18		K		Natural monoclonal	human		 	52.3467	6.37489	28	286	3562
VRC29.01	gp120 V3 // V3 glycan (V3g)		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDRWSDSYDIRSPFDI	12		3-20*01	1*01	9	HQYDRSPRT	6		K		Natural monoclonal	human		 	35.8774	10.0761	28	287	3563
VRC29.02	gp120 V3 // V3 glycan (V3g)		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDVWSKGYDIRSPFDF	16		3-20*01	1*01	9	QQFDFSPRT	9		K		Natural monoclonal	human		 	23.9047	11.3537	28	288	3564
VRC29.03	gp120 V3 // V3 glycan (V3g)		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDVWSNGYDIRSPYDF	15		3-20*01	1*01	9	QQYDFSPRT	9		K		Natural monoclonal	human		 	28.0365	9.06713	444	289	3565
VRC29.04	gp120 V3 // V3 glycan (V3g)		N170 	VRC29	Longo2016(27654288) 		Longo2016(27654288) 	IMGT/V-QUEST JoinSolver	4-59*08		3*02	20	ARHRYDPWSKGYDIRSPFDF	16		3-20*01	1*01	9	EQYDVSPRT	8		K		Natural monoclonal	human		 	16.199	14.5892	28	290	3566
VRC34.01	fusion peptide // near gp41-gp120 interface	5I8C(BG505 Fusion Peptide in Complex with VRC34.01 Fab);5I8E(VRC34.01 Fab);5I8H(BG505 SOSIP.664 Prefusion Env Trimer in Complex with PGT122 Fab and VRC34.01 Fab);6NC3(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody VRC34);EMD-0434(AMC011 v4.2 SOSIP Env trimer in complex with fusion peptide targeting antibody VRC34 fragment antigen binding)	N123 	VRC34	Kong2016a(27174988) 	Mutation affects neutralization by VRC34;Mutation reduces binding/neutralization of fusion peptide mAbs;Mutations affecting binding of VRC34.01 to fusion peptide epitope;mutations affecting VRC34.01 binding;VRC34.01 contacts;VRC34.01 contacts;VRC34.01 mutations affect neutralization	Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKYYGNEAVGMDV	15		1-9*01	4*01	9	QHMSSYPLT	10		K		Natural monoclonal	human	N123-VRC34.01	 	4.89902	22.209	1373	259	3490
VRC34.02	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 		Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKYYGNEAVGMDV	15		1-9*01	4*01	9	QHMSSYPLT	10		K		Natural monoclonal	human	N123-VRC34.02	 	1.87277	14.5418	22	555	3496
VRC34.03	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 		Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKYYGDEAVGMDV	14		1-9*01	4*01	9	QHMSSYPLT	10		K		Natural monoclonal	human	N123-VRC34.03	 	14.9115	11.9376	22	556	3497
VRC34.04	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 		Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DMYYSNEAVGMDV	22		1-9*01	4*01	9	QQMNSLPLT	14		K		Natural monoclonal	human	N123-VRC34.04	 	16.5412	14.9627	22	557	3498
VRC34.05	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 	VRC34.05 contacts	Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKTYSDEATGMDI	23		1-9*01	4*01	9	QQLNSFPLT	13		K		Natural monoclonal	human	N123-VRC34.05	 	98.6298	1.21957	460	558	3499
VRC34.06	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 		Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKTYNDEFTAMDI	22		1-9*01	4*01	9	QQLSAFPLT	17		K		Natural monoclonal	human	N123-VRC34.06	 	77.8393	3.15201	22	559	3500
VRC34.07	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Kong2016a(27174988) 		Kong2016a(27174988) 	IMGT/V-QUEST	1-2*02		6*02	13	DKTYNDEFTAMDI	23		1-9*01	4*01	9	QQLSAFPLT	15		K		Natural monoclonal	human	N123-VRC34.07	 	100	1	22	560	3501
VRC34-pI1	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	1		1-9*01	4*01	9	QHLNSYPLT	0		K		UCA or intermediate	human	VRC34.01-pI1	Unpublished VRC34-pI1 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) 			22	688	4254
VRC34-pI2	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	6.1		1-9*01	4*01	9	QHMSSYPLT	2.1		K		UCA or intermediate	human	VRC34.01-pI2	Unpublished VRC34-pI2 info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) 			22	689	4255
VRC34-pI2'	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKTYSDEATGMDI	9.4		1-9*01	4*01	9	QQLNSFPLT	10.5		K		UCA or intermediate	human	VRC34.01-pI2'	Unpublished VRC34-pI2' info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) 			22	694	4260
VRC34-pI2 H33P	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV			1-9*01	4*01	9	QHMSSYPLT			K		Engineered monoclonal	human	VRC34.01-pI2 H33P	Unpublished info via personal communication (C. Shen) but related to Shen2020 (PMID 32130953) 			22	693	4259
VRC34-pI3	fusion peptide // near gp41-gp120 interface	6UCE(VRC34-pI3 with HIV fusion peptide residues 512-519)	N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	11.1		1-9*01	4*01	9	QHMSSYPLT	7.3		K		UCA or intermediate	human	VRC34.01-pI3	 	3.92824	22.7977	438	690	4256
VRC34-pI3'	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKTYNDEFTAMDI	18.9		1-9*01	4*01	9	QQLSAFPLT	14.7		K		UCA or intermediate	human	VRC34.01-pI3'	Unpublished VRC34-pI3' info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) 			22	695	4261
VRC34-pI3HCpI2LC	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	11.1		1-9*01	4*01	9	QHMSSYPLT	2.1		K		Engineered monoclonal	human	VRC34.01-pI3HCpI2LC	Chimera of pI3 HC and pI2 LC. Unpublished VRC34-pI2 info via personal communication (C. Shen) related to Shen2020 (PMID 32130953) 			22	692	4258
VRC34-pI4	fusion peptide // near gp41-gp120 interface	6UCF(VRC34-pI4 with HIV fusion peptide residues 512-519)	N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	13.2		1-9*01	4*01	9	QHMSSYPLT	8.7		K		UCA or intermediate	human	VRC34.01-pI4	 	6.00755	21.0346	438	691	4257
VRC34-UCA	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Shen2020(32130953) 		Shen2020(32130953) 		1-02*02		6*02	13	DKYYGNEAVGMDV	0		1-9*01	4*01	9	QQLNSYPLT	0		K		UCA or intermediate	human	VRC34.01-UCA	Unpublished VRC34-UCA info via personal communication (C. Shen) but isolated as described in Shen2020 (PMID 32130953) 	100	1	436	687	4253
VRC34YD.01	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	3.12972	10.735	22	441	4004
VRC34YD.02	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	11.6997	9.14855	22	442	4005
VRC34YD.03	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	5.57011	13.5579	22	443	4006
VRC34YD.04	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	4.45401	11.4055	22	444	4007
VRC34YD.05	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	7.22189	12.5243	22	445	4008
VRC34YD.06	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	4.8491	15.4402	22	446	4009
VRC34YD.07	fusion peptide // near gp41-gp120 interface		N123 	VRC34	Wang2018(29309060) 																			Natural monoclonal	human		 	5.76716	12.7636	22	447	4010
VRC38.01	gp120 V2 // V2 glycan(V2g) // V2 apex	5EWI(Fab VRC38.01);5VGJ(Fab VRC38.01 bound to a scaffolded WITO V1V2 domain)	N90 	VRC38	Cale2017(28514685) 	Mutation affects neutralization by V1V2 glycan mAbs;Mutations at the trimer apex that affect sensitivity;VRC38.01 contacts	Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYWGLGV	17.5		2-28*01	4	10	MEARQTPRLT	8.5		K		Natural monoclonal	human	N90-VRC38.01, VRC38	 	18.7342	21.8929	775	325	3775
VRC38.02	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	20		2-28*01	4	10	MQSLETPRLS	10.9		K		Natural monoclonal	human	N90-VRC38.02	 	41.1956	11.3714	31	326	3776
VRC38.03	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPASGWWYHDYYGLYV	14.7		2-28*01	4	10	MQARQTPRLS	5.4		K		Natural monoclonal	human	N90-VRC38.03	 	46.7849	6.35166	31	327	3777
VRC38.04	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	18.9		2-28*01	4	10	MQSLETPRLS	10.2		K		Natural monoclonal	human	N90-VRC38.04	 	37.8086	11.7498	31	328	3778
VRC38.05	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWHLHYYFGMGL	18.6		2-28*01	4	10	MQSLETPRLS	10.2		K		Natural monoclonal	human	N90-VRC38.05	 	79.3197	3.55723	31	329	3779
VRC38.06	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYFGLGV	17.5		2-28*01	4	10	MQARQTPRLS	11.2		K		Natural monoclonal	human	N90-VRC38.06	 	11.7522	28.1813	31	330	3780
VRC38.07	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYWGLGA	19.6		2-28*01	4	10	MEARQTPRLT	9.2		K		Natural monoclonal	human	N90-VRC38.07	 	12.3217	29.2906	31	331	3781
VRC38.08	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHDYYGLDV	15.4		2-28*01	4	10	MQAVQTPRLS	13.3		K		Natural monoclonal	human	N90-VRC38.08	 	25.6964	10.557	30	332	3782
VRC38.09	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPSSGWWYHYYFGLHL	17.5		2-28*01	4	10	MQARQTPRLS	5.4		K		Natural monoclonal	human	N90-VRC38.09	 	18.8304	14.5252	31	333	3783
VRC38.10	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPMSGWWYHDYYGLDV	15.1		2-28*01	4	10	MQAVETPRLS	11.9		K		Natural monoclonal	human	N90-VRC38.10	 	34.5202	8.85779	31	334	3784
VRC38.11	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHDYYGLDA	18.6		2-28*01	4	10	MQAVQTPRLS	15.3		K		Natural monoclonal	human	N90-VRC38.11	 	23.958	13.3844	31	335	3785
VRC38.12	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPMSGWWYHDYYGLDA											Fab or heavy-chain-only	human	N90-VRC38.12	VRC38.12 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 	40.5342	8.4795	31	336	3786
VRC38.13	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPESGWFYHYYFGLGV											Fab or heavy-chain-only	human	N90-VRC38.13	VRC38.13 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 	18.4321	20.3122	31	337	3787
VRC38.14	gp120 V2 // V2 glycan(V2g) // V2 apex		N90 	VRC38	Cale2017(28514685) 		Cale2017(28514685) 	Cloanalyst IMGT/V-QUEST	3-13*01		6	16	GPTSGWWYHQYYGLDV											Fab or heavy-chain-only	human	N90-VRC38.14	VRC38.14 is an orphan heavy chain; neutralization results were obtained by expressing with the light chain of VRC38.01. 	23.4647	14.1259	31	338	3788
VRC41.01	gp120 V3 // V3 glycan (V3g)		CH765 	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		21		3-20	4	9		14		K		Natural monoclonal	human	CH765-VRC41.01	 	4.93196	22.1047	146	311	3819
VRC41.02	gp120 V3 // V3 glycan (V3g)		CH765 	VRC41	Alam2017(28298421) 	Mutation affects neutralization of V3 mAbs	Alam2017(28298421) 	Cloanalyst IMGT/V-QUEST	4-39	3-3	4-1	21		20		3-20	4	9		13		K		Natural monoclonal	human	CH765-VRC41.02	 	12.5647	7.41578	34	312	3820
VRC42.01	gp41 MPER (membrane proximal external region)	6MTO(Crystal structure of VRC42.01 Fab in complex with T117-F MPER scaffold)	40512 	VRC42	Krebs2019(30876875) 	Residues important for neutralization or binding by VRC42.01;VRC42.01 contacts	Zhang2019a(31772165) 	IMGT/V-QUEST	1-69*10	3-10*01	4*03	15	EGAGWFGKPVGAMGY	10.8		3-20*01	1*01	9	QQYGGSFGT	5.7		K		Natural monoclonal	human	RV217-VRC42.01	 	4.43392	4.39672	446	496	4068
							Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	15	EGAGWFGKPVGAMGY	10.5		3-20*01		9	QQYGGSFGT	6.9				
VRC42.02	gp41 MPER (membrane proximal external region)		40512 	VRC42	Krebs2019(30876875) 	Residues that affect neutralization or binding by VRC42.02	Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	16	EATEGWLAKPVGALGV	12.5		3-20*01		9	QQFDKSHAT	5.5		K		Natural monoclonal	human	RV217-VRC42.02	 	10.4029	6.09119	446	783	4069
VRC42.03	gp41 MPER (membrane proximal external region)		40512 	VRC42	Krebs2019(30876875) 	Residues important for neutralization or binding by VRC42.03	Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	16	EATEGWLSKPVGALGV	13.1		3-20*01		9	QQFDKSHST	5.9		K		Natural monoclonal	human	RV217-VRC42.03	 	18.7831	4.3654	30	784	4070
VRC42.04	gp41 MPER (membrane proximal external region)	6MTP(Crystal structure of VRC42.04 Fab in complex with gp41 peptide)	40512 	VRC42	Krebs2019(30876875) 	Residues important for neutralization or binding by VRC42.04;VRC42.04 contacts	Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	15	EASGWFDKPLGAMGV	10.9		3-20*01		9	QQYYKPPGT	9.7		K		Natural monoclonal	human	RV217-VRC42.04	 	23.6438	4.6235	30	785	4071
VRC42.05	gp41 MPER (membrane proximal external region)		40512 	VRC42	Krebs2019(30876875) 		Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	15	EGATYHGKPVGALGV	8.5		3-20*01		9	QHYSNSAAT	7.2		K		Natural monoclonal	human	RV217-VRC42.05	 	100	1	30	786	4072
VRC42.I3	gp41 MPER (membrane proximal external region)		40512 	VRC42	Krebs2019(30876875) 		Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	15	EGTGWFGKPLGALGV	2.4		3-20*01		9	QQYGSSPGT	1.7		K		UCA or intermediate	human	RV217-VRC42.I3	 	28.0901	4.84146	416	792	4281
VRC42.N1	gp41 MPER (membrane proximal external region)	6MTQ(Crystal structure of VRC42.N1 Fab in complex with T117-F MPER scaffold)	40512 	VRC42	Krebs2019(30876875) 	VRC42.N1 contacts	Krebs2019(30876875) 	IMGT/V-QUEST	1-69*10	3-10	6	18	EGAEGWGWFAKPVGALGV	11.2		3-20*01		9	QQFDKSHVT	6.6		K		Engineered monoclonal	human	RV217-VRC42.N1	 	1.34507	5.73287	416	791	4282
VRC43.01	gp41 MPER (membrane proximal external region)	6MTR(Crystal structure of VRC43.01 Fab)	40512 	VRC43	Krebs2019(30876875) 	Residues important for neutralization or binding by VRC43.01	Krebs2019(30876875) 	IMGT/V-QUEST	4-4			19	RWDSSGWFSRHSYDYAVDV	11		7-43		9	LVQYSGVWV	9.4		L		Natural monoclonal	human	RV217-VRC43.01	 	6.55987	12.0878	446	787	4073
VRC43.02	gp41 MPER (membrane proximal external region)		40512 	VRC43	Krebs2019(30876875) 	Residues important for neutralization by VRC43.02	Krebs2019(30876875) 	IMGT/V-QUEST	4-4			19	RWDSSGWITRHTFDYGVDV	12.7		7-43		9	LVHYRGAWV	8.7		L		Natural monoclonal	human	RV217-VRC43.02	 	6.79846	7.72311	30	788	4074
VRC43.03	gp41 MPER (membrane proximal external region)	6MTS(Crystal structure of VRC43.03 Fab)	40512 	VRC43	Krebs2019(30876875) 	Residues important for neutralization by VRC43.03	Krebs2019(30876875) 	IMGT/V-QUEST	4-4			19	RWDSSGWITRHTYDYGVDV	9.6		7-43		9	LVHYRGAWV	8.7		L		Natural monoclonal	human	RV217-VRC43.03	 	14.1571	4.54006	30	789	4075
VRC46.01	gp41 MPER (membrane proximal external region)	6MTT(Crystal structure of VRC46.01 Fab in complex with gp41 peptide)	40512 	VRC46	Krebs2019(30876875) 	Residues important for neutralization or binding by VRC46.01;VRC46.01 contacts	Krebs2019(30876875) 	IMGT/V-QUEST	1-69			14	HSNSWFSPKWYFDV	8.5		1-39		9	QQSYSSPYT	4.7		K		Natural monoclonal	human	RV217-VRC46.01	 	43.5286	4.81997	446	790	4076
VRC-CH30	gp120 CD4bs		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		23		1-33*01	2*01	5		16		K		Natural monoclonal	human	CH30	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.43176	18.5182	40	46	2573
VRC-CH31	gp120 CD4bs	4LSP(VRC-CH31 complexed with gp120 (93TH057));4LSQ(VRC-CH31 complexed with gp120 (93TH057/3514 chimera));4LSR(VRC-CH31 complexed with gp120 (93TH057/KER2008 chimera));6NNJ(BG505 SOSIP.664 Prefusion Env Trimer Bound to CH31 scFv in Complex with Crystallization Chaperones 3H109L Fab and 35O22 scFv)	CH0219 	VRC-CH31	Wu2011(21835983) 	Signature Analysis Summary;VRC-CH31 signature predictions	Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		24		1-33*01	2*01	5		15		K		Natural monoclonal	human	CH31, CHA31, VRC-CH31 d0219, VRC-CHA31	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	1.06961	16.5289	1346	20	2574
VRC-CH32	gp120 CD4bs		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		23		1-33*01	2*01	5		17		K		Natural monoclonal	human	CH32	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.88113	19.1793	40	47	2575
VRC-CH33	gp120 CD4bs		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		25		1-33*01	2*01	5		17		K		Natural monoclonal	human	CH33	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.44584	16.2125	40	48	2576
VRC-CH34	gp120 CD4bs		CH0219 	VRC-CH31	Wu2011(21835983) 		Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	3-16*01	4*02	15		23		1-33*01	2*01	5		17		K		Natural monoclonal	human	CH34	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.82068	15.5751	40	49	2577
VRC-PG04	gp120 CD4bs	3J5M(BG505 Env trimer with 3 PGV04 Fabs);3SE9(VRC-PG04 complexed with gp120);4I3R(gp120 complexed with VRC-PG04 space group P3221);4I3S(gp120 complexed with VRC-PG04 space group P21);6CRQ(Glutaraldehyde-treated BG505 SOSIP.664 in complex with PGV04 Fab);7RSN(AMC018 SOSIP.v4.2 in complex with PGV04 Fab);7RSO(AMC016 SOSIP.v4.2 in complex with PGV04 Fab);EMD-7107(PC64M4c054 SOSIP in complex with PGV04 Fab);EMD-8302(SOSIP trimer from patient AMC011 in complex with Fab from IgG PGV04)	Donor 74 	VRC-PG04 	Wu2011(21835983) 	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization;Mutation decreases binding to CD4BS mAbs;Signature Analysis Summary;VRC-PG04 alanine scanning;VRC-PG04 contacts;VRC-PG04 signature predictions	Mascola2012() 	IMGT/V-QUEST	1-2*02	2-8*02	2*01	16	ARQKFYTGGQGWYFDLWGRGTLIVVSS			3-11*01	5*01	5	QQLEF			K	Yes	Natural monoclonal	human	PG-04, PG04, PGV04, PV04, VRC04, VRC-PG-04, VRC-PG04 d74	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	0.81585	15.4112	2119	8	2571
							Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	5-12*01	2*01	16		30		3-20*01	5*01	5		19				
VRC-PG04b	gp120 CD4bs		Donor 74 	VRC-PG04 	Wu2011(21835983) 	VRC-PG04b signature predictions	Wu2011(21835983) 	IMGT/V-QUEST JoinSolver	1-2*02	5-12*01	2*01	16		30		3-20*01	5*01	5		19		K		Natural monoclonal	human	PG04b	 Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.Wu2011 %SHM calculated for heavy chain = VH+DH+JH and light chain = VK+JK.	1.38148	22.7156	355	19	2572
VRC-PG05	gp120 silent face	6BF4(HIV-1 Clade AE Strain CNE55 gp120 Core in Complex with VRC-PG05)	Donor 74 		Zhou2018(29548671) 	Signature Analysis Summary;VRC-PG05 contacts;VRC-PG05 sensitivity and escape	Mascola2012() 	IMGT/V-QUEST	3-7*01	3-3*01	3*02	19	ARIRQVSKYLQWYPGVFEMWGQGTMVTVSS			4-1*01	2*03	8	QQYFFLYS			K		Natural monoclonal	human	PG-05, PG05, VRC-PG-05	 	22.7512	10.7914	949	292	3370
							Zhou2018(29548671) 	IMGT/V-QUEST	3-7*01			17	IRQVSKYLQWYPGVFEM	9		4-1*01		8	QYFFLYSF	6				
VRC-PG19	gp120 V2-CD4bs	6B0N(clade A BG505 isolate in complex with Fabs PGT122 and PGV19)	IAVI 23 		Zhou2013a(23911655) 	Mutations allowing binding of germline Abs;VRC-PG19 contacts	Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			11	MGAAREWDFQY			2-14*01	2*01	5	NAYEF			L		Natural monoclonal	human	PG19, PGV19, VRC-PG19 d23	 	1.60753	16.0011	40	80	3015
VRC-PG20	gp120 CD4bs	4LSU(VRC-PG20 in complex with HIV-1 clade A/E 93TH057 gp120)	IAVI 23 		Zhou2013a(23911655) 	Altered glycosylation affects neutralization by CD4BS bnAbs;Mutations allowing binding of germline Abs;Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	Zhou2013a(23911655) 	IgBlast IMGT/V-QUEST	1-02*02			12	RRSQDREWDFQH			2-14*01	2*01	5	NAYEF			L		Natural monoclonal	human	PGV20, VRC20, VRC-PG20 d23	 	0.69508	24.9562	578	73	3017
X5	gp120 CD4i	1RHH(Fab X5);2B4C(gp120 core protein containing V3 complexed with CD4 and the X5 antibody)	FDA2 		Moulard2002(11997472) 		Zhang2013(24100711) 	IMGT/V-QUEST	1-69*01	3-22*01	4*02	24				3-20	2	9				K	Yes	Fab or heavy-chain-only	human	Fab X5	 			21	547	1121
Y498	gp120 CD4bs		XJ1981 		Sun2017(28968970) 	Mutation decreases binding of Y498	Sun2017(28968970) 	IMGT/V-QUEST	1-18*01	3-3*01	3*02	20	ARSLLRSLERLMGGTDAFDI	10.76		1-39*01	1*01	9	QQSYSTPRT	1.06		K		Natural monoclonal	human		 Sun2017 %SHM calculated for VH and VL only.	50.8973	5.24214	70	398	3963
Z13e1	gp41 MPER (membrane proximal external region)	3FN0(Fab Z13e1 in complex with a 12-residue peptide containing the Z13e1 epitope on gp41);3Q1S(Z13e1 in complex with epitope display protein)	FDA2 		Nelson2007(17287272) 	Mutation affects Z13e1 binding;Q563R affects binding and neutralization of MPER mAbs;Signature Analysis Summary;Z13e1 contacts	Morris2011(21980336) 	SoDA	4-59*03		6*03	19			17	3-11*01		9			3.5	K		Engineered monoclonal	human		 Morris2011 SHM data are entered for AA, but it's unclear if the data are NT or AA.	73.133	2.17745	549	281	1589
